thiazoles has been researched along with dasatinib in 1258 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 400 (31.80) | 29.6817 |
| 2010's | 851 (67.65) | 24.3611 |
| 2020's | 7 (0.56) | 2.80 |
| Authors | Studies |
|---|---|
| Travis, J | 1 |
| Chen, P; Lee, FY; Norris, D; Sawyers, CL; Shah, NP; Tran, C | 1 |
| Nelson, L | 1 |
| Barrish, JC; Behnia, K; Borzilleri, RM; Castaneda, S; Chen, P; Cornelius, LA; Das, J; Doweyko, AM; Fairchild, C; Hunt, JT; Inigo, I; Johnston, K; Kamath, A; Kan, D; Klei, H; Lee, FY; Lombardo, LJ; Marathe, P; Norris, D; Pang, S; Peterson, R; Pitt, S; Schieven, GL; Schmidt, RJ; Tokarski, J; Wen, ML; Wityak, J | 1 |
| Doggrell, SA | 1 |
| Ahmed, S; Assouline, S; Gambacorti-Passerini, C; Gasser, M; Scapozza, L | 1 |
| Cowan-Jacob, SW; Deininger, MW; Druker, BJ; Heinrich, MC; Jia, T; Lee, FY; Manley, PW; Mestan, J; O'Hare, T; Stoffregen, EP; Walters, DK | 1 |
| Donato, NJ; Johnson, FM; Saigal, B; Talpaz, M | 1 |
| Deininger, MW; Druker, BJ; Heinrich, MC; O'Hare, T; Sherbenou, DW; Stoffregen, EP; Walters, DK | 1 |
| Buettner, R; Cheng, JQ; Jove, R; Kim, D; Lee, FY; Lee, JH; Mirosevich, J; Nam, S; Zhang, S | 1 |
| D'Antonio, J | 1 |
| Shah, NP | 2 |
| Corbin, AS; Druker, BJ; O'Hare, T | 1 |
| Bokemeyer, C; Corbin, AS; Deininger, MW; Druker, BJ; Griffith, D; Heinrich, MC; Lee, FY; Schittenhelm, MM; Schroeder, A; Shiraga, S | 1 |
| Biggs, WH; Chao, LH; Kuriyan, J; Lockhart, DJ; Milanov, ZV; Patel, HK; Sawyers, CL; Seeliger, M; Shah, NP; Treiber, DK; Young, MA; Zarrinkar, PP | 1 |
| Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP | 1 |
| Hampton, T | 2 |
| Bhalla, KN; Chen, Z; Lee, FY; Wu, J | 1 |
| Allan, EK; Baird, JW; Barow, M; Copland, M; Elrick, LJ; Hamilton, A; Holyoake, TL; Jordanides, N; Mountford, JC | 1 |
| Meier, KE; Zhang, Z | 1 |
| Abbruzzese, JL; Baker, CH; Donato, NJ; Gallick, GE; Hong, DS; Lee, FY; Lesslie, DP; Parikh, NU; Summy, JM; Trevino, JG | 1 |
| Calabretta, B; Cattelani, S; Donato, NJ; Ferrari-Amorotti, G; Guerzoni, C; Iotti, G; Keeshan, K; Zattoni, M | 1 |
| Million, RP | 1 |
| Ohnishi, K | 2 |
| Abruzzese, E; Amadori, S; Barbato, R; Coletta, AM; De Fabritiis, P; Del Poeta, G; Francesconi, F; Fratoni, S; Patroi, IM; Santeusanio, G; Trawinska, MM; Zangrilli, D | 1 |
| Cortes, J; Quintás-Cardama, A | 4 |
| Bagui, T; Haura, EB; Jove, R; Lee, FY; Morris, M; Song, L | 1 |
| Borzillerri, R; Chang, CY; Cheng, JD; Kiefer, SE; Kish, K; Klei, HE; Lee, FY; Lombardo, LJ; Newitt, JA; Tokarski, JS; Wittekind, M; Xie, D; Zhang, Y | 1 |
| Bradeen, HA; Deininger, MW; Druker, BJ; Eide, CA; Johnson, KJ; Lee, FY; O'Hare, T; Willis, SG | 1 |
| Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M | 1 |
| Druker, BJ | 1 |
| Assouline, S; Gambacorti-Passerini, C; Laneuville, P | 1 |
| Gautschi, O; Lee, D | 1 |
| Bramanti, S; Fabio, G; Fantini, NN; Greco, I; Lambertenghi-Deliliers, G; Radaelli, F | 1 |
| Fricker, J | 2 |
| Chomel, JC; Guilhot, F; Martineau, G; Roy, L; Sorel, N; Turhan, AG | 1 |
| Kathula, SK | 1 |
| Chu, SC; Li, CC; Tang, JL | 1 |
| Curtiss, FR | 1 |
| Cortes, J; Giles, F; Jones, D; Kantarjian, H; Nicaise, C; O'Brien, S; Quintas-Cardama, A; Talpaz, M | 1 |
| Grimley, J; Jabbour, E; Kantarjian, H; Kirkpatrick, P | 1 |
| Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K | 1 |
| Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R | 1 |
| Ahmed, S; Andreoni, F; Boschelli, F; Cleris, L; Coluccia, AM; Donella-Deana, A; Formelli, F; Gambacorti-Passerini, C; Magistroni, V; Marchesi, E; Piazza, R; Puttini, M; Redaelli, S; Scapozza, L | 1 |
| Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 2 |
| Cheah, FK; Chuah, C; Goh, YT; Lee, F; Lim, AS; Lim, CH; Lim, TH; Linn, YC; Loh, AH; Soong, R; Tien, SL | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Countouriotis, AM; Druker, BJ; Ezzeddine, R; Facon, T; Goldberg, SL; Hochhaus, A; Hughes, TP; Kantarjian, HM; Lipton, JH; Muller, MC; Niederwieser, D; Shah, NP; Silver, RT; Stone, RM | 1 |
| Blackwood-Chirchir, A; Camuso, A; Castaneda, S; Fager, K; Flefleh, C; Inigo, I; Kan, D; Kramer, R; Lee, FY; Luo, FR; McGlinchey, K; Smykla, R; Wen, ML; Yang, Z | 1 |
| Ashton, GH; Brunton, VG; Clark, EA; Evans, TR; Frame, MC; Lee, FY; Macpherson, IR; Sansom, OJ; Serrels, A | 1 |
| Barrish, JC; Behnia, K; Chen, P; Cook, LS; Das, J; de Fex, HF; Doweyko, AM; Fang, Q; Gillooly, KM; Lin, J; McIntyre, KW; Moquin, RV; Norris, D; Padmanabha, R; Pang, S; Pitt, S; Schieven, GL; Shen, DR; Shen, Z; Shuster, DJ; Wityak, J | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 2 |
| Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N | 1 |
| Chabane, K; Hayette, S; Magaud, JP; Michallet, M; Nicolini, FE; Tigaud, I | 1 |
| Akahane, D; Nunoda, K; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Sashida, G; Takaku, T; Tauchi, T | 1 |
| Dent, P; Grant, S; Harada, H; Nguyen, TK; Rahmani, M | 1 |
| Chen, XG; Liu, H | 1 |
| Czyz, M; Jakubowska, J | 1 |
| Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M | 1 |
| Dering, J; Finn, RS; Ginther, C; Glaspy, P; Slamon, DJ; Tchekmedyian, N; Wilson, CA | 1 |
| Tuma, RS | 2 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Maekawa, T | 1 |
| Kimura, S | 5 |
| Countouriotis, A; Golenkov, A; Hamerschlak, N; Hellmann, A; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Khoroshko, N; Masszi, T; Pasquini, R; Radich, J; Robak, T; Rousselot, P; Shah, N; Skotnicki, A; Zaritsky, A | 1 |
| Baccarani, M; Castagnetti, F; Colarossi, S; Gnani, A; Martinelli, G; Paolini, S; Rondoni, M; Rosti, G; Soverini, S | 1 |
| Clark, E; Fairchild, C; Han, X; Huang, F; Lee, F; Platero, S; Reeves, K; Shaw, P; Wong, TW | 1 |
| Altundag, K; Bulut, N; Dede, DS; Dizdar, O | 1 |
| Chu, JJ; Yang, PL | 1 |
| Jove, R; Keschman, EA; Lee, FY; Letson, GD; Muro-Cacho, C; Pledger, WJ; Shor, AC; Trent, JC | 1 |
| Agaram, NP; Antonescu, CR; Besmer, P; Busam, KJ; Chen, CT; Clarkson, BD; Francone, TD; Gimbel, M; Guo, T; Jungbluth, A; Paty, PB; Veach, D; Weiser, MR; Wong, GC | 1 |
| Scheinfeld, N | 1 |
| Heaney, NB; Holyoake, TL | 1 |
| Aguilon, P; Charbonnier, A; Gisserot, O; Mozziconacci, MJ; Olschwang, S; Popovici, C; Rémy, V | 1 |
| von Mehren, M | 1 |
| Fizazi, K | 1 |
| Kamath, AV; Lee, FY; Marathe, PH; Wang, J | 1 |
| Bhalla, K; Jove, R; Lee, FY; List, A; Nam, S; Smith, D; Vultur, A; Williams, A | 1 |
| Cannell, E | 1 |
| Ault, P | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 4 |
| Ohyashiki, K; Tauchi, T | 1 |
| Abdelhalim, A; Barcos, M; Block, AW; Sait, SN; Starostik, P; Wang, ES; Wetzler, M | 1 |
| Apanovitch, AM; Coutre, S; Dombret, H; Gollerkeri, A; Guilhot, F; Hochhaus, A; Larson, RA; Martinelli, G; Ottmann, O; Radich, J; Rege-Cambrin, G; Simonsson, B | 1 |
| Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W | 1 |
| Corm, S; Grardel, N; Preudhomme, C; Quesnel, B; Rad-Quesnel, E; Renneville, A | 1 |
| Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Kantarjian, H; Kebriaei, P; Shpall, E | 1 |
| Manzione, L; Olivieri, A | 1 |
| Bergeron, A; Bruzzoni-Giovanelli, H; Calvo, F; Levy, V; Meignin, V; Picard, C; Réa, D; Rousselot, P; Tamburini, J; Tazi, A | 1 |
| Bakkannagari, S; He, D; Hong, WK; Johnson, FM; Lee, JJ; Liu, S; Ordonez, NG; Saigal, B; Tsao, AS; Wistuba, I | 1 |
| Schiffer, CA | 1 |
| Donato, NJ; Johnson, FM; Saigal, B; Tran, H | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| Bennett, KL; Bürckstümmer, T; Colinge, J; Ellmeier, W; Hantschel, O; Kneidinger, M; Rix, U; Schmidt, U; Schütze, G; Superti-Furga, G; Valent, P | 1 |
| Oestreicher, P | 2 |
| Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC | 1 |
| Martinelli, G; Paolini, S; Piccaluga, PP | 1 |
| Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ | 1 |
| Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM | 1 |
| Bennett, KL; Colinge, J; Dürnberger, G; Fernbach, NV; Hantschel, O; Kaupe, I; Köcher, T; Planyavsky, M; Remsing Rix, LL; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Borthakur, G; Bruzzi, J; Cortes, J; Kantarjian, H; Munden, R; O'brien, S; Quintás-Cardama, A | 1 |
| Siu, LL | 1 |
| Bacher, U; Haferlach, C; Haferlach, T; Hertenstein, B; Kern, W; Schnittger, S | 1 |
| Brodzik, F; Mehdi, S; Pasquale, D; Ramanarayanan, J | 1 |
| Antolino, A; Berretta, S; Di Raimondo, F; Giustolisi, R; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C | 1 |
| Rotella, D | 1 |
| Billups, CA; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, RB; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Tajbakhsh, M | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Apperley, JF; De Melo, VA; Goldman, JM; Khorashad, JS; Marin, D; Milojkovic, D; Reid, AG | 1 |
| Chiusolo, P; Farina, G; Fiorini, A; Leone, G; Reddiconto, G; Sica, S; Sorà, F | 1 |
| Antczak, C; Beresten-Kochetkov, T; Clarkson, B; Djaballah, H; Lambek, C; Larson, SM; Namavari, M; Pillarsetty, N; Punzalan, BJ; Santos, EB; Smith-Jones, PM; Veach, DR | 1 |
| Holyoake, TL; Jørgensen, HG | 1 |
| Jankowska, AM; Maciejewski, JP; Schade, AE; Schieven, GL; Susulic, V; Szpurka, H; Townsend, R; Zhang, R | 1 |
| Thomas, X | 1 |
| Frame, D | 3 |
| Anand, M; Apperley, JF; Babb, A; de Lavallade, H; De Melo, V; Ghorashian, S; Goldman, JM; Kaeda, JS; Khorashad, JS; Marin, D; Mehta, P; Milojkovic, D; Olavarria, E; Reid, AG | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Hochhaus, A | 2 |
| Aichberger, KJ; Baumgartner, C; Fabbro, D; Gleixner, KV; Gruze, A; Lee, FY; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| Brandwein, J | 1 |
| Clark, E; Huang, F; Lee, F; Luo, FR; Reeves, K; Wang, XD; Xu, LA | 1 |
| Fausel, C; Frame, D; Sessions, J | 1 |
| Fausel, C | 1 |
| Chemaly, RF; Torres, HA | 1 |
| Kujawski, L; Talpaz, M | 1 |
| Cuesta, B; Fernandez-Alonso, M; Galar, A; García-Muñoz, R; Merino, J; Moreno, C; Panizo-Morgado, E; Panizol, C; Ponz-Sarvisê, M; Prosper, F; Rodríguez-Otero, P; Rubio, M | 1 |
| Dobrovic, A; Kovalenko, S; McBean, M; Ritchie, DS; Seymour, JF; Westerman, DA | 1 |
| Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R | 1 |
| Steinberg, M | 1 |
| Baumgartner, C; Bennett, KL; Ellmeier, W; Gleixner, KV; Herrmann, H; Kneidinger, M; Lee, FY; Lupinek, C; Rix, U; Schebesta, A; Schmidt, U; Superti-Furga, G; Thomas, WR; Valent, P; Valenta, R; Vales, A; Vrtala, S; Weghofer, M | 1 |
| Hirano, I; Nakamura, S; Ohnishi, K; Okinaka, K; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y | 1 |
| Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T | 1 |
| Cordero di Montezemolo, L; Crescenzio, N; Doria, A; Fandi, A; Foglia, L; Timeus, F | 1 |
| Keam, SJ | 1 |
| Corm, S; Hetuin, D; Idziorek, T; Joha, S; Liu, J; Philippe, N; Preudhomme, C; Quesnel, B | 1 |
| Booth, B; Brave, M; Bullock, J; Farrell, A; Gobburu, J; Goodman, V; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kenna, L; Men, A; Morse, D; Noory, C; Pazdur, R; Pope, S; Ramchandani, R; Saber, H; Sridhara, R; Timmer, W | 1 |
| Humphreys, WG; Josephs, JL; Li, W; Skiles, GL | 1 |
| Baldwin, AS; Duncan, EA; Goetz, CA; Mayo, KJ; Sawyers, CL; Skaggs, BJ; Stein, SJ; Ziegelbauer, K | 1 |
| Bjerrum, OW; Dufva, IH; Hasselbalch, HC; Stentoft, J | 1 |
| Augustson, B; Cannell, P; Carnley, B; Cooney, J; Cull, G; Purtill, D; Sinniah, R | 1 |
| Barrett, YC; Blackwood-Chirchir, A; Camuso, A; Fager, K; Galbraith, S; Lee, FY; Luo, FR; McGlinchey, K; Palme, H; Smykla, R; Wen, ML; Wild, R; Yang, Z | 1 |
| Apperley, J; Chaidos, A; Dannie, E; Davis, J; Gabriel, I; Goldman, J; Marin, D; Sorouri, J | 1 |
| Liu, XL; Zhang, S; Zhu, HQ | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Muscaritoli, M; Stefanizzi, C | 1 |
| Akhmetshina, A; Axmann, R; Dees, C; Distler, JH; Distler, O; Gay, S; Jüngel, A; Maurer, B; Pileckyte, M; Schett, G; Zwerina, J | 1 |
| Apperley, JF; Bua, M; Chaidos, A; de Lavallade, H; Gabriel, IH; Goldman, JM; Khorashad, JS; Marin, D; Milojkovic, D; Olavarria, E; Punnialingam, S | 1 |
| Aulitzky, WE; Duyster, J; Fanta, S; Miething, C; Skorta, I; Sonnenberg, M; van der Kuip, H | 1 |
| Buchanan, S; Burley, SK; Corbin, AS; Deininger, MW; Eide, CA; Holme, K; Jessen, KA; Lewis, HA; O'Hare, T; Romero, RD; Tang, C; Tyner, JW; Wong, MJ | 1 |
| Blake, S; Hughes, TP; Lyons, AB; Mayrhofer, G | 1 |
| Cortes, J; Kantarjian, H | 2 |
| Blake, SJ; Bruce Lyons, A; Fraser, CK; Hayball, JD; Hughes, TP | 1 |
| Hantschel, O; Rix, U; Superti-Furga, G | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Corm, S; Countouriotis, AM; Deininger, M; Dombret, H; Ezzeddine, R; Goldberg, SL; Hochhaus, A; Hughes, T; Kantarjian, HM; Larson, RA; Lipton, JH; Müller, MC; Niederwieser, D; Roy, L; Shah, NP; Silver, RT; Stone, RM | 1 |
| Cools, J; Cortes, J; Garcia-Manero, G; Gilliland, DG; Kantarjian, H; Lee, F; Lennon, PA; Manshouri, T; Quintás-Cardama, A; Tong, W; Vega, F | 1 |
| Fandi, A; Lee, F; Voi, M | 1 |
| Clement, M; Dix, C; Einsele, H; Fenton-May, A; Gostick, E; Greiner, E; Price, DA; Seggewiss, R; Sewell, AK; Weichsel, R; Wooldridge, L; Zezula, J | 1 |
| Allentoff, A; Barros, A; Blackwood-Chirchir, A; Bonacorsi, SJ; Christopher, LJ; Cui, D; Galbraith, S; He, K; Humphreys, WG; Iyer, RA; Lago, M; Lee, FY; Luo, R; Manning, JA; McCann, B; Reitberg, DP; Wu, C | 1 |
| Arora, VK; Barros, A; Bonacorsi, SJ; Christopher, LJ; Cui, D; Fletcher, AM; He, K; Humphreys, WG; Iyer, RA; Lago, M; Li, W; Manning, JA; Ogan, M; Wang, L; Zhang, D; Zhang, H | 1 |
| Cowan-Jacob, SW; Fendrich, G; Grzesiek, S; Jahnke, W; Manley, PW; Strauss, A; Vajpai, N | 1 |
| Barańska, M; Gniot, M; Iwoła, M; Komarnicki, M; Lewandowska, M; Lewandowski, K | 1 |
| DiPersio, JF; Ramirez, P | 1 |
| Araujo, JC; Gallick, GE; Gelovani, JG; Kim, SJ; Najjar, AM; Park, SI; Phillips, KA; Volgin, AY; Wang, Z; Zhang, J | 1 |
| Cobanoglu, U; Omay, SB; Ovali, E; Sonmez, M | 1 |
| Bajel, A; Bassili, S; Seymour, JF | 1 |
| Atzeni, S; Azzena, L; Caocci, G; La Nasa, G; Ledda, A; Littera, R; Martorana, L; Orrù, N | 1 |
| Anagnostopoulos, A; Athanasiadou, A; Fassas, A; Gaitatzi, M; Lalayanni, C; Papaioannou, G | 1 |
| Arnan, M; Brethon, B; Brito-Babapulle, F; Dombret, H; Duarte, RF; Eccersley, L; Elonen, E; Gruber, F; Hjorth-Hansen, H; Höglund, M; Klamova, H; Knutsen, H; Koskenvesa, P; Lee, FY; Lundán, T; Luo, R; Mustjoki, S; Paquette, R; Parikh, S; Porkka, K; Raffoux, E; Rimpiläinen, J; Smykla, R; Wild, R; Zwaan, CM | 1 |
| Craig, J; Cunningham, J; Gelly, K; Pippard, MJ; Sales, M; Tauro, S; Walker, K | 1 |
| Barlow, A; Doig, A; Drummond, MW; Robertson, M; Stewart, W | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J; Tam, CS | 1 |
| Cirulli, T; Colanardi, MC; Coluccia, AM; Dammacco, F; Di Renzo, N; Gambacorti-Passerini, C; Gnoni, A; Mangieri, D; Neri, P; Ribatti, D; Tassone, P; Vacca, A | 1 |
| Valent, P | 3 |
| Bleickardt, E; Charbonnier, A; Collins, RH; Deininger, M; Dorlhiac-Llacer, PE; Francis, S; Hochhaus, A; Hughes, T; Kantarjian, HM; Khoroshko, N; Khoury, HJ; Kim, DW; Milone, JH; Otero, I; Paquette, RL; Réa, D; Shah, NP; Silver, RT; Strauss, L; Vela-Ojeda, J | 1 |
| Hagist, S; Hallek, M; Krause, G; Pallasch, CP; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Appell, KC; Beasley, JR; Carroll, CD; Lin, T; Rokosz, LL; Webb, ML; Zhao, J | 1 |
| Christopher, LJ; Cui, D; Humphreys, WG; Iyer, R; Li, W; Wang, L; Zhang, D | 1 |
| Dang, P; Eadie, L; Frede, A; Hewett, D; Hiwase, DK; Hughes, TP; Kumar, S; Melo, J; Saunders, V; To, LB; White, DL; Zrim, S | 1 |
| Akin, C; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Manshouri, T; O'Brien, S; Pardanani, A; Tefferi, A; Thomas, D; Verstovsek, S | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Deininger, MW | 1 |
| Barrientos, JC; Chadburn, A; Knowles, DM; Lee, FY; Leonard, JP; Lu, P; Wang, YL; Yang, C; Ye, F; Zhang, D | 1 |
| Arnold, R; Guilhot, F; Koren-Michowitz, M; le Coutre, P; Leiba, M; Martineau, G; Nagler, A; Renaud, M; Ribakovski, E; Schleuning, M; Shimoni, A | 1 |
| Bonvin, A; Cotte, L; Descotes, J; Mesnil, A; Michallet, M; Nicolini, FE; Vial, T | 1 |
| Baumgartner, C; Bennett, KL; Esterbauer, H; Ferenc, V; Gleixner, KV; Gruze, A; Lee, FY; Peter, B; Pickl, WF; Remsing Rix, LL; Samorapoompichit, P; Sillaber, C; Superti-Furga, G; Valent, P | 1 |
| Bunjes, D; Chen, B; Döhner, H; Fei, F; Götz, M; Greiner, J; Guillaume, P; Rojewski, MT; Schmitt, A; Schmitt, M; Yu, Y | 1 |
| Amabile, M; Arruga, F; Baccarani, M; Baruzzi, A; Berton, G; Chiaretti, S; Cilloni, D; Foà, R; Giannoulia, P; Iacobucci, I; Lonetti, A; Martinelli, G; Messa, F; Ottaviani, E; Pane, F; Paolini, S; Papayannidis, C; Perini, G; Piccaluga, PP; Poerio, A; Saglio, G; Soverini, S; Vitale, A | 1 |
| Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Lucas, CM; Pirmohamed, M | 1 |
| Gisslinger, H; Jaeger, E; Oehler, L; Schwarzinger, I; Streubel, B; Valent, P; Wappl, M | 1 |
| Wong, SF | 2 |
| Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C | 1 |
| Bengoufa, D; Bergeron, A; Dombret, H; Fieschi, C; Oksenhendler, E; Rea, D | 1 |
| Blackwood-Chirchir, A; Dai, G; Pfister, M; Roy, A | 1 |
| Distler, JH; Distler, O | 1 |
| Cools, J; De Keersmaecker, K; Hantschel, O; Superti-Furga, G; Versele, M | 1 |
| Brownlow, N; Dibb, NJ; Ghaem-Maghami, S; Hayford, C; Mol, C | 1 |
| Christopher, LJ; He, K; Humphreys, WG; Iyer, RA; Lago, MW; Shyu, WC | 1 |
| Cools, J; Debiec-Rychter, M; Dewaele, B; Marynen, P; Prenen, H; Schöffski, P; Sciot, R; Vandenberghe, P; Wasag, B; Wozniak, A | 1 |
| Chang, Q; Hedley, DW; Jorgensen, C; Pawson, T | 1 |
| Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N | 1 |
| Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
| Wang, ES; Wetzler, M; Zeidan, A | 1 |
| Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F | 1 |
| Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Usui, N | 1 |
| Kubuki, Y | 1 |
| Hohl, RJ; Holstein, SA; Stokes, JB | 1 |
| Bewry, NN; Boulware, D; Emmons, MF; Hazlehurst, LA; Nair, RR; Pinilla-Ibarz, J | 1 |
| Clement, M; Edwards, E; Gallagher, K; Godkin, AJ; Gostick, E; Jones, E; Ladell, K; Lissina, A; Melenhorst, JJ; Peakman, M; Price, DA; Seggewiss, R; Sewell, AK; Skowera, A; van den Berg, HA; Wooldridge, L | 1 |
| Alnadaf, T; Buchdunger, E; Day, E; Jarai, G; Manley, PW; Spiegel, K; Walker, C; Waters, B | 1 |
| Fang, JW; Gelman, IH; Gutowski, A; Hangauer, D; Lau, GM; Yu, GL | 1 |
| Ingley, E; Klinken, SP; Lucet, IS; Rossjohn, J; Williams, NK | 1 |
| Flaim, B; Rasheed, W; Seymour, JF | 1 |
| Bhalla, K; Corless, CL; Fiskus, W; Heinrich, MC; Jillella, A; Kepten, I; Lewis, G; Manaloor, E; Ramalingam, P; Savage, N; Ustun, C | 1 |
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Valk, PJ; van der Poel-van de Luytgaarde, SC; van Esser, JW; Wattel, MM | 1 |
| Buettner, R; Jove, R; Lee, F; Mesa, T; Vultur, A | 1 |
| Verstovsek, S | 1 |
| Bunjes, D; Chen, B; Döhner, H; Fei, F; Götz, M; Rojewski, MT; Schmitt, A; Schmitt, M; Yu, Y | 1 |
| Aichberger, KJ; Gleixner, KV; Kretschmer, A; Sperr, WR; Valent, P | 1 |
| Del Cañizo, MC; González, M; Gonzalez, T; Lopez-Jimenez, J; Sanchez-Guijo, FM; Santamaría, C | 1 |
| Augustin, M; Baumgartner, C; Bennett, KL; Colinge, J; Hantschel, O; Müller, A; Remsing Rix, LL; Rix, U; Stranzl, T; Superti-Furga, G; Till, JH; Valent, P | 1 |
| Bhatia, R; Chu, S; Copland, M; Holyoake, TL; Jove, R; Konig, H | 1 |
| Belanger, C; Belloc, F; Etienne, G; Hayette, S; Lagarde, V; Leroy, C; Mahon, FX; Manley, PW; Nicolini, F; Pasquet, JM; Roche, S; Turcq, B | 1 |
| Blake, SJ; Brown, MP; Diener, KR; Fraser, CK; Hayball, JD; Hughes, TP; Lyons, AB | 1 |
| Balbas, M; Bleickardt, E; Kasap, C; Nicaise, C; Nicoll, JM; Sawyers, CL; Shah, NP; Weier, C | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Chang, H; Jung, CW; Kamel-Reid, S; Kim, DH; Kim, HJ; Lee, JJ; Lipton, JH; Sutherland, R | 1 |
| Chuah, C; Melo, JV | 1 |
| Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R | 1 |
| Gora-Tybor, J; Robak, T | 1 |
| Cervantes, F | 1 |
| Bik To, L; Dewar, AL; Farrugia, AN; Fitter, S; Hughes, TP; Vandyke, K; Zannettino, AC | 1 |
| Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W | 1 |
| Bernasconi, P; Beroukhim, R; Burns, M; Carr, SA; Clauser, KR; Du, J; Finn, SP; Golub, TR; Hieronymus, H; Julian, B; Kung, AL; Lewis, TA; Liau, LM; Loda, M; Louis, DN; Maglathlin, RL; Mani, DR; Mellinghoff, IK; Nghiemphu, P; Peng, XP | 1 |
| Baird, JW; Bhatia, R; Brunton, VG; Hamilton, A; Helgason, GV; Holyoake, TL; Jørgensen, HG; Koschmieder, S; Modi, H; Mountford, JC; Myssina, S; Schemionek, M; Serrels, A | 1 |
| Feola, M; Gallamini, A; Mattei, D; Mordini, N; Orzan, F; Rapezzi, D | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Müller, BA | 1 |
| Cayuela, JM; Dombret, H; Maarek, O; Raffoux, E; Rea, D | 1 |
| Dipersio, JF; Gao, F; Procknow, E; Vij, R; Wildes, TM | 1 |
| Saad, F | 1 |
| Cortes, JE; Jabbour, E; Kantarjian, HM | 1 |
| de Groot, J; LaFortune, T; Milano, V; Piao, Y | 1 |
| Kantarjian, H | 1 |
| Cortes, JE; Guilhot, F; Hughes, TP; Khoury, HJ; Kim, DW | 1 |
| Brizard, F; Chomel, JC; Cividin, M; Guilhot, F; Méchinaud, F; Millot, F | 1 |
| Tallman, M | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carotti, A; Santopietro, M; Stefanizzi, C | 1 |
| Gallick, G; Johnson, FM; Parikh, N; Saigal, B; Sen, B | 1 |
| Hantschel, O; Kuriyan, J; Superti-Furga, G; Winger, JA | 1 |
| Cortés, JE; Jabbour, E; Kantarjian, H | 2 |
| Cortés, JE; Kantarjian, H; Quintás-Cardama, A | 1 |
| Bixby, DL; Talpaz, M | 1 |
| Cortes, J; Fava, C; Kantarjian, H; Verma, D | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, KI; Jinnai, I; Miyawaki, S; Miyazaki, Y; Morishima, Y; Motoji, T; Nagai, T; Naoe, T; Ohnishi, K; Ohno, R; Okada, M; Okamoto, S; Sakamaki, H; Seriu, T; Tanimoto, M; Taniwaki, M; Tobinai, K; Uoshima, N; Usui, N; Utsunomiya, A | 1 |
| Snyder, DS | 1 |
| Beijnen, JH; Hillebrand, MJ; Lagas, JS; Lankheet, N; Rosing, H; Schinkel, AH; van Tilburg, VA; van Waterschoot, RA | 1 |
| Armstrong, EA; Dunn, EF; Harari, PM; Huang, S; Iida, M; Kruser, TJ; Nechrebecki, MM; Wheeler, DL | 1 |
| Cortes, J; Kantarjian, H; Kornblau, S; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Vidal-Senmache, G; Wierda, W | 1 |
| Cameron, MD; He, Y; Koenig, M; Li, X; Ruiz, CH; Vojkovsky, T | 1 |
| Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Alimena, G; Breccia, M; Capria, S; De Propris, MS; Diverio, D; Grammatico, S; Latagliata, R; Matturro, A; Meloni, G | 1 |
| Barry, WT; Febbo, PG; Guinney, J; Mendiratta, P; Mostaghel, E; Nelson, PS; Porrello, A; Tewari, AK | 1 |
| Arstila, TP; Dybedal, I; Ekblom, M; Epling-Burnette, PK; Guilhot, F; Hjorth-Hansen, H; Höglund, M; Kovanen, P; Laurinolli, T; Liesveld, J; Mustjoki, S; Paquette, R; Pinilla-Ibarz, J; Porkka, K; Rauhala, A; Shah, N; Simonsson, B; Sinisalo, M; Steegmann, JL; Stenke, L | 1 |
| Au, K; Clements, PJ; Furst, DE; Khanna, D; Tashkin, DP | 1 |
| Cortes, JE; Kantarjian, H; Pavlovsky, C | 1 |
| Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J | 1 |
| Czernin, JG; Dumont, RA; Haubner, R; Hildebrandt, I; Mischel, PS; Reischl, G; Su, H; Weber, WA | 1 |
| Tyler, T | 1 |
| Mauro, MJ | 4 |
| McFarland, KL; Wetzstein, GA | 1 |
| Duncan, C; Galviz, G; Hsieh, Y; Zhou, Q | 1 |
| Giles, FJ | 2 |
| Bellodi, C; Calabretta, B; Dinsdale, D; Donato, N; Dyer, MJ; Galavotti, S; Hamilton, A; Helgason, GV; Holyoake, T; Hunter, A; Lidonnici, MR; Nicotera, P; Ronchetti, M; Salomoni, P; Selmi, T; Soliera, AR; Tirrò, E; Van Etten, RA; Vigneri, P; Yacobi, R; Young, KW | 1 |
| Akin, RS; Cobos, E; Smith, J; Sun, A | 1 |
| Alimena, G; Breccia, M; Cannella, L; Napoleone, L; Santopietro, M; Stefanizzi, C | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Bilban, M; Burkard, TR; Colinge, J; Gstoettenbauer, A; Hantschel, O; Kaupe, I; Superti-Furga, G; Valent, P | 1 |
| Abbruzzese, JL; Chandra, J; Dallas, NA; Ellis, LM; Gallick, GE; Johnson, M; Kim, MP; Kopetz, S; Lesslie, DP; Parikh, NU; Park, SI | 1 |
| Albitar, M; Bornmann, W; Estrov, Z; Faderl, S; Harris, D; Hazan-Halevy, I; Kantarjian, HM; Liu, Z; Maxwell, D; Pal, A; Peng, Z; Van, Q | 1 |
| Gruber, F; Mustjoki, S; Porkka, K | 1 |
| Jillella, AP; Salama, ME; Ustun, C | 1 |
| Agrawal, S; Bertz, R; Blackwood-Chirchir, A; Eley, T; Li, T; Luo, FR; Manning, J; Sanil, A | 1 |
| Lee, FY; Majumdar, AP; Majumder, P; Nautiyal, J; Patel, BB | 1 |
| Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Scuffham, PA; Taylor, MJ | 1 |
| Cortes, J; Han, X; Kantarjian, H; Quintás-Cardama, A | 1 |
| Isidori, A; Malagola, M; Piccaluga, P; Visani, G | 1 |
| Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M | 1 |
| Cubitt, CL; Daud, AI; Homsi, J; Jove, R; Messina, JL; Munster, PN; Sullivan, DM; Yu, H; Zhang, S | 1 |
| de Groot, J; Milano, V | 1 |
| Arcamone, M; Di Francia, R; Frigeri, F; Luciano, L; Pane, F; Pinto, A | 1 |
| Brunton, VG; Edwards, J; Leung, HY; Mitchell, TJ; Seywright, M; Tatarov, O | 1 |
| Gorlick, R; Hingorani, P; Kolb, EA; Zhang, W | 1 |
| Agrawal, S; Bradley-Garelik, MB; Caguioa, PB; Dai, D; Goh, YT; Hsiao, HH; Jootar, S; Kim, D; Kim, DW; Kim, WS; Mukhopadhyay, J; Roy, A; Saikia, T | 1 |
| Ambrosetti, A; Nichele, I; Pizzolo, G; Tecchio, C; Todeschini, G | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V | 1 |
| Storey, S | 1 |
| Aplenc, R; Blanchard, EG; Corey, SJ; Guerrouahen, BS; Lee, FY; Wieder, E | 1 |
| Abruzzese, E; Apperley, JF; Bullorsky, EO; Cortes, JE; de Souza, CA; Erben, P; Heim, D; Hochhaus, A; Hughes, TP; Khoury, HJ; Kim, DW; Kim, HJ; Larson, RA; Lipton, JH; Roboz, GJ; Rosti, G; Roy, L; Sillaber, C; Stone, RM; Van Tornout, J | 1 |
| Agarwal, S; Chen, C; Chen, Y; Elmquist, WF; Shaik, NM; Yang, Z | 1 |
| Allart, S; Garcia, C; Gratacap, MP; Martin, V; Payrastre, B; Recher, C; Sié, P; Valéra, MC | 1 |
| Bryant, G | 1 |
| Buchanan, S; Galinsky, I | 1 |
| Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Arvanitis, C; Corey, SJ; Frost, JA; Hartig, SM; Lee, FY; Monisvais, D; Pichot, CS; Xia, L | 1 |
| Awais, A; Borthakur, G; Cortes, J; De Souza Santos, FP; Faderl, S; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Bleickardt, E; Cortes, J; Dejardin, D; Hamerschlak, N; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Lévy, V; Pasquini, R; Shah, NP | 1 |
| Damaj, G; Garidi, R; Marolleau, JP; Parcelier, A; Roszkiewicz, F; Royer, B; Vaida, I | 1 |
| Kim, DJ; Kim, JH; Yi, YW | 1 |
| Ottmann, OG; Pfeifer, H | 2 |
| Dazzi, F; Garland, P; Marin, D | 1 |
| Borthakur, G; Burger, JA; Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; Koller, C; O'Brien, S; Tam, C; Wierda, WG | 1 |
| Cetkovský, P; Klamová, H; Machová Poláková, K; Marková, M; Moravcová, J; Sisková, M | 1 |
| Breitenstein, A; Goede, J; Kühne, R; Marek, A; Minder, EI; Renner, C; Schanz, U | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S | 1 |
| Bovée, JV; Briaire-de Bruijn, IH; de Miranda, NF; Hogendoorn, PC; Schrage, YM; Taminiau, AH; van Oosterwijk, J; van Wezel, T | 1 |
| Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR | 1 |
| Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Müller, MC; Niederwieser, D; Pelz-Ackermann, O; Pfirrmann, M; Porkka, K | 1 |
| Brunetto, AL; de Castro, CG; Gregianin, LJ; Meneses, CF | 1 |
| Cortes, J; Fava, C | 1 |
| Jabbour, E; Soverini, S | 1 |
| Calabretta, B; Cesi, V; Dominici, C; Mancini, C; Mancuso, M; Pasquali, E; Piscitelli, M; Raschellà, G; Sesti, F; Tanno, B; Vitali, R | 1 |
| Bleickardt, E; Branford, S; Hanfstein, B; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Lambert, A; Lipton, JH; Müller, MC; Radich, J; Rousselot, P | 1 |
| Daub, H; Mann, M; Olsen, JV; Pan, C | 1 |
| Arai, T; Hayasaka, K; Ito, M; Iwaba, A; Izumino, H; Kanno, M; Kawakami, T; Mitsui, T; Sendo, D; Shimokaze, T; Takahashi, N; Takeda, H | 1 |
| Davies, MA; Fermeglia, M; Gopal, YN; Hwu, P; Ivan, D; Kim, KB; Lazar, AJ; Mills, GB; Papadopoulos, N; Pavan, GM; Podoloff, DA; Pricl, S; Stemke-Hale, K; Trent, JC; Woodman, SE; Yang, D | 1 |
| Balachandran, H; Carayol, N; Dumka, D; Lumby, C; Parmar, S; Platanias, LC; Puri, P; Schuster, K; Terada, LS; Verma, AK | 1 |
| Ahkavan, D; Bergers, G; Caldwell, JS; Cavenee, WK; Chakravari, A; Chen, Z; Cloughesy, TF; Cvrljevic, A; Dang, J; Dinca, EB; Furnari, FB; Graeber, T; Huang, TT; James, CD; Johns, TG; Lee, FY; Lee, Y; Loo, JA; Lu, KV; Mischel, PS; Nelson, SF; Oderberg, I; Plaisier, SB; Sarkaria, S; Seligson, D; Weinmann, R; Xie, Y; Zhu, S | 1 |
| Cooper, JM; Copland, M; Faley, SL; Kolch, W; Seale, KT; Wikswo, JP; Wlodkowic, D | 1 |
| Adrian, LT; Deininger, MW; Druker, BJ; Eide, CA; Lange, T; O'Hare, T; Snead, JL | 1 |
| Abakumov, EM; Chelysheva, EIu; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Khoroshko, ND; Kuznetsov, SV; Misiurin, AV; Sokolova, MA; Stakhina, OV; Turkina, AG; Vinogradova, OIu; Vorontsova, AV | 1 |
| Botta, M; Bruno, O; Radi, M; Schenone, S | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Berger, MG; Chabane, K; Hayette, S; Nicolini, FE; Tchirkov, A; Tournilhac, O | 1 |
| Auclair, C; Bougherara, H; Crépin, R; Poul, MA; Subra, F; Tauc, P | 1 |
| Baumgartner, C; Bennett, K; Böhm, A; Herndlhofer, S; Herrmann, H; Jäger, U; Rix, U; Sillaber, C; Superti-Furga, G; Tschachler, E; Valent, P | 1 |
| Amano, M; Fujii, Y; Seriu, T | 1 |
| Aloyz, R; Amrein, L; Gibson, SB; Johnston, JB; Panasci, L; Soulières, D | 1 |
| Aloyz, R; Baker, K; Dirnhofer, S; Foulkes, W; Grygorczyk, C; Grygorczyk, R; Hollmann, CA; Martínez-Marignac, VL; Nadeau, J; Tzankov, A | 1 |
| Bruccoleri, RE; Cao, J; Cockett, MI; de Silva, H; He, A; Huang, W; Ji, RR; Jin, Y; Kayne, PS; Neubauer, MG; Neuhaus, IM; Ott, KH; Penhallow, B; Ross-Macdonald, P; Siemers, NO | 1 |
| Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Branford, S; Cortes, JE; Druker, BJ; Erben, P; Hochhaus, A; Hughes, TP; Kim, DW; Mukhopadhyay, J; Müller, MC; Pasquini, R; Ploughman, L; Radich, JP | 1 |
| Apáti, A; Hegedus, C; Katona, M; Kéri, G; Magócsi, M; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Szakács, G; Takáts, Z; Váradi, A | 1 |
| Diener, KR; Fraser, CK; Hayball, JD; Hughes, TP; Kumar, R; Lousberg, EL | 1 |
| Agrawal, S; Brunton, VG; Demetri, GD; Evans, TR; Lo Russo, P; MacPherson, IR; Morgan, JA; Paliwal, P; Voi, M; Wang, D | 1 |
| Bauer, S; Romvari, E | 1 |
| Almqvist, A; Hernesniemi, S; Kähkönen, M; Lundán, T; Mustjoki, S; Porkka, K; Rauhala, A | 1 |
| Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P | 1 |
| Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Chalukya, M; Gondek, L; Jasek, M; Maciejewski, J; Nicoll, J; Paquette, RL; Sawyers, CL; Shah, NP | 1 |
| Divoka, M; Divoky, V; Faber, E; Indrak, K; Jarosova, M; Mojzikova, R; Plachy, R; Rozmanova, S; Stastny, M | 1 |
| Goldstein, JL | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R | 1 |
| Doelken, P; Goldblatt, M; Gurung, P; Huggins, JT; Sahn, SA | 1 |
| Berretta, S; Buscarino, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; Massimino, M; Messina, A; Pennisi, MS; Restuccia, N; Stagno, F; Stella, S; Tibullo, D; Tirrò, E; Vigneri, P | 1 |
| Sos, ML; Thomas, RK | 1 |
| Clynes, M; McMahon, G; O'Connor, R; Roche, S | 1 |
| Araujo, JC; Corn, P; Darnay, BG; Lee, F; Logothetis, CJ; Parikh, NU; Poblenz, A; Starbuck, MW; Thompson, JT | 1 |
| Bendit, I; Conchon, M; de Barros Ferreira, P; Dulley, FL; Filho, UA; Llacer-Dorliac, PE; Novaes, MM; Saboya, R; Sanabani, SS; Serpa, M | 1 |
| Tojo, A | 2 |
| Bracco, E; Ceppi, P; Lo Iacono, M; Monica, V; Mussino, S; Novello, S; Papotti, M; Pautasso, M; Saviozzi, S; Scagliotti, GV; Volante, M | 1 |
| Brugge, J; Dering, J; Finn, RS; Gao, G; Ginther, C; Glas, R; Hong, KL; Konecny, GE; Manivong, K; Qi, J; Slamon, DJ; Winterhoff, B; Yang, GR | 1 |
| Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP | 1 |
| Branford, S; Hughes, TP; Melo, JV | 1 |
| Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Pane, F; Radich, J; Saglio, G; Silver, RT; Simonsson, B | 1 |
| Czyz, A; Komarnicki, M; Kroll, R; Lewandowski, K | 1 |
| Gorospe, G; Masiello, D; Yang, AS | 1 |
| Matsunaga, T | 1 |
| Calabrò, F; Cheng, S; Culine, S; Gross, M; Hudes, G; Massard, C; Morris, MJ; Paliwal, P; Posadas, E; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Cortes, JE; Khoury, HJ; Matloub, Y; Paquette, RL; Porkka, K; Sinha, R | 1 |
| Guilhot, F; Roy, L | 1 |
| Marin, D; Pavlů, J | 1 |
| Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T | 1 |
| Stock, W | 1 |
| Kambhampati, S | 1 |
| Borthakur, G; Cortes, JE; Jabbour, E; Jones, D; Kantarjian, H; Koller, C; O'Brien, S; Ravandi, F; Shan, J; Walker, B; Zhao, W | 1 |
| Hiwase, DK; Hughes, TP; Melo, JV; Saunders, V; White, D; Zrim, S | 1 |
| Ravandi, F; Santos, FP | 1 |
| Chen, J | 1 |
| Azam, M; Clackson, T; Daley, GQ; Dalgarno, D; Einhorn, W; Huang, WS; Powers, JT; Sawyer, TK; Shakespeare, WC; Zhu, X | 1 |
| Johnson, DE; Kropf, PL; Redner, RL; Wang, L; Zang, Y | 1 |
| Attar, EC; DeAngelo, DJ | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Kiselev, Y; Mikkola, I | 1 |
| Bondada, S; Chelvarajan, RL; Jennings, CD; Ke, J; Lekakis, L; Robertson, DA; Sindhava, V | 1 |
| Gotoh, M; Kiguchi, T; Kimura, Y; Kitahara, T; Ohyashiki, K; Tauchi, T; Yoshizawa, S | 1 |
| Arduini, RM; Baker, DP; Cullen, PF; Hession, CA; Hong, V; Hopkins, BT; Jenkins, TJ; Liu, YT; Marcotte, DJ; Mertsching, E; Miatkowski, K; Romanowski, MJ; Silvian, LF; Wildes, CP | 1 |
| Baird, K; Bishop, MR; Cowen, EW; Pavletic, SZ; Pulanic, D | 1 |
| Coleman, M; Furman, RR; Knowles, DM; Lee, FY; Leonard, JP; Lu, P; Martin, P; Song, Z; Tyrell, L; Wang, YL | 1 |
| Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B | 1 |
| Hochhaus, A; Lindauer, M | 2 |
| Hodgson, L; Kelley, MJ; Kratzke, RA; Miller, AA; Otterson, GA; Pang, H; Ramnath, N; Vokes, EE | 1 |
| Chung, AS; Ferrara, N | 1 |
| Herrmann, A; Jove, R; Kujawski, M; Lee, F; Liang, W; Loera, S; Lu, J; Wen, W; Wu, J; Yen, Y; Yu, H | 1 |
| Agrawal, S; Blackwood-Chirchir, A; Burris, H; Chiappori, AA; Dhillon, N; Hong, D; Johnson, FM; Kaul, S; Luo, FR; Rosen, L; Sy, O | 1 |
| Bornmann, WG; Daniels, L; Donato, NJ; Meng, F; Peng, Z; Peterson, LF; Quintás-Cardama, A; Roulston, D; Talpaz, M; Wu, J; Ying, Y | 1 |
| Fei, F; Groffen, J; Heisterkamp, N; Kim, YM; Müschen, M; Stoddart, S | 1 |
| Haura, EB; Kim, LC; Rix, U | 1 |
| Acikalin, MF; Ozkurt, S; Soydan, M; Temiz, G | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P | 1 |
| D'Andrea, RJ; Frede, AK; Guthridge, MA; Hiwase, DK; Hughes, TP; Kumar, S; Lopez, AF; Melo, JV; Powell, JA; Saunders, VA; To, LB; White, DL; Zrim, SA | 1 |
| Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C | 1 |
| Fullmer, A; Jabbour, E | 1 |
| Frankel, AE; Hogge, DE; Kim, HP | 1 |
| Enrico, A; Hochhaus, A; Kantarjian, H; Khoury, HJ; Kim, DW; Lambert, A; Llacer, PE; Matloub, Y; Müller, MC; Rousselot, P; Shah, NP; Silver, RT; Vela-Ojeda, J | 1 |
| Ashihara, E; Fujiyama, Y; Imoto, M; Kawatani, M; Kimura, S; Kuroda, J; Maekawa, T; Nagao, R; Nakahata, T; Osada, H; Takeuchi, M; Tanaka, R; Tsuruo, T; Umezawa, K; Yasui, E; Yokota, A | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A | 1 |
| Arceci, R; Blanchard, EG; Cayre, YE; Corey, SJ; Futami, M; Guerrouahen, BS; Kanerva, J; Kornblau, SM; Lee, FY; Nwawka, K; Robinson, LJ; Vaklavas, C; Whichard, ZL; Wieder, E | 1 |
| Bijlmakers, MJ; Dibb, NJ; Giannini, AL; Lee, KC; Ouwehand, I; Thomas, NS | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Bai, Y; Bennett, KL; Colinge, J; Edwards, A; Eschrich, S; Fang, B; Gao, J; Haura, EB; Koomen, J; Li, J; Rix, U; Song, L; Superti-Furga, G | 1 |
| Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T | 1 |
| Bocanegra, M; Choi, YL; Godwin, AK; Kao, J; Kwon, MJ; Nam, SJ; Pollack, JR; Shin, YK; Yang, JH | 1 |
| Condorelli, F; Genazzani, AA | 1 |
| Dewar, AL; Diamond, P; Fitter, S; Schultz, CG; Sims, NA; Vandyke, K; Zannettino, AC | 1 |
| Araujo, J; Logothetis, C | 1 |
| Araujo, JC; Chu, K; deCrombrugghe, B; Gallick, GE; Huang, CF; Lee, YC; Lin, SH; Murshed, M; Ye, X; Yu-Lee, LY | 1 |
| Barr, PM; Caimi, PF; Distelhorst, CW; Harr, MW; McColl, KS; Patel, SN; Zhong, F | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Martinelli, G; Palandri, F; Rosti, G | 1 |
| Athineos, D; Brunton, VG; Doyle, B; Evans, TR; Frame, MC; Graham, K; Heung, MY; Jamieson, N; Karim, SA; McKay, C; Morton, JP; Oien, KA; Sansom, OJ; Timpson, P | 1 |
| Alkhatib, R; Bailleul, F; Biabiany, M; Güzel, Y; Hennebelle, T; Idziorek, T; Joha, S; Preudhomme, C; Quesnel, B; Roumy, V; Sahpaz, S | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Chen, J; Shen, J; Zheng, Z; Zhou, Y | 1 |
| Kasada, A; Munemoto, S; Murata, R; Ueda, M; Yamaguchi, M | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Brixey, AG; Light, RW | 1 |
| Hatsumi, N; Hoshino, T; Miyawaki, K; Miyawaki, S; Sakura, T; Tahara, K; Takada, S | 1 |
| Earp, HS; Gioeli, D; Karaca, M; Liu, Y; Whang, YE; Zhang, Z | 1 |
| Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M | 1 |
| Han, L; Mulder, A; Schuringa, JJ; Vellenga, E | 1 |
| Fei, F; Groffen, J; Heisterkamp, N; Stoddart, S | 1 |
| Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Economopoulou, C; Ionnidou, ED; Konsioti, F; Papageorgiou, E; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vasilatou, D | 1 |
| Akiyama, H; Fukuda, S; Kamata, N; Nagata, Y; Ohashi, K; Sakamaki, H | 1 |
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G; Yamashita, H | 1 |
| Arao, T; Fukuoka, M; Hatashita, E; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Okamoto, W; Takezawa, K; Yamada, Y; Yanagihara, K; Yoshida, T | 1 |
| Duesberg, P; Fabarius, A; Giehl, M; Haferlach, C; Hochhaus, A; Hofheinz, R; Hofmann, WK; Leitner, A; Seifarth, W | 1 |
| Ekblom, M; Juvonen, V; Kairisto, V; Kreutzman, A; Mustjoki, S; Porkka, K; Seggewiss, R; Stenke, L | 1 |
| Beyer, C; Distler, JH; Distler, O | 1 |
| Ambudkar, SV; Bates, SE; Brendel, C; Deeken, JF; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Volkmann, T | 1 |
| Hatzis, C; Hess, KR; Hortobagyi, GN; Huang, F; Liedtke, C; Lin, F; Moulder, S; Pusztai, L; Symmans, WF; Yan, K | 1 |
| Schiffer, CA; Zonder, JA | 1 |
| Alvarado, Y; Cortes, J; Giles, FJ; Swords, R | 1 |
| Brezinova, J; Cetkovsky, P; Cmunt, E; Dvorakova, D; Faber, E; Indrak, K; Jarosova, M; Klamova, H; Machova-Polakova, K; Markova, M; Mayer, J; Michalova, K; Moravcova, J; Novakova, L; Oltova, A; Voglova, J; Zackova, D | 1 |
| Ballestrero, A; Cagnetta, A; Cea, M; Cirmena, G; Colombo, N; Fugazza, G; Garuti, A; Gobbi, M; Grasso, R; Moran, E; Nencioni, A; Palermo, C; Patrone, F; Rocco, I | 1 |
| Bennett, KL; Breitwieser, F; Colinge, J; Hartler, J; Remsing Rix, L; Rix, U; Superti-Furga, G; Thallinger, GG; Trajanoski, Z; Ubaida Mohien, C; Winter, GE | 1 |
| Borthakur, G; Burger, J; Champlin, R; Cortes, J; Dara, S; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Garris, R; Jones, D; Jorgensen, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Billström, R; Ekblom, M; Fioretos, T; Larsson, N; Lassen, C; Lilljebjörn, H; Richter, J | 1 |
| Bazarbachi, A; Mahfouz, RA; Otrock, ZK; Oweini, H | 1 |
| Banerjee, S; Kanwar, SS; Majumdar, AP; Nautiyal, J; Patel, BB; Sarkar, FH; Yu, Y | 1 |
| Hjorth-Hansen, H; Jönsson, S; Olsson, B; Standal, T; Sundan, A; Wadenvik, H | 1 |
| Lasho, T; Pardanani, A; Tefferi, A | 1 |
| Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D | 1 |
| Albano, F; Anelli, L; Casieri, P; Coccaro, N; Liso, V; Rocchi, M; Rossi, AR; Specchia, G; Vicari, L; Zagaria, A | 1 |
| Baccarani, M; Saglio, G | 1 |
| Aboukameel, A; Das, JK; Du, J; Kanwar, SS; Majumdar, AP; Mohammad, RM; Nautiyal, J; Patel, BB; Rishi, AK; Sarkar, FH; Yu, Y | 1 |
| Abruzzese, E; Baccarani, M; Bhatia, R; Bosly, A; Cortes, J; Dünzinger, U; Facon, T; Fischer, T; Gallagher, NJ; Giles, FJ; Goldberg, S; Jagasia, M; Kam, GL; Kantarjian, HM; Kim, DW; Larson, RA; Mahon, FX; Marin, D; Mendrek, W; Mueller, MC; Rosti, G; Shou, Y | 1 |
| Sawyers, CL | 1 |
| Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C | 1 |
| Deininger, MW; Traer, E | 1 |
| Cortés, JE; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Cortes, J; Fava, C; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Santos, FP; Shan, J; Thomas, D; Wierda, W | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 2 |
| Bradley-Garelik, MB; Cortes, J; Dombret, H; Erben, P; Goh, YT; Hochhaus, A; Maloisel, F; Masszi, T; Paquette, R; Pasquini, R; Saglio, G; Zhu, C | 1 |
| Body, JJ; Ghanem, G; Id Boufker, H; Journé, F; Lagneaux, L; Najar, M; Piccart, M | 1 |
| Gleixner, KV; Hadzijusufovic, E; Mirkina, I; Peter, B; Pickl, WF; Schuch, K; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Aloyz, R; Amrein, L; Johnston, JB; Soulières, D | 1 |
| Aulitzky, WE; Friedel, G; Haubeiss, S; Mürdter, TE; Schmid, JO; Sonnenberg, M; van der Kuip, H | 1 |
| Graves, LM; Lawrence, DS; Martin, TD; Toutchkine, A; Wang, Q; Zimmerman, EI | 1 |
| Alvarez-Calderon, F; Degregori, J; Druker, BJ; Eide, CA; Gregory, MA; Neviani, P; O'Hare, T; Perrotti, D; Phang, TL; Williams, RT; Zaberezhnyy, V | 1 |
| Ghatnekar, O; Hjalte, F; Taylor, M | 1 |
| Bast, RC; Carter, BZ; Le, XF; Lu, Z; Mao, W | 1 |
| Ames, MB; Fenske, TS; Kroll, T; Pruett, JA | 1 |
| Fielding, AK | 1 |
| Barbany, G; Engdahl, I; Hermansson, M; Höglund, M; Lundán, T; Ohm, AC; Olsson-Strömberg, U; Porkka, K; Simonsson, B | 1 |
| Mustjoki, S; Porkka, K; Rohon, P | 1 |
| Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Dunn, EF; Iida, M; Li, C; Wheeler, DL | 1 |
| Chabane, K; Cony-Makhoul, P; Hayette, S; Magaud, JP; Maguer-Satta, V; Michallat, E; Michallet, M; Nicolini, FE; Salesse, S | 1 |
| Pitini, VV | 1 |
| Brown, MP; Diener, KR; Fraser, CK; Guerin, LR; Hayball, JD; Hughes, TP; Lousberg, EL | 1 |
| Joseph, A; Kingham, BF; Martin, SE; Sausen, M | 1 |
| Merchant, NB; Nagaraj, NS; Revetta, F; Smith, JJ; Washington, MK | 1 |
| Smith, BD; Stein, B | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Coindre, JM; Debiec-Rychter, M; Dewaele, B; Finalet-Ferreiro, J; Fletcher, CD; Floris, G; Guillou, L; Hogendoorn, PC; Marynen, P; Schöffski, P; Sciot, R; Vandenberghe, P; Vanspauwen, V; Wozniak, A | 1 |
| Del Fabro, V; Di Raimondo, F; Fidilio, A; Massimino, M; Messina, A; Spina, P; Stagno, F; Vigneri, P | 1 |
| Aldred, VL; Bendit, I; Cavalcante, M; de Paula, HM; Dorlhiac-Llacer, PE; Nardinelli, L; Seguro, F; Serpa, M; Steinbaum, D; Xavier, F | 1 |
| Alimena, G; Breccia, M | 6 |
| Chen, Y | 1 |
| Antonescu, CR; Besmer, P; Clarkson, B; de Stanchina, E; Giancotti, FG; Manova, K; Rossi, F; Veach, D; Yozgat, Y | 1 |
| Dawood, BB; Makris, M; Mumford, A; Nash, CA; Senis, YA; Séverin, S; Watson, SP; Wilde, J | 1 |
| Kron, SJ; Sylvester, JE; Veach, DR; Wu, D; Zhou, G | 1 |
| Buclin, T; Decosterd, LA; Duchosal, MA; Haouala, A; Montemurro, M; Widmer, N | 1 |
| Montero, JC; Ocaña, A; Pandiella, A; Seoane, S | 2 |
| Becker, H; Chevalier, N; Gärtner, F; Hübner, J; Lübbert, M; Maul-Pavicic, A; Pantic, M; Schmitt-Gräff, A; Solari, ML; Wäsch, R | 1 |
| Birge, RB; Matsuda, M; Tunceroglu, A | 1 |
| Ashizawa, M; Ishida, Y; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Yamazaki, R | 1 |
| Hibi, T; Iwao, Y; Kato, J; Mori, T; Okamoto, S; Ono, Y; Yajima, T; Yamane, A | 1 |
| Adrián, FJ; Bursulaya, B; Che, J; Choi, Y; Cowan-Jacob, SW; Deng, X; Ding, Q; Gray, NS; Okram, B; Rummel, G; Sim, T; Wojciechowski, A; Zhang, G; Zhang, J | 1 |
| Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Ibrahim, AR; Khorashad, JS; Marin, D; Milojkovic, D; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Bekele, BN; Blumenschein, GR; Erasmus, JJ; Feng, L; Hwang, LL; Johnson, FM; Lippman, SM; Stewart, DJ; Takebe, N; Tang, XM; Tran, HT; Wistuba, I | 1 |
| Apperley, JF; Clark, RE; Daghistani, M; De Melo, VA; Foroni, L; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Paliompeis, C; Reid, AG; Wang, L | 1 |
| Asada, T; Fujimori, Y; Fujita, K; Ikegame, K; Ogawa, H; Okada, M; Satake, A; Tamaki, H | 1 |
| Deininger, M; Hochhaus, A; Jabbour, E | 1 |
| Bovée, JV; Bruijn, IH; Hogendoorn, PC; Schrage, YM; Szuhai, K; Willems, SM | 1 |
| Shayani, S | 1 |
| Breccia, M | 1 |
| Schiffer, CA; Valent, JN | 1 |
| Cortes, J; Mauro, MJ; Pinilla-Ibarz, J | 1 |
| Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J | 1 |
| Aul, C; Erlemann, R; Giagounidis, A; Haase, S; Heinsch, M; Radkowski, R; Russwurm, G | 1 |
| Hassan, AQ; Sharma, SV; Warmuth, M | 1 |
| Herndlhofer, S; Krauth, MT; Mitterbauer-Hohendanner, G; Schlögl, E; Schmook, MT; Valent, P | 1 |
| Alimena, G; Breccia, M; Capria, S; Foà, R; Iori, AP; Meloni, G | 1 |
| Egleston, BL; Golemis, EA; Izumchenko, E; Klein-Szanto, AJ; Singh, MK; Wolfson, M | 1 |
| Gong, Y; Liu, T; Meng, W; Xing, H | 1 |
| Hallek, M; Krause, G | 1 |
| Ahluwalia, MS; de Groot, J; Gladson, CL; Liu, WM | 1 |
| Bencivenga, D; Borriello, A; Caldarelli, I; Cucciolla, V; Danise, P; Della Ragione, F; Oliva, A; Perrotta, S; Ronzoni, L; Usala, E | 1 |
| Bosco, R; Capitani, S; Celeghini, C; Corallini, F; Rabusin, M; Secchiero, P; Voltan, R | 1 |
| Bongarzone, I; Caccia, D; Casalini, P; Cassinelli, G; Miccichè, F; Mondellini, P | 1 |
| Armstrong, EA; Campbell, DA; Dunn, EF; Hintz, KA; Iida, M; Li, C; Myers, RA; Wheeler, DL | 1 |
| Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Sonoo, H; Watanabe, M | 1 |
| Hori, A; Tanimoto, T; Tsubokura, M | 1 |
| Akard, LP | 1 |
| Porkka, K; Richter, J; Simonsson, B | 1 |
| Beyazit, Y; Haznedaroglu, IC; Kekilli, M | 1 |
| Dempke, W; Zippel, R | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Wierda, W | 1 |
| Bollu, VK; Griffin, JD; Guerin, A; Guo, A; Wu, EQ; Yu, AP | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Aota, Y; Gotoh, A; Sakurai, M; Takagi, Y | 1 |
| Camitta, B; Prestidge, T; Schultz, KR | 1 |
| Clackson, T; Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T | 1 |
| Etienne, G; Huguet, F | 1 |
| Johnson, FM; Peng, S; Saigal, B; Sen, B; Williams, MD | 1 |
| Bosco, R; Cuneo, A; Marmiroli, S; Melloni, E; Rigolin, GM; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Liu, D; Rafiyath, S; Wei, G | 1 |
| Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; Leitner, A; Lorentz, C; Müller, MC; Schenk, T; Schwindel, U | 1 |
| Babic, I; Cai, H; Huang, J; Wei, X; Witte, ON | 1 |
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Shah, R; Wang, L | 1 |
| Beroukhim, R; Ciampa, AS; Doherty, LM; Drappatz, J; Lafrankie, DC; Lu-Emerson, C; Norden, AD; Quant, EC; Ruland, S; Wen, PY | 1 |
| Barbaric, D; Bhadri, VA; Satharasinghe, K; Sugo, E; Trahair, TN | 1 |
| Cortés, JE; Holyoake, T; Kantarjian, H; Ranganathan, A; Saglio, G | 1 |
| Han, K; Kim, M; Kim, Y; Lee, SA; Lim, J | 1 |
| Dunphy, MP; Larson, S; Lewis, J; Pillarsetty, N; Somwar, R; Veach, D; Zanzonico, P | 1 |
| Chakravarty, D; Challa, R; Cortez, V; Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S | 1 |
| Hamšíková, E; Humlová, Z; Janatková, I; Klamová, H; Králíková, P; Malíčková, K; Roth, Z; Sterzl, I; Vonka, V | 1 |
| Kruser, TJ; Traynor, AM; Wheeler, DL | 1 |
| Adams, DJ; Ayeni, TA; Barry, WT; Berchuck, A; Grace, L; Murphy, SK; Rubatt, JM; Secord, AA; Starr, MD; Teoh, D | 1 |
| Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I | 1 |
| Badu-Nkansah, K; Hynes, RO; Liu, H; Ong, SE; Schindler, J; White, FM | 1 |
| Cross, NC; Ernst, T; Hochhaus, A; La Rosée, P; Müller, MC | 1 |
| Gnoni, A; Lorusso, V; Marech, I; Silvestris, N; Vacca, A | 1 |
| Clynes, M; Crown, J; Doolan, P; Dowling, P; Eustace, AJ; Henry, M; Meleady, P; O'Donovan, N | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Okimoto, RA; Van Etten, RA | 1 |
| Burchert, A; Neubauer, A | 1 |
| Adamson, PC; Agrawal, S; Aplenc, R; Balis, FM; Blaney, SM; Ingle, AM; Shusterman, S; Strauss, LC; Sun, J; Wright, JJ | 1 |
| Boulos, N; Calabrese, CR; Morrison, JB; Mulder, HL; Rehg, JE; Relling, MV; Sherr, CJ; Williams, RT | 1 |
| Engen, JR; Gray, NS; Iacob, RE; Zhang, J | 1 |
| Anderson, KI; Brunton, VG; Carragher, NO; Doyle, B; Edward, M; Frame, MC; Karim, SA; McGhee, EJ; Morton, JP; Olson, MF; Quinn, JA; Sansom, OJ; Schwarz, JP; Timpson, P; von Kriegsheim, A | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Baker, AM; Bird, D; Cox, TR; Erler, JT; Lang, G; Murray, GI; Southall, SM; Sun, XF; Wilson, JR | 1 |
| Gough, W; Hulkower, KI; Lee, JA; Lynch, R; McGlynn, P; Uhlik, M; Yan, L | 1 |
| Chen, Y; Li, D; Li, S; Peng, C | 1 |
| Hobernicht, SL; Hunger, SP; Schweiger, B; Wang, M; Zeitler, P | 1 |
| Baccarani, M; Cortes, JE; Jabbour, E; Kantarjian, HM; Saglio, G | 1 |
| Aziz, SA; Camp, RL; Chakraborty, A; Davies, MA; Dudek, A; Jilaveanu, LB; Kluger, HM; Rimm, DL; Sznol, M; Zito, CR | 1 |
| Quintás-Cardama, A; Santos, FP | 1 |
| Bouvresse, S; Clérici, T; de Masson, A; Mahé, E; Saïag, P | 1 |
| Cosimo, E; Leach, MT; McCaig, AM; Michie, AM | 2 |
| Collins, DM; Corkery, B; Crown, J; Duffy, MJ; Evoy, D; Flanagan, L; McDermott, EW; O'Donovan, N; Pierce, A; Quinn, C; Tryfonopoulos, D; Walsh, S | 1 |
| Harnicar, S | 1 |
| Aydin, Y; Eskazan, AE; Ferhanoglu, B; Gulturk, E; Ongoren, S; Soysal, T | 1 |
| Branford, S; Prime, J | 1 |
| Ghevaert, C; Massberg, S; Mazharian, A; Watson, SP; Zhang, L | 1 |
| Amrein, PC; Armand, P; Attar, EC; Ballen, KK; Brown, JR; Fisher, DC; Hasserjian, RP; Hochberg, EP; Jacobsen, ED; Lacasce, AS; Leahy, KM; Neuberg, D; Takvorian, T; Werner, L | 1 |
| Abbruzzi, A; Bromberg, J; Chang, J; D'Andrea, G; Dang, C; Dickler, M; Fornier, MN; Gilewski, T; Hudis, CA; Modi, S; Morris, PG; Norton, L; Seidman, AD; Sklarin, N | 1 |
| Griffiths, EA; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Maruta, A; Motohashi, K; Numata, A; Sakai, R; Tachibana, T; Tanaka, M; Tomita, N | 1 |
| Jung, CW; Kim, DH; Kim, DY; Kim, HJ; Kim, IH; Kwak, JY; Lee, KH; Lee, SJ; Park, S; Sohn, SK | 1 |
| Pardanani, A | 1 |
| Angiolini, M | 1 |
| Hughes, TP; White, DL | 1 |
| Gaultney, JG; Janssen, JJ; Redekop, WK; Sanhueza, E; Uyl-de Groot, CA | 1 |
| Silver, RT | 1 |
| Breccia, M; Isidori, A; Montefusco, E; Morra, E; Santini, V; Visani, G | 1 |
| Avcu, F; Baran, Y; Gencer, EB; Ural, AU | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Federico, V; Loglisci, G; Loglisci, MG; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Amrein, PC | 1 |
| Bueso-Ramos, C; Chen, SS; Cortes, JE; Esmaeli, B; Katz, RL; Khanna, A; Manning, JT; Miranda, RN; Shinder, R; Verstovsek, S; Vigil, CE; Wang, SA; You, MJ | 1 |
| Craddock, C; Novitzky-Basso, I | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Oyekunle, AA; Rosti, G; Soverini, S | 1 |
| Drummond, M; Gallipoli, P; Holyoake, T; Irvine, D; Shepherd, P | 1 |
| Eadens, M; Messersmith, W; Puls, LN | 1 |
| Bekele, BN; Brooks, HD; Culotta, KS; El-Naggar, A; Ginsberg, LE; Glisson, BS; Johnson, FM; Papadimitrakopoulou, VA; Takebe, N; Tran, HT; Wright, J | 1 |
| Dudek, AZ; Jilaveanu, LB; Kluger, HM; McCann, C; Molinaro, A; Ritacco, J; Southard, N; Sznol, M | 1 |
| Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Shan, J; Verstovsek, S | 1 |
| Betts, KA; Bollu, VK; DeAngelo, DJ; Guo, A; Kantor, E; Parikh, K; Signorovitch, JE; Wei, LJ; Williams, D; Wu, EQ | 1 |
| Harbord, N | 1 |
| Castro, MJ; Jessurun, J; Pambuccian, SE | 1 |
| Carducci, MA; Culine, S; Fizazi, K; Gross, ME; Hudes, G; Massard, C; Paliwal, P; Posadas, EM; Sternberg, CN; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Dror, RO; Eastwood, MP; Kim, ET; Seeliger, MA; Shan, Y; Shaw, DE | 1 |
| Bollong, M; Bouchez, LC; Brinker, A; Charette, BD; Cho, CY; Foreman, RK; Gao, Q; Garcia, M; Jaenisch, R; Janes, J; Lairson, LL; Lyssiotis, CA; Medeiro, LA; Schultz, PG; Staerk, J; Supekova, L; Zhu, S | 1 |
| Miura, M; Sawada, K; Takahashi, N | 1 |
| Amir, el-AD; Balderas, RS; Bendall, SC; Bruggner, RV; Finck, R; Krutzik, PO; Melamed, R; Nolan, GP; Ornatsky, OI; Pe'er, D; Plevritis, SK; Qiu, P; Sachs, K; Simonds, EF; Tanner, SD; Trejo, A | 1 |
| Kindler, HL; Knost, JA; Modi, S; Polite, BN; Sharma, MR; Sleckman, BG; Stadler, WM; Taber, D; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
| Ravandi, F | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K | 1 |
| Liang, R; Rubin, BP; Schadendorf, D; Wallace, AR | 1 |
| Geoerger, B; Leblond, P | 1 |
| Bensdorf, K; Cai, X; Cao, P; Gust, R; Huang, W; Li, Z; Liu, W; Qi, F; Qian, H; Wellner, A; Zhang, H; Zhou, J | 1 |
| Baumann, HJ; Bokemeyer, C; Brümmendorf, TH; Hennigs, JK; Honecker, F; Keller, G; Klose, H; Kluge, S | 1 |
| Ardissone, F; Billè, A; Ceppi, P; Giorcelli, J; Lo Iacono, M; Papotti, M; Pautasso, M; Rapa, I; Righi, L; Scagliotti, GV | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S | 1 |
| Al-Lazikani, B; Alumkal, JJ; Atkins, KM; Beer, TM; Brewer, D; Cassidy, AM; De-Bono, J; Gao, L; Geng, H; Gore, ME; Graf, M; Huang, P; Kaye, SB; Larkin, J; Moch, H; Nelson, P; Qian, DZ; Sawyers, CL; Schraml, P; Suwaki, N; Swabey, K; Thomas, G; Thomas, GV; Vanhecke, E; Workman, P | 1 |
| Akin, C; DeRemer, DL; Ustun, C | 1 |
| Bareford, MD; Cruickshanks, N; Dai, Y; Dent, P; Grant, S; Hamed, HA; Hubbard, N; Mitchell, C; Tang, Y; Tye, G; Yacoub, A | 1 |
| Ichikawa, K; Komatsu, N; Sato, E; Sunami, Y; Yasuda, H | 1 |
| Einsele, H; Ekblom, M; Gostick, E; Koechel, C; Kreutzman, A; Ladell, K; Melo, T; Mustjoki, S; Porkka, K; Price, DA; Seggewiss, R; Stenke, L | 1 |
| Bane, F; Byrne, C; deBlacam, C; Hill, AD; Hughes, E; McIlroy, M; Young, LS | 1 |
| Cortes, J; Kantarjian, H; Mathisen, MS; O'Brien, S; Ravandi, F; Thomas, D | 1 |
| Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rodrigues, AS; Rueff, J; Tavares, P | 1 |
| Andrich, K; Dalhoff, C; Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Michaelis, S; Schrey, AK; Sefkow, M | 1 |
| Cortes, J; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Hiwase, DK; White, DL; Yeung, DT | 1 |
| Guo, L; He, L; Li, J; Xu, G; Yu, S | 1 |
| Bennett, KL; Cerny-Reiterer, S; Gleixner, KV; Gotlib, J; Hadzijusufovic, E; Hörmann, G; Horny, HP; Mayerhofer, M; Meyer, RA; Mitterbauer-Hohendanner, G; Pickl, WF; Reiter, A; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Pane, F; Pregno, P; Rege-Cambrin, G; Rosti, G; Russo Rossi, A; Santini, V; Sica, S; Specchia, G; Stagno, F; Vigneri, P | 1 |
| Abdool, A; Bruey, JM; Yeh, CH | 1 |
| Aban, A; Brown, H; Gray, NS; Herring, C; Jagannathan, S; Kozarich, JW; Lee, JD; Nomanbhoy, TK; Nordin, B; Okerberg, E; Patricelli, MP; Weissig, H; Wu, J; Yang, Q; Zhang, J; Zhou, D | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Binotto, G; Breccia, M; Castagnetti, F; Cavazzini, F; Crisà, E; Fava, C; Feo, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Occhini, U; Pregno, P; Rossi, AR; Rosti, G; Santini, V; Sorà, F; Stagno, F; Tiribelli, M; Ulisciani, S; Vigneri, P | 1 |
| Radich, JP | 1 |
| Hughes, TP; Moore, S; Parker, WT; Prime, JA; Schafranek, L; Tang, C; Watkins, DB; White, DL | 1 |
| Dumitrescu, D; Erdmann, E; Gerhardt, F; Rosenkranz, S; Seck, C; ten Freyhaus, H | 1 |
| Colado, E; de Queiroz Crusoe, E; Delgado, M; Fernandez-Lazaro, D; Garayoa, M; Garcia-Gomez, A; Gutierrez, NC; Lee, FY; Maiso, P; Martin-Sanchez, J; Ocio, EM; San-Segundo, L | 1 |
| Armaiz-Pena, GN; Bottsford-Miller, JN; Enomoto, T; Frumovitz, M; Gallick, GE; Huang, J; Im, DD; Kimura, T; Komurov, K; Lu, C; Matsuo, K; Nagano, T; Nishimura, M; Ram, PT; Roh, JW; Rosenshien, NB; Sakakibara, A; Sanguino, AM; Schmeler, KM; Shahzad, MM; Sood, AK; Stone, RL; Wong, KK; Yamasaki, M | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Bongarzone, I; Caccia, D; Carniti, C; De Bortoli, M; Miccichè, F; Mondellini, P; Zanetti Domingues, L | 1 |
| Fan, X; Guo, B; Guo, W; Jiang, Y; Li, K; Liang, S; Qin, S; Wang, L; Wang, R; Zhao, Y | 1 |
| Flomenberg, N; Goldberg, AF; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pavlides, S; Pestell, RG; Sotgia, F; Wang, C | 1 |
| Hatake, K; Ito, Y; Miyazaki, M; Nakagawa, K; Okamoto, I; Seriu, T; Takahashi, S; Ueda, K | 1 |
| Smith, BD; Stein, BL | 1 |
| Beeharry, N; Connolly, DC; Godwin, AK; Golemis, EA; Li, T; Litwin, S; Pathak, HB; Ratushny, V; Tikhmyanova, N; Weiner, LM; Xiao, F; Yen, TJ | 1 |
| Ikegame, K; Kaida, K; Kato, R; Nakata, J; Ogawa, H; Okada, M; Satake, A; Tamaki, H; Yoshihara, S | 1 |
| Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Bacus, S; Blackwell, KL; Chadaram, V; Favaro, J; Hamilton, E; Herold, CI; Hopkins, J; Kimmick, GG; Marcom, PK; Peterson, BL; Welch, RA | 1 |
| Ahmed, AA; Bast, RC; Claret, FX; He, G; Hung, MC; Le, XF; Mao, W; Siddik, ZH; Xia, W | 1 |
| Demarquet, M; Labussière-Wallet, H; Nicolas-Virelizier, E; Nicolini, FE | 1 |
| Engh, RA; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Porkka, K | 1 |
| Harada, H; Harada, Y; Imagawa, J; Kimura, A; Matsumoto, K; Morita, K; Tarutani, M; Yoshida, T | 1 |
| Brunton, VG; Canel, M; Frame, MC; Graham, K; Kinnaird, A; McLeod, K; Serrels, A | 1 |
| Bartley, PA; Goyne, J; Grigg, AP; Morley, AA; Ross, DM; Seymour, JF | 1 |
| Alimena, G; Breccia, M; Cannella, L; Colafigli, G; De Cuia, MR; Loglisci, G; Nanni, M; Salaroli, A; Serrao, A | 1 |
| Arshad Siddiqui, M; Belanger, DB; Bracken, JB; Curran, PJ; Malkowski, M; Miao, H; Shipps, GW; Wang, Y; Zeng, H | 1 |
| Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X | 1 |
| Brossart, P; Grünebach, F; Gutknecht, M; Rittig, SM; Salih, HR; Salih, J; Schwarzbich, MA | 1 |
| Guilhot, F; Roy, L; Tomowiak, C | 1 |
| Akhavan, D; Cavenee, WK; Cvrljevic, AN; Furnari, FB; Guo, D; Hoogenraad, NJ; Johns, TG; Johnston, AJ; Martinello, P; Mischel, PS; Pike, L; Scott, AM; Wu, M | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Agrawal, S; Appleman, LJ; Argiris, A; Egloff, AM; Feinstein, TM; Grandis, JR; Stoller, RG; Wang, L; Yang, T | 1 |
| Ahmed, N; Burke, J; Chang, CY; Gao, M; Muckelbauer, J; Sack, JS; Tebben, AJ; Tino, J; Xie, D | 1 |
| Bagadi, S; Das, B; Pany, A; Saikia, T | 1 |
| Ghio, S; Orlandi, EM; Pazzano, AS; Rocca, B | 1 |
| Cho, BS; Goh, HG; Kim, D; Kim, DW; Kim, SH | 1 |
| Keam, SJ; McCormack, PL | 1 |
| Awada, A; Baurain, JF; Campone, M; Fumoleau, P; Llombart-Cussac, A; Mayer, EL; Rugo, H; Sparano, J; Strauss, L; Sy, O | 1 |
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Baccarani, M; Candoni, A; Castagnola, C; Cimino, G; De Propris, MS; Elia, L; Fazi, P; Ferrara, F; Foà, R; Fozza, C; Guarini, A; Iacobucci, I; Leoni, P; Luppi, M; Mandelli, F; Martinelli, G; Meloni, G; Nobile, F; Paoloni, F; Sica, S; Soverini, S; Vignetti, M; Vitale, A; Zuffa, E | 1 |
| Cowell, JK; Qin, H; Ren, M; Ren, R; Tidwell, J | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
| Matsumura, I | 2 |
| Garcia, C; Gratacap, MP; Lhermusier, T; Payrastre, B; Van Rothem, J | 1 |
| Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC | 1 |
| Agrawal, S; Furlong, MT; Hawthorne, D; Krueger, L; Lago, M; Stouffer, B; Unger, S | 1 |
| Branford, S; Ho, M; Hughes, TP; Irwin, DL; Lawrence, RM; Parker, WT; Scott, HS | 1 |
| Chang, VY; Eckardt, MA; Federman, N; Rao, NP | 1 |
| Bengala, C; Fairchild, J; Finn, RS; Goldstein, LJ; Ibrahim, N; Roché, H; Sparano, J; Strauss, LC; Sy, O | 1 |
| Cornelison, AM; Jabbour, E; Koller, C; Welch, MA | 1 |
| Ariaudo, A; Baietto, L; Cusato, J; D'Avolio, A; De Francia, S; Di Carlo, F; Di Perri, G; Fava, C; Saglio, G; Simiele, M | 1 |
| Celie, PH; de Esch, IJ; Farenc, C; Siegal, G; Tensen, CP | 1 |
| Chang, BH; Druker, BJ; Glover, JM; Loriaux, M; Tyner, JW | 1 |
| Gridling, M; Rix, U; Superti-Furga, G | 1 |
| Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O | 1 |
| Krusch, M; Salih, HR | 1 |
| Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T | 1 |
| Bendit, I; de Barros Ferreira, P; Dorlhiac-Llacer, PE; Martins, TF; Nardinelli, L; Sanabani, SS; Seguro, F; Serpa, M | 1 |
| Cianchetti, M; Forastiere, A; Gunn, GB; Marur, S; McNutt, T; Rao, N; Ricchetti, F; Sanguineti, G; Sormani, MP; Wu, B | 1 |
| Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H | 1 |
| Chen, XQ; Li, G; Zhao, YN; Zhu, K | 1 |
| Algazi, AP; Andrews, SC; Daud, AI; DeConti, RC; Hwang, J; McCalmont, T; Messina, JL; Munster, PN; Sondak, VK; Urbas, P; Weber, JS | 1 |
| Beaumont, T; Breij, EC; Eldering, E; Elias, JA; Geest, CR; Kater, AP; Luijks, DM; Tromp, JM; van Laar, J; van Oers, MH | 1 |
| Lepler, S; Pampo, C; Rice, L; Siemann, DW | 1 |
| Combs, CK; Dhawan, G; Floden, AM | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Harrington, KJ; Marshall, CJ; Muller, WJ; Sourisseau, T; White, DE | 1 |
| Miura, M; Niioka, T; Sawada, K; Takahashi, N | 1 |
| Kalaycio, M; Tiu, R | 1 |
| Reed, SD | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K | 1 |
| Agarwal, MB; Baccarani, M; Bradley-Garelik, MB; Cortes, JE; Hochhaus, A; Ipiña, JJ; Junghanss, C; Kantarjian, HM; Kim, DW; Milone, JH; Nicolini, FE; Ogura, M; Pavlovsky, C; Robak, T; Shah, NP; Undurraga, MS; Van Droogenbroeck, J; Vellenga, E; Wang, J; Zhu, C | 1 |
| Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N | 1 |
| Basile, MA; Bencivenga, D; Borriello, A; Caldarelli, I; Della Ragione, F; Oliva, A; Perrotta, S; Tramontano, A | 1 |
| Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU | 1 |
| Aoki, J; Hirashima, Y; Kakihana, K; Kobayashi, T; Ohashi, K; Sakamaki, H | 1 |
| Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Asa, SL; Ezzat, S; Mayr, T; Tateno, T; Ullrich, A; Zheng, L | 1 |
| Congleton, J; MacDonald, R; Yen, A | 1 |
| Balci, TB; Karakus, S; Ozdogu, H; Sahin, FI | 1 |
| Allan, EK; Bhatia, R; Brunton, VG; Hamilton, A; Helgason, GV; Holyoake, TL; Koschmieder, S; Müller-Tidow, C; Myssina, S; Nicolini, FE; Schemionek, M; Zhang, B | 1 |
| Alessandro, R; De Leo, G; Flugy, A; Garfield, SH; Kohn, EC; Mineo, M; Taverna, S | 1 |
| Agarwal, N; Sonpavde, G; Sternberg, CN | 1 |
| Branford, S; Ho, M; Hughes, TP; Parker, WT; Scott, HS | 1 |
| Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Katayama, T; Koh, H; Nakamae, H; Nakamae, M; Nakane, T; Nakao, Y; Terada, Y | 1 |
| Cai, J; Chen, J; Ji, M; Wu, X; Zhang, S; Zheng, M | 1 |
| Beltrami, G; Carella, A; Carella, AM; Catania, G; Pica, G | 1 |
| Anur, P; Bagby, GC; Cappelli, E; Dufour, C; Garbati, MR; Hays, LE; Keeble, W; Rathbun, K; Svahn, J; Tyner, JW; Vanderwerf, S; Yates, J | 1 |
| Arras, M; Atzeni, S; Caocci, G; Greco, M; La Nasa, G; Ledda, A; Littera, R; Murgia, F; Piras, E; Vacca, A | 1 |
| Chen, GY; Shi, H; Yao, SQ; Zhang, CJ | 1 |
| Erba, HP; Pham, DC; Tai, S; Vu, H; Zaiden, R | 1 |
| Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J | 1 |
| Coluccia, AM; De Leo, S; de Luca, E; De Matteis, S; Di Renzo, N; Dini, L; Maffia, M; Palamà, I; Passerini, CG; Reddiconto, G; Toto, C | 1 |
| Ahmed, SI; Al-akhrass, F; Rallapalli, V; Rodriguez, GH; Safdar, A | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W | 1 |
| Dreosti, L; Jogessar, V; Louw, VJ; Moodley, D; Novitzky, N; Patel, M; Ruff, P; Schmidt, A; Willem, P | 1 |
| Abbott, BL | 1 |
| Corey, SJ; Park, BJ; Whichard, ZL | 1 |
| Barbaccia, V; Borroni, G; Brazzelli, V; Giorgiani, G; Grasso, V; Manna, G; Rivetti, N; Vassallo, C; Zecca, M | 1 |
| Celeghini, C; Melloni, E; Norcio, A; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Auewarakul, CU; Thongnoppakhun, W; Wongboonma, W | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Cooper, JM; Copland, M; Faley, S; Reboud, J | 1 |
| Cao, B; Chen, G; Chu, A; Han, K; Ling, C; Mao, X; Yin, J; Zhang, Z; Zhao, Y | 1 |
| Baccarani, M; Besson, N; Brümmendorf, TH; Cortes, JE; Countouriotis, A; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Zaritskey, A | 1 |
| Fukushima, N; Ichinohe, T; Kimura, S | 1 |
| Herbolsheimer, P; Jelinek, J; Kapoor, R; Perry, D; Smith, KL; Swain, SM; Verma, N; Veytsman, I | 1 |
| Kim, HS; Kwak, JY; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Goulden, S; Stevens, A; Sutcliffe, F | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Futosi, K; Mócsai, A; Németh, T; Pick, R; Vántus, T; Walzog, B | 1 |
| Einsele, H; Hassold, N; Kempf, K; Seggewiss-Bernhardt, R; Seystahl, K; Urlaub, D; Watzl, C; Wischhusen, J; Zekl, M | 1 |
| Andreoli, A; Anselem, O; Berveiller, P; Chapuis, N; Delezoide, AL; Mir, O; Sauvageon, H; Tsatsaris, V | 1 |
| Pfirrmann, M; Saussele, S | 1 |
| Dudek, AZ; Hodgson, L; Kindler, HL; Kratzke, RA; Otterson, GA; Pang, H; Vokes, EE | 1 |
| Caley, MP; Calle, Y; Khatun, H; Macpherson, L; Mufti, GJ; Ramasamy, K; Schey, SA; Sturge, J | 1 |
| Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintas-Cardama, A | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Wise, J | 1 |
| Atallah, E; Haddad, RY; Torgerson, SR | 1 |
| Force, T | 1 |
| Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC | 1 |
| Bronson, R; Christie, AL; Daley, JF; Galinsky, I; Gray, N; Griffin, JD; Hur, W; Kung, AL; Liu, Q; Mitsiades, C; Nelson, E; Sanda, T; Sattler, M; Smith, R; Stone, R; Weisberg, E; Zhao, Z | 1 |
| Bednash, JS; Chiosea, SI; Grandis, JR; Morariu, EM; Otte, CG; Seethala, RR; Wheeler, SE | 1 |
| Boxer, SG; Levinson, NM | 1 |
| Di Raimondo, F; Stagno, F; Vigneri, P | 1 |
| Koskela, H; Koskenvesa, P; Mustjoki, S; Porkka, K | 1 |
| Jootar, S | 1 |
| Berghausen, EM; Brandes, RP; Butrous, E; Butrous, G; Dabral, S; Dahal, BK; Ghofrani, HA; Grimminger, F; Pullamsetti, SS; Rosenkranz, S; Savai, R; Schermuly, RT; Seeger, W; Tretyn, A; Weissmann, N | 1 |
| Blake, SJ; Hughes, TP; Lyons, AB | 1 |
| Cho, NL; Du, J; Ito, H; Lin, CI; Moore, FD; Ruan, DT; Whang, EE | 1 |
| Laufer, TM; Stephen, TL; Wilson, BS | 1 |
| Gai, R; He, Q; Luo, P; Wu, H; Wu, Y; Xue, T; Yang, B; Yang, X; Zhao, Y; Zhu, H | 1 |
| Blanco, JF; Briñón, JG; Crusoe, E; Fisac-Herrero, RM; Garayoa, M; Garcia-Gomez, A; Hernández-Campo, P; Hernández-Iglesias, T; Lee, FY; Ocio, EM; Pandiella, A; San Miguel, JF; Sanchez-Guijo, FM; Santamaria, C | 1 |
| DeSimone, JM; Finniss, M; Gullapalli, A; Luft, JC; Napier, ME; Pandya, A; Parrott, MC | 1 |
| Cheng, Y; Gust, R; Liu, W; Qi, F; Qian, H; Wang, J; Zhang, H; Zheng, Y; Zhou, J | 1 |
| Giles, F; Gjertsen, B; Labar, B; Mahon, FX; Rosti, G; Swords, R; Turkina, A | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Granot, G; Lahav, M; Mor-Tzuntz, R; Raanani, P; Shapira, S; Shpilberg, O; Uziel, O | 1 |
| Blatt, K; Ghanim, V; Herrmann, H; Kneidinger, M; Marth, K; Valent, P; Valenta, R | 1 |
| Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E | 1 |
| Calcabrini, A; Gómez-Domínguez, D; Gómez-López, G; Martín-Forero, E; Martín-Pérez, J; Molinari, A; Morte, B; Sánchez-Bailón, MP; Wagner, KU | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX | 1 |
| Chan, CM; Haugen, BR; Jing, X; Lim, DJ; Lund, GS; Pike, LA; Sams, SB; Schweppe, RE; Sharma, V; Zhou, Q | 1 |
| Miura, M; Niioka, T; Sawada, K; Scott, SA; Takahashi, N | 1 |
| Goto, M; Igarashi, H; Konno, H; Maeda, M; Nagura, K; Nakamura, S; Natsume, H; Shinmura, K; Sugimura, H; Suzuki, M; Tao, H; Yamada, H | 1 |
| Cen, O; Dargart, JL; Fish, K; Gordon, LI; Longnecker, R | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Blencke, S; Godl, K; Kaminski, M; Klammer, M; Marx, S; Müller, S; Oppermann, F; Schaab, C; Tebbe, A; Zedler, A | 1 |
| Zarbock, A | 1 |
| Katagiri, S; Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Apperley, J; Clark, RE; Foroni, L; Goldman, JM; Hedgley, C; Marin, D; Milojkovic, D; O'Brien, S; Pocock, C | 1 |
| Erickson, HS; Galindo, H; Johnson, FM; Mazumdar, T; Peng, S; Sen, B; Stewart, DJ; Tang, X; Wistuba, I | 1 |
| Antonescu, CR; Besmer, P; Bosbach, B; de Stanchina, E; Deshpande, S; Manova-Todorova, K; Moore, MA; Rossi, F; Scandura, JM; Shieh, JH; Sommer, G; Veach, DR | 1 |
| Hughes, TP; Leclercq, TM; Schafranek, L; White, DL | 1 |
| Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA | 1 |
| Combs, CK; Dhawan, G | 1 |
| Kanzaki, S; Kure, A; Okuno, K; Sano, H; Tamoto, N; Ueyama, J | 1 |
| Crombet, O; Lastrapes, K; Morales-Arias, J; Zieske, A | 1 |
| Bear, JE; Castrillon, DH; Chan, KT; Liu, W; Miller, CR; Monahan, KB; Ollila, DW; Perou, CM; Pfefferle, AD; Roadcap, DW; Sharpless, NE; Shimamura, T; Sorrentino, J; Thomas, NE; Wong, KK | 1 |
| Alpaugh, RK; Brady, WE; Fiorica, JV; Godwin, AK; Hu, W; Lankes, HA; Mannel, RS; Pathak, HB; Schilder, RJ; Shahin, MS; Sood, AK; Zhou, XC | 1 |
| Alvarez, S; Blanco, R; Bretones, G; Caraballo, JM; Cigudosa, JC; Delgado, MD; Ferrándiz, N; García-Alegria, E; Gómez-Casares, MT; León, J; López-Jorge, CE; Martín-Perez, J; Sánchez-Bailón, P; Vaqué, JP | 1 |
| Beard, L; Carlin, C; Guo, A; Markowitz, SD; Polakiewicz, RD; Possemato, A; Wang, C; Wang, Z; Zhang, P | 1 |
| Imamura, M; Shigematsu, A; Shiratori, S; Sugita, J; Tanaka, J | 1 |
| Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ | 1 |
| Nakashima, S; Tanaka, H; Usuda, M | 1 |
| Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M | 1 |
| Chen, CC; Chen, KF; Cheng, AL; Chuang, SH; Lin, YC; Wei, TT; Wu, MH | 1 |
| Bayraktar, S; Escalón, MP; Morency, B | 1 |
| Harada, H; Harada, Y; Imagawa, J; Matsumoto, K; Morita, K; Tanaka, H | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Luciano, L; Martino, B; Musto, P; Pregno, P; Rosti, G; Russo Rossi, A; Sgherza, N; Specchia, G; Stagno, F; Tiribelli, M; Visani, G | 1 |
| Alimena, G; Annunziata, M; Breccia, M; Calistri, E; Capodanno, I; Castagnetti, F; Cavazzini, F; Crugnola, M; Fava, C; Ferrero, D; Gozzini, A; Gugliotta, G; Iurlo, A; Latagliata, R; Luciano, L; Musto, P; Stagno, F; Tiribelli, M; Vigneri, P; Visani, G | 1 |
| Fava, C; Rege-Cambrin, G; Saglio, G | 1 |
| Ali, S; Alsuliman, A; Apperley, JF; Clark, RE; Cooper, N; Foroni, L; Gabriel, IH; Gerrard, G; Gilleece, M; Goldman, JM; Hedgley, C; Khoder, A; Marin, D; Milojkovic, D; O'Brien, SG; Rezvani, K; Sergeant, R; Stringaris, K | 1 |
| Barry, WT; Berchuck, A; Broadwater, G; Havrilesky, LJ; Lancaster, J; Lee, PS; Secord, AA; Teoh, DK; Wenham, RM; Yu, M | 1 |
| Cayuela, JM; Ekblom, M; Greco, D; Guerci-Bresler, A; Hjorth-Hansen, H; Jaatinen, T; Kreutzman, A; Lipton, J; Mahon, FX; Melo, T; Mustjoki, S; Paquette, R; Partanen, J; Porkka, K; Richter, J; Rousselot, P; Seggewiss-Bernhardt, R; Stenke, L; Talbot, A; Vakkila, E | 1 |
| Dingermann, T; Marschalek, R; Zündorf, I | 1 |
| Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Kralj, E; Kristl, A; Pajič, T; Trontelj, J | 1 |
| Auberger, P; Aumann, K; Braun, S; Brummer, T; Daly, RJ; Halbach, S; Laßmann, S; Pahl, HL; Penninger, JM; Schramek, D; Schwemmers, S; Waller, CF; Werner, M; Wöhrle, FU; Zeiser, R | 1 |
| Gaston, K; Jayaraman, PS; Noy, P | 1 |
| Bantscheff, M; Becher, I; Doce, C; Savitski, MM; Sweetman, G; Werner, T | 1 |
| Birch, M; Flanagan, RJ; Handley, S; Ho, A; Ireland, R; Morgan, PE | 1 |
| Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL | 1 |
| Agarwal, S; Decker, SA; Donelson, R; Elmquist, WF; Gallardo, JL; Mittapalli, RK; Ohlfest, JR; Pokorny, JL; Santacruz, KS; Sarkaria, JN; Seiler, C; Zellmer, DM | 1 |
| Bahl, A; Gupta, R; Kumar, L; Raina, V; Sharma, A | 1 |
| Appelbaum, FR; Deininger, M; Druker, BJ; Emanuel, P; Kamel-Reid, S; Kopecky, KJ; Larson, RA; Lipton, J; Malnassy, G; Paietta, E; Radich, JP; Stock, W; Tallman, M; Turner, AR; Wadleigh, M | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Hwu, P; Liu, C; Liu, Y; Lizée, G; Overwijk, WW; Peng, W; Woodman, SE; Yang, Y | 1 |
| Azam, M | 1 |
| Jabbour, E; Mathisen, MS; O'Brien, S | 1 |
| Hayashi, H; Katoh, H; Ohnishi, K; Sano, M; Saotome, M; Satoh, H; Urushida, T | 1 |
| Badura, S; Khateb, M; Mahajna, J; Metodieva, A; Mian, AA; Najajreh, Y; Ottmann, OG; Ruimi, N; Ruthardt, M | 1 |
| Cortes, J; Santos, FP | 1 |
| Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O | 1 |
| Ang, KK; Glisson, B; Johnson, FM; Milas, L; Molkentine, DP; Molkentine, JM; Raju, U; Riesterer, O; Wang, ZQ | 1 |
| Jung, SH; Ryu, WS; Sun, X; Yang, BS | 1 |
| Bowles, DW; Green, K; Thienelt, CD | 1 |
| Araki, E; Furukawa, N; Kawaguchi, T; Kikukawa, Y; Ono, K; Shimomura, T; Suzushima, H; Watanabe, Y | 1 |
| Dan, K; Inokuchi, K; Tamai, H; Yamaguchi, H | 1 |
| Alimena, G; Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Zacheo, I | 1 |
| Adachi, H; Huang, Z; Ishigaki, S; Katsumata, R; Katsuno, M; Kawai, K; Sobue, G; Sone, J; Tanaka, F; Urano, F | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Cambrin, GR; Castagnetti, F; Fanin, R; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Pane, F; Pregno, P; Rosti, G; Stagno, F; Tiribelli, M; Vigneri, P | 1 |
| Covell, DG | 1 |
| Cross, M; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Müller, MC; Niederwieser, D; Pfirrmann, M | 1 |
| Hiwase, DK; Hughes, TP; Nievergall, E; Ross, DD; Saunders, VA; White, DL | 1 |
| Gleave, ME; Loriot, Y; Zoubeidi, A | 1 |
| Jabbour, E; Kantarjian, H | 1 |
| Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C | 1 |
| Furukawa, T; Iwabuchi, M; Narita, M; Sato, N; Sone, H; Takahashi, M; Uchiyama, T; Yamahira, A | 1 |
| Fujita, H; Kadowaki, N; Kamihira, S; Kitawaki, T; Maeda, T; Sato, T; Takaori-Kondo, A | 1 |
| Arock, M; Auclair, C; Bougherara, H; Damaj, G; Dubreuil, P; Georgin-Lavialle, S; Hermine, O; Launay, JM; Lhermitte, L; Poul, MA | 1 |
| Hirase, C; Matsumura, I | 1 |
| Anderson, R; Ciani, O; Cooper, C; Crathorne, L; Garside, R; Hoyle, M; Jones-Hughes, T; Osipenko, L; Pavey, T; Rudin, C; Ukoumunne, O; Venkatachalam, M | 1 |
| Khagga, M; Thappali, SR; Vakkalanka, SK; Varanasi, KV; Veeraraghavan, S | 1 |
| Bremner, RM; Fowler, AJ; Inge, LJ; Paquette, KM; Richer, AL; Tran, N | 1 |
| Cortes, J | 1 |
| Dervenoulas, I; Dimitriadis, G; Girkas, K; Karakitsos, P; Kontsioti, F; Kottaridi, C; Mpakou, VE; Papageorgiou, S; Pappa, V; Spathis, A | 1 |
| Bicocca, VT; Chang, BH; Druker, BJ; Loriaux, MM; Masouleh, BK; Muschen, M; Tyner, JW | 1 |
| Choe, JH; Choe, JM; Falchook, GS; Gallick, GE; George, GC; Hong, DS; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, S; Strauss, LC; Wheler, JJ | 1 |
| Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S | 1 |
| Chang, AY; Wang, M | 2 |
| Auvinen, K; Bouchet, S; Hautaniemi, S; Hernesniemi, S; Jalkanen, S; Kreutzman, A; Lahesmaa-Korpinen, AM; Lee, FY; Melo, T; Molimard, M; Mustjoki, S; Porkka, K; Rousselot, P; Salmi, M; Smykla, R; Vakkila, J | 1 |
| Dai, M; Meng, F; Wang, Q; Wei, Y; Xu, N; Yin, C; Zhou, HS | 1 |
| Caux, C; Marabelle, A | 1 |
| Eyrich, M; Langhammer, F; Schlegel, PG; Wiegering, V; Wölfl, M | 1 |
| Marin, D | 2 |
| Auberger, P; Cassuto, JP; Cassuto, O; Dubois, A; Dufies, M; Ginet, C; Hamouda, A; Jacquel, A; Karsenti, JM; Legros, L; Lenain, P; Luciano, F; Puissant, A; Robert, G | 1 |
| Amitay-Laish, I; Berman, E; Busam, KJ; Drucker, AM; Lacouture, ME; Wu, S | 1 |
| Girotti, MR; Gore, M; Hayes, A; Jorgensen, C; Larkin, J; Lorigan, P; Marais, R; Niculescu-Duvaz, D; Pedersen, M; Sanchez-Laorden, B; Sinclair, J; Springer, C; Turajlic, S; Viros, A; Zambon, A | 1 |
| Baxendale, IR; Deadman, BJ; Hopkin, MD; Ley, SV | 1 |
| Connelly, SF; Gomes, EG; Summy, JM | 1 |
| Duong, VH; Jaglal, MV; Kale, V; Komrokji, RS; Lancet, JE; List, AF; Zhang, L | 1 |
| Cushman, I; Hurwitz, HI; Jia, J; Liu, Y; Marshall, DJ; Nixon, AB; Starodub, A | 1 |
| Kamel-Reid, S; Kim, DD; Lee, H; Lipton, JH | 1 |
| Dolgin, E | 1 |
| Aleshin, A; Busuttil, RW; Dering, J; Desai, A; Finn, RS; Ginther, C; Slamon, DJ; von Euw, E; Yang, P; Zhao, D | 1 |
| Carboni, JM; Chatterji, T; Dayyani, F; Gallick, GE; Gottardis, MM; Logothetis, CJ; Maity, SN; Moorthy, S; Parikh, NU; Song, JH; Varkaris, AS; Wolfe, AR | 1 |
| Chen, HC; Hwang, WL; Teng, CL; Yu, JT | 1 |
| Benezra, M; Bradbury, MS; Hambardzumyan, D; Holland, EC; Larson, SM; Longo, V; Ozawa, T; Penate-Medina, O; Phillips, E; Pillarsetty, N; Smith-Jones, P; Veach, DR; Zanzonico, PB | 1 |
| Arnaldez, FI; Asante, A; Grohar, PJ; Helman, LJ; Hewitt, SM; Khan, J; Khanna, C; Ngo, VN; Staudt, LM; Wan, X; Yeung, CL | 1 |
| Bellisola, G; Cinque, G; Gambacorti Passerini, C; Moratti, E; Redaelli, S; Silvestri, G; Sorio, C; Vezzalini, M; Wehbe, K | 1 |
| Apollonio, B; Barbaglio, F; Bertilaccio, MT; Caligaris-Cappio, F; Ghia, P; Ponzoni, M; Scarfò, L; Scielzo, C; Stamatopoulos, K; ten Hacken, E | 1 |
| Barbany, G; Dybedal, I; Ehrencrona, H; Fioretos, T; Gedde-Dahl, T; Gjertsen, BT; Hernesniemi, S; Hjorth-Hansen, H; Hovland, R; Josefsen, D; Koskenvesa, P; Markevärn, B; Mustjoki, S; Olofsson, T; Olsson-Strömberg, U; Porkka, K; Rapakko, K; Richter, J; Simonsson, B; Stenke, L; Thunberg, S | 1 |
| Elmquist, WF; Mittapalli, RK; Sane, R | 1 |
| de Castro, JP; Kaplan, HJ; Liu, L; McDonald, K; Scott, PA; Tamiya, S; Umazume, K | 1 |
| Hu, JD; Huang, XJ; Jin, J; Li, JY; Liu, T; Meng, FY; Shen, ZX; Wang, JM; Wang, JX; Wu, DP | 1 |
| Bonkobara, M; Ito, K; Kobayashi, M; Kuroki, S; Ono, K; Washizu, T | 1 |
| Araujo, JC; Chatterji, T; Dayyani, F; Gallick, GE; Logothetis, CJ; Song, JH; Trudel, GC; Varkaris, A | 1 |
| Simoneau, CA | 1 |
| Cetkovsky, P; Cmunt, E; Dusek, L; Dvorakova, D; Jurcek, T; Klamova, H; Machova Polakova, K; Mayer, J; Muzik, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Bua, M; Clark, R; Gerrard, G; Goldman, J; Lucas, C; Marin, D; May, P; Milojkovic, D; Neelakantan, P; O'Brien, S; Paliompeis, C; Reid, A; Rezvani, K; Wang, L | 1 |
| Jabbour, EJ; Quintás-Cardama, A | 1 |
| Bunda, S; Favre, H; Irwin, MS; Kang, MW; Loh, ML; Ohh, M; Shin, DH; Sybingco, SS; Weng, J | 1 |
| Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT | 1 |
| Bai, WL; Ji, WY; Song, Y; Sun, X | 1 |
| Noronha, S; Sawyer, S | 1 |
| Koutna, I; Mayer, J; Potesil, D; Potesilova, M; Simara, P; Stejskal, S; Tesarova, L; Zdrahal, Z | 1 |
| Kim, DH; Kim, JC; Kim, SH; Kwan, J; Park, KS; Shin, SH; Woo, SI; Yi, HG | 1 |
| Aung, T; Beutler, M; Cameron, S; Chapuy, B; Haase, D; Hupfeld, T; Koch, R; Larosee, P; Schrader, V; Truemper, L; Veltkamp, C; Wulf, GG | 1 |
| Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L | 1 |
| Costantini, A; Lasala, R; Rizzo, RC; Santoleri, F; Sorice, P | 1 |
| Antonescu, CR; Jain, S; Martz, J; Mosquera, JM; Popa, EC; Qin, L; Vahdat, LT | 1 |
| Anastasiadis, PZ; Carlson, BL; Galanis, E; Giannini, C; Huveldt, D; Lewis-Tuffin, LJ; Rodriguez, F; Sarkaria, JN; Schroeder, MA | 1 |
| Gómez Casares, MT; León, LG | 1 |
| Distler, E; Einsele, H; Herr, W; Köchel, C; Nerreter, T; Seggewiss-Bernhardt, R | 1 |
| Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ | 1 |
| Deshmukh, M; Hoshida, Y | 1 |
| Abraham, J; Bracha, S; Davis, LE; Helfand, SC; Hofmann, NE; Huang, ET; Keller, C; Li, G; Loriaux, MM; Mansoor, A; Marley, K; Mata, JE; Séguin, B; Tyner, JW | 1 |
| Broniscer, A; Gajjar, A; Kaste, SC; Kaufman, RA | 1 |
| Baker, JN; Baker, SD; Broniscer, A; Chin, TK; Davidoff, AM; Gajjar, A; Huang, J; Kaste, SC; Merchant, TE; Onar-Thomas, A; Pai Panandiker, AS; Panetta, JC; Stewart, CF; Wetmore, C | 1 |
| Chumley, P; Fatima, H; Jaimes, EA; Lyndon, W; Wallace, E | 1 |
| Raanani, P | 1 |
| Hino, M; Koh, H; Koh, KR; Kosaka, S; Matsumoto, K; Morita, K; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M | 1 |
| Keam, SJ; Keating, GM; Lyseng-Williamson, KA; McCormack, PL | 1 |
| Irvine, E; Williams, C | 1 |
| Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Cai, J; Chen, J; Ji, M; Sun, M; Wang, P; Wu, X; Zong, X | 1 |
| Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M | 1 |
| Büttner, R; Endl, E; Friedrichs, N; Hartmann, W; Heukamp, L; Huss, S; Kawai, A; Kindler, D; Kirfel, J; Larsson, O; Mechtersheimer, G; Michels, S; Penzel, R; Renner, M; Schirmacher, P; Sievers, E; Sonobe, H; Steiner, S; Tanaka, S; Trautmann, M; Wardelmann, E; Wurst, P | 1 |
| Feng, LY; Li, XR; Lin, NM; Pan, JP; Wang, BM; Wang, JB; Zhang, C; Zhang, DY; Zhang, LH; Zhou, SS | 1 |
| Scher, KS; Somlo, G | 1 |
| Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L | 1 |
| Borroni, G; Brazzelli, V; Grasso, V | 1 |
| Carrascosa, R; Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Steegmann, JL | 1 |
| Brunton, VG; Carragher, NO; Creedon, H; Evans, TR; Gusterson, B; Karim, SA; Morton, JP; Muller, WJ; Patel, H; Sansom, OJ | 1 |
| de Wispelaere, M; LaCroix, AJ; Yang, PL | 1 |
| Bell, J; Butt, NM; Clark, RE; De Soysa, L; Francis, S; Kaleel-Rahman, M; Knight, K; Lane, S; Lee, E; Lucas, C; O'Brien, D; Sadik, W; Salim, R; Seale, JR; Wang, L; Watmough, S | 1 |
| Borthakur, G; Cardenas-Turanzas, M; Cortes, J; Jabbour, E; Jain, P; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintás-Cardama, A; Ravandi, F; Romo, CG; Verstovsek, S | 1 |
| Erben, P; Hochhaus, A; Klag, T; La Rosée, P; Leitner, A; Martiat, P; Müller, MC; Saussele, S; Schenk, T | 1 |
| Beumer, JH; Chatta, GS; Chen, CS; Christner, SM; Kraft, AS; Lilly, MB; Mitsuhashi, M; Twardowski, PW; Ye, W | 1 |
| Behrsing, H; Kaur, G; Millin, MD; Parchment, RE; Teicher, BA | 1 |
| Jiang, J; Lang, LW; Liu, F; Lu, HJ; Wang, JM; Wang, SC | 1 |
| Kataoka, T; Kayukawa, S; Kusumoto, S; Narita, T; Yoshida, T | 1 |
| Costa, FF; De Souza, CA; Fachel, AA; Moreira, YB; Pagnano, KB; Silveira, RA; Verjovski-Almeida, S | 1 |
| Chu, E; Kim, EJ; Loren, A; Rook, A; Rosenbach, M; Samimi, S; Seykora, J; Vittorio, C | 1 |
| Barber, DL; Huang, K; Javadi, M; Richmond, TD | 1 |
| Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A | 1 |
| Blakely, KM; Fathers, KE; Hansford, LM; Kaplan, DR; Marra, M; Moffat, J; Moran, MF; Morozova, O; Smith, KM; Taylor, P; Vojvodic, M | 1 |
| Ji, J; Liu, B; Lou, B; Shi, H; Shi, M; Yu, Y; Zhang, J; Zhou, C; Zhu, Z | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Barbara, JE; Buckley, DB; Horrigan, MJ | 1 |
| Chen, Y; Clayman, GL; Frederick, MJ; Gallick, GE; Henderson, YC; Lai, SY; Ryu, J; Toro-Serra, R; Zhou, G | 1 |
| Chao, YH; Peng, CT; Tamamyan, G; Wang, CH; Weng, T; Wu, HP; Wu, KH | 1 |
| Gentile, M; Guido, M; Lucia, E; Mazzone, C; Morabito, F; Recchia, AG; Vigna, E | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Hattori, Y; Kato, J; Kohashi, S; Matsuki, E; Matsushita, M; Mori, T; Okamoto, S; Tonegawa, K | 1 |
| Anderson, KI; Brunton, VG; Campbell, AD; Carragher, NO; Edward, M; Evans, TR; Frame, MC; Karim, SA; McGarry, LC; McGhee, EJ; Morton, JP; Nobis, M; Quinn, J; Sansom, OJ; Schwarz, JP; Timpson, P; Wang, Y | 1 |
| Brown, RJ; Dhall, G; Eisenstat, D; Finlay, JL; Goldman, S; Osorio, DS | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Pregno, P; Riccomagno, P | 1 |
| Asami, K; Chansu, S; Imamura, M; Ogawa, A; Watanabe, A | 1 |
| Baker, SD; Fujita, KI; Furmanski, BD; Gibson, AA; Hu, S; Janke, LJ; Li, L; Schuetz, JD; Sparreboom, A; Williams, RT | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL | 1 |
| Ge, Z; Hong, M; Li, JY; Pan, LQ; Qian, SX; Song, P; Tian, T; Yu, H; Zhang, SJ; Zhu, Y | 1 |
| Fermeglia, M; Gibbons, DL; Laurini, E; Posocco, P; Pricl, S; Quintás-Cardama, A | 1 |
| Fang, Y; He, Q; Jing, H; Lin, M; Luo, P; Yang, B; Ying, M; Zhong, L; Zhou, X | 1 |
| Baldwin, AS; Christopherson, RI; Cooper, MJ; Cox, NJ; Dewar, BJ; Duncan, JS; Frye, SV; Ghose Roy, S; Graves, LM; Jin, J; Johnson, GL; Jones, LS; Kuan, PF; Nguyen, TA; Richards, KL; Smalley, DM; Whittle, MC; Zimmerman, EI | 1 |
| Ayala, VI; Beilhack, A; Braun, M; Chopra, M; Eyrich, M; Ohlen, C; Reß, ML; Schlegel, PG; Schreiber, SC; Schwinn, S; Wölfl, M; Yoo, YE | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Betkier-Lipińska, K; Cwetsch, A; Góra-Tybor, J; Ryczek, R | 1 |
| Bhatia, R; Dos Santos, C; Forman, SJ; Ho, YW; Kuo, YH; Lin, A; Liu, H; McDonald, T | 1 |
| Boerner, J; Gartner, E; Kim, EM; Mueller, K | 1 |
| Altiok, S; Bennett, KL; Chamrád, I; Colinge, J; Gridling, M; Haura, EB; Müller, AC; Parapatics, K; Rix, U; Stukalov, A; Superti-Furga, G | 1 |
| Klamová, H | 1 |
| Borthakur, G; Burger, JA; Cortes, JE; Falchi, L; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Luthra, R; O'Brien, S; Quintás-Cardama, A; Ravandi-Kashani, F; Verma, D; Verstovsek, S; Wang, X | 1 |
| Bovée, JV; Briaire-de Bruijn, IH; Gelderblom, H; Herpers, B; van de Water, B; van Oosterwijk, JG; van Ruler, MA | 1 |
| Altavilla, G; Arrigo, C; Di Mirto, C; Mondello, P; Pitini, V | 1 |
| Hochhaus, A; Kantarjian, H | 1 |
| Saglio, G; Savona, MR | 1 |
| Chen, JZ; Coraggio, M; Hau, J; Imperio, J; Liu, L; Lubach, JW; Wong, H | 1 |
| Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C | 1 |
| Dalziel, G; Dean, B; Pang, J; Salphati, L; Ware, JA | 1 |
| Clark, R; Drummond, M; Gallipoli, P; Heaney, N; Holyoake, TL; Hughes, T; McLintock, L; Michor, F; Nicolini, FE; Paul, J; Stobo, J; Tighe, J; Wilson, G | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Abruzzese, E; Breccia, M; Latagliata, R | 1 |
| Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V | 1 |
| Miura, M; Takahashi, N | 1 |
| Bergman, M; Bokar, J; Brell, J; Chee, CE; Dowlati, A; Fu, P; Gibbons, J; Gudena, V; Krishnamurthi, S; Meropol, NJ; Nock, CJ; O'Brien, T; Reese, A; Saltzman, J; Teston, L; Wright, JJ | 1 |
| Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G | 1 |
| Jabbour, E; Lipton, JH | 1 |
| Chen, CY; Chen, YC; Cheng, YW; Lee, H; Lee, MC; Wu, DW; Wu, JY; Wu, TC | 1 |
| Chirovsky, DR; Davis, CC; Goren, A; Gupta, S; Hirji, I; Moadel, AB; Olavarria, E; Victor, TW | 1 |
| Eadie, LN; Hughes, TP; White, DL | 1 |
| Ayyagari, R; Chen, L; Reichmann, WM; Signorovitch, J; Wu, EQ | 1 |
| Ezzeldin, E; Kassem, MG; Korashy, HM; Mostafa, GA | 1 |
| Gerhardt, D; Hopf, C; Matheis, K; Meyer, B; Schubach, B; Schulz, S; Seegel, M | 1 |
| Geletu, M; Guy, S; Raptis, L | 1 |
| Bai, A; Bielawska, A; Bielawski, J; Boppana, NB; Breen, P; Gudz, TI; Joseph, N; Korbelik, M; Kraveka, JM; Li, L; Pierce, JS; Rahmaniyan, M; Separovic, D; Van Buren, E | 1 |
| Butte, AJ; De Vusser, K; Fischbein, MP; Gong, Y; Khatri, P; Kimura, N; Morgan, AA; Naesens, M; Robbins, RC; Roedder, S; Sarwal, MM | 1 |
| Brunner, AM; Costa, DB; Garcia, E; Hammerman, PS; Heist, RS; Johnson, BE; Lindeman, NI; Oxnard, GR; Sholl, LM | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Álvarez Álvarez, CM; Buchelli Ramirez, HL; Casan Clarà, P; García Clemente, MM; Rodríguez Reguero, JJ | 1 |
| Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Barth, C; Massard, C; Vignot, S | 1 |
| Berger, F; Chassagne-Clément, C; Giraudier, S; Legros, L; Mollica, L; Niault, M; Nicolini, FE; Rea, D; Rousselot, P; Roux, C; Tigaud, I; Tulliez, M; Turhan, A | 1 |
| Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL | 1 |
| Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY | 1 |
| Giannouli, A; Hatzitolios, AI; Kaiafa, G; Kakaletsis, N; Papadopoulos, N; Perifanis, V; Savopoulos, C; Zisekas, S | 1 |
| Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Peeters, WJ; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Wheeler, DL | 1 |
| Chandran, P; Gupta, N; Koyakutty, M; Malarvizhi, GL; Nair, S; Ramachandran, R; Retnakumari, AP | 1 |
| Paydas, S | 1 |
| Araujo, JC; Armstrong, AJ; Begbie, S; Bellmunt, J; Cheng, S; de Bono, JS; Durham, S; Efstathiou, E; Gallardo, E; Goebell, PJ; Heidenreich, A; Hong, JH; Logothetis, CJ; Matveev, VB; McCaffrey, J; Morris, MJ; Oudard, S; Paliwal, P; Richardet, E; Saad, F; Serrano, SV; Sizer, B; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Bartholomae, S; Bullinger, L; Corbacioglu, S; Debatin, KM; Herrmann, MD; Holzmann, K; Lennerz, JK; Westhoff, MA | 1 |
| Erdmann, F; Henze, C; Rohe, A; Schmidt, M; Sippl, W | 1 |
| Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
| Fujiwara, D; Imano, M; Itoh, T; Komai, M; Mashimo, K; Mukai, J; Nishida, S; Ogawa, N; Sakaguchi, K; Sakamoto, K; Satou, T; Shimaoka, H; Takeda, T; Tsubaki, M | 1 |
| Kameoka, Y; Kume, M; Nagao, T; Noguchi, S; Ohyagi, H; Sawada, K; Shinohara, Y; Takahashi, N | 1 |
| Fukuda, I; Hirabayashi-Ishioka, Y; Morita, A; Ota, T; Sakikawa, I; Uchiumi, T; Yokoyama, M | 1 |
| Ando, T; Kimura, S; Kojima, K | 1 |
| Coffey, RJ; Hanks, SK; Liu, H; Luo, W; Manning, HC; McDonald, WH; McKinley, ET; Zhao, P | 1 |
| Dehesa, L; Kerdel, F; Nuno-Gonzalez, A; Ricotti, C | 1 |
| Duek, A; Grisouard, J; Hao-Shen, H; Jeandidier, E; Karow, A; Looser, R; Lundberg, P; Ojeda-Uribe, M; Skoda, RC | 1 |
| Atanackovic, D; Goekkurt, E; Harbaum, L; Marx, A; Schafhausen, P | 1 |
| Augustine, CK; Beasley, GM; Lidsky, ME; Sharma, K; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS; Ueno, T | 1 |
| Chang, M; Kim, DW; Kim, JG; Lee, KY; Moon, D; Park, GS; Yi, JE; Youn, HJ | 1 |
| Bradley-Garelik, MB; Chuah, CT; Kim, DW; Nakamae, H; Shen, ZX | 1 |
| Busca, A; Daraio, F; Fava, C; Gottardi, E; Rege-Cambrin, G; Saglio, G | 1 |
| Alexis, F; Grimes, SW; Lewis, RL; Moore, TL | 1 |
| Bass, AJ; Beauchamp, EM; Dulak, AM; Gray, NS; Hammerman, PS; Meyerson, M; Tan, L; Wong, KK; Woods, BA; Xu, C | 1 |
| Fujisawa, S; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Nishiwaki, K; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Beamish, M; Grabek, J; Mohamed, M | 1 |
| Arai, H; Handa, T; Iso, H; Mitani, K; Nagasawa, F; Nakamura, Y; Sasaki, K; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Baccarani, M; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; Kim, DW; Mayer, J; Mohamed, H; Pavlovsky, C; Saglio, G; Shah, NP; Steegmann, JL; Wildgust, M | 1 |
| Hughes, T; White, D | 1 |
| Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S | 1 |
| Abruzzo, L; Alattar, ML; Borthakur, G; Champlin, R; Cortes, JE; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Luthra, R; O'Brien, S; Ohanian, M; Pierce, S; Quintas-Cardama, A; Ravandi, F; Trinh, LX; Verstovsek, S | 1 |
| Adams, E; Chen, H; Chopra, S; Van Schepdael, A; Wang, X | 1 |
| Brahmanday, GR; Chisti, MM; Khachani, A; Klamerus, J | 1 |
| Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A | 1 |
| Li, JY; Qiu, ZY; Xu, W | 1 |
| Akiyama, H; Fujisawa, S; Ishida, Y; Ishizawa, K; Matsue, K; Nakamae, H; Ogura, M; Onishi, S; Takamatsu, Y; Tanimoto, M; Taniwaki, M; Usuki, K; Utsunomiya, A | 1 |
| Autran, B; Calin, R; Calvez, V; Katlama, C; Lambert, S; Papagno, L; Pogliaghi, M | 1 |
| Asmussen, J; Burlingame, A; Craik, CS; Jun, YW; Lasater, EA; Oses-Prieto, J; Shah, NP; Tajon, C; Taylor, BS | 1 |
| Iijima, K; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Mori, T; Okita, H; Osumi, T; Saito, M; Shimizu, T; Tomita, O | 1 |
| Eng, KH; Gao, L; Gelman, IH; Gillard, B; Su, B | 1 |
| Kurosu, T; Miura, O; Nagao, T; Nogami, A; Oshikawa, G; Tohda, S; Umezawa, Y; Yamamoto, M | 1 |
| Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D | 1 |
| Fukami, K; Ito, Y; Sakai, R; Takanashi, M; Yamaguchi, H; Yanagihara, K; Yashiro, M; Yoshida, N | 1 |
| Chen, CC; Huang, LY; Huang, WC; Lin, YC; Lin, YT; Wei, TT; Wu, MH | 1 |
| Bottsford-Miller, J; Broaddus, R; Coleman, RL; Dalton, HJ; Deavers, MT; Fellman, B; Han, HD; Hu, W; Huang, J; Huang, L; Jennings, NB; Kang, Y; Liu, T; Lu, C; Pecot, CV; Pradeep, S; Roh, JW; Rupaimoole, R; Sood, AK; Thanapprapasr, D; Urbauer, D; Zand, B | 1 |
| Inokuchi, K; Nakayama, K | 1 |
| Irie, T; Izumiyama, K; Kato, T; Meguro, T; Mori, A; Morioka, M; Musashi, M; Saga, A; Saito, M; Tanaka, M; Tanino, M | 1 |
| Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA | 1 |
| Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS | 1 |
| Baldus, CD; Bock, J; Hofmann, WK; Kühl, AA; Mochmann, LH; Neumann, M; Nowak, V; Ortiz-Tanchez, J; von der Heide, EK | 1 |
| Al-Husein, B; DeRemer, DL; Goc, A; Katsanevas, K; Lou, U; Sabbineni, H; Somanath, PR; Steinbach, A | 1 |
| Arrizabalaga, G; Checkley, L; Ferdig, MT; Gaji, RY; Reese, ML | 1 |
| Brümmendorf, TH; Cortes, JE; Cunningham, M; Guilhot, F; Healey, D; Hochhaus, A; Kantarjian, HM; le Coutre, P; Mohamed, H; Rousselot, P; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Adwan, TS; Anderson, SM; DeGregori, J; Reyland, ME; Wie, SM | 1 |
| Hatta, Y | 1 |
| Cao, J; Fang, Y; He, Q; Liu, L; Qi, X; Xie, N; Yang, B; Ying, M; Zhong, L | 1 |
| McElligott, F; O'Marcaigh, A; O'Rafferty, C; Smith, O; Storey, L | 1 |
| Beristain, AG; Chang, MC; Di Grappa, MA; Joshi, PA; Khokha, R; Kirschner, LS; Molyneux, SD; Pomroy, NC; Privé, GG; Pujana, MA | 1 |
| Bae, I; Duong, HQ; Jang, YJ; Kang, HJ; Kwak, SJ; Seong, YS; Yi, YW | 1 |
| Congleton, J; MacDonald, R; Malavasi, F; Shen, M; Yen, A | 1 |
| Abdissa, TT; Johnson, GL; Scott, JE; Tarpley, M | 1 |
| Dolan, M; Rabenau, KE; Ustun, C; Yohe, S | 1 |
| Dagger, SA; Duyvestyn, JM; Langdon, WY; Morse, HC; Orandle, M; Taylor, SJ; Thien, CB | 1 |
| Brea, EJ; Dao, T; Dubrovsky, L; Liu, C; O'Reilly, RJ; Pankov, D; Scheinberg, DA; Scott, A; Yan, S | 1 |
| Abraham, J; Aslam, MI; Druker, BJ; Keller, C; Mansoor, A; Tyner, JW | 1 |
| Akin, C; Bindslev-Jensen, C; Broesby-Olsen, S; Maurer, M; Siebenhaar, F | 1 |
| Arai, T; Imataki, O; Matsuoka, A; Uemura, M; Yamaoka, G | 1 |
| Bengió, RM; Bianchini, M; Ferri, CA; Gonzalez, MS; Larripa, IB; Moiraghi, EB; Noriega, MF | 1 |
| Benjamini, O; Burger, J; Champlin, R; Cortes, J; Dumlao, TL; Faderl, S; Garcia-Manero, G; Garris, R; Jabbour, E; Jorgensen, J; Kantarjian, H; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, D | 1 |
| De Vita, S; Ebert, BL; Garcia, M; Gavillet, M; Gerbaulet, A; Levine, RL; Mullally, A; Roers, A; Schneider, RK; Williams, DA; Wood, J | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Kassem, MG; Korashy, HM; Rahman, AF | 1 |
| Anwer, F; Vincelette, ND; Yun, S | 1 |
| Faiz, SA; Jimenez, CA; Sahay, S | 1 |
| Ding, Q; Fathallah-Shaykh, HM; Filippova, N; Friedman, GK; Gillespie, GY; Han, X; Langford, CP; Nabors, LB; Wheeler, CG; Wu, L; Yang, X; Zhang, W | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Brazzelli, V; Croci, G; Grasso, V; Vassallo, C | 1 |
| Cho, H; Gray, NS; Liu, S; Vetter, ML; Wang, J; Yang, PL; Zhang, J; Zhang, W; Zhang, Z | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Elverdi, T; Eskazan, AE; Eyice, D; Ferhanoglu, B; Kurt, EA; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Soysal, T; Tuzuner, N; Yalniz, FF | 1 |
| Shen, J; Zhou, H | 1 |
| Almeida, DR; Chin, EK; Grant, LW | 1 |
| Dalm, VA; Dik, WA; Hirankarn, N; Paridaens, D; van den Bosch, WA; van Hagen, PM; Virakul, S | 1 |
| Eichelbrönner, I; Einsele, H; Jesper, D; Köchel, C; Nerreter, T; Putz, E; Seggewiss-Bernhardt, R | 1 |
| Baturin, D; Christians, U; DeGregori, J; Gardner, LA; Gore, L; Gregory, MA; Klawitter, J; Pollyea, DA; Porter, CC; Takebe, N; Zaberezhnyy, V | 1 |
| Heo, SK; Jo, JC; Kim, H; Noh, EK; Park, JH; Yoon, DJ | 1 |
| Andersen, MH; Berthelsen, J; Bonefeld, CM; Francavilla, C; Fredholm, S; Geisler, C; Hu, T; Krejsgaard, T; Odum, N; Olsen, JV; Petersen, DL; Sibbesen, NA; Wasik, MA; Willerslev-Olsen, A; Woetmann, A; Zhang, M | 1 |
| Chang, H; Chou, WC; Hung, YS | 1 |
| Bhatia, R; Chen, W; Chu, S; Liu, Z; Roth, M; Wang, J; Wang, Z; Wu, X; Yuan, H; Yuan, YC | 1 |
| Handa, H; Ishizaki, T; Koiso, H; Mitsui, T; Murakami, H; Nojima, Y; Ogawa, Y; Saitoh, T; Sekigami, T; Takizawa, M; Tsukamoto, N; Yokohama, A | 1 |
| Chen, Y; Li, L; Lu, F; Zhang, J; Zheng, T; Zhou, S; Zhu, JJ | 1 |
| Arteaga, CL; Chen, H; Gagea, M; González-Angulo, AM; Liu, S; Liu, W; Lu, Y; Meng, X; Meric-Bernstam, F; Miller, T; Mills, GB; Murph, M; Zhang, F | 1 |
| Alfonso, A; Botana, LM; Tobío, A | 1 |
| Chandran, P; Gupta, N; Koyakutty, M; Malarvizhi, GL; Menon, D; Nair, S; Panikar, D; Ramachandran, R | 1 |
| Abdul-Karim, FW; Booth, CN; Flask, CA; Keri, RA; Lozada, KL; Mosley, JD; Seachrist, DD; Yori, JL | 1 |
| Adeoye, OO; Bouthors, V; Hubbell, MC; Pearce, WJ; Williams, JM | 1 |
| Hori, S; Yamamoto, K | 1 |
| Liu, B; Mi, Y; Wang, J; Wang, Y | 1 |
| Chen, HJ; Hsu, JL; Huang, CC; Hung, MC; Kuo, TT; Kuok, QY; Lai, LC; Lin, CY; Lu, TP; Sher, YP; Sung, SY; Tseng, GC | 1 |
| Balart, J; Baro, M; de Llobet, LI; Figueras, A; Mesia, R; Skvortsova, I | 1 |
| Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M | 1 |
| Clayman, E; Davé, V; Kathiriya, JJ; Pathak, RR; Uversky, VN; Xue, B | 1 |
| Cho, YJ; Liu, J; MacDonald, TJ; Petersen, W; Schneiderjan, M; Yuan, L; Zhang, H | 1 |
| Choi, HG; Dančík, V; Gagnon, J; Graham, DB; Gray, NS; Hussain, MM; Khor, B; Narayan, K; O'Connell, DJ; Perez, JR; Reinecker, HC; Russell, CN; Schreiber, SL; Shamji, AF; Song, JH; Sundberg, TB; Xavier, RJ | 1 |
| Fialho, A; Sami, MB; Yousaf, F | 1 |
| Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W | 1 |
| Ahmad, S; Anderson, DJ; Arpin, CC; Baron, R; Deininger, MW; Eiring, AM; Engar, AJ; Gunning, PT; Heaton, WL; Khorashad, JS; Kraft, IL; Mason, CC; Moriggl, R; O'Hare, T; Page, BDG; Pomicter, AD; Resetca, D; Reynolds, KR; Senina, A; Tantravahi, SK; Todic, A; Vellore, NA; Wilson, DJ; Zabriskie, MS; Zhang, TY | 1 |
| Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V | 1 |
| Lawrence, HR; Lawrence, NJ; Mahajan, K; Mahajan, NP | 1 |
| Asmussen, J; Craik, CS; Jun, YW; Seo, D; Shah, N; Tajon, CA | 1 |
| Altan, M; Avritscher, R; Esteva, FJ; Hatzis, C; Hortobagyi, GN; Kwiatkowski, D; Moulder, S; Pusztai, L; Qi, Y; Strauss, L; Symmans, WF; Ueno, NT; Valero, V | 1 |
| Braley, J; Branford, S; Dang, P; Heatley, SL; Hughes, TP; Moore, S; Moulton, DJ; Mullighan, CG; Nievergall, E; White, DL; Yeung, DT | 1 |
| Cho, EH; Chung, Y; Eom, HS; Kong, SY; Lee, H; Park, S; Shim, H | 1 |
| Cheng, S; Coleman, M; Guo, A; Lu, P; Ma, J; Wang, YL | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Fukushima, N; Hayashi, S; Kimura, S; Kojima, K; Sueoka, E; Tomimasu, R; Yoshimura, M | 1 |
| Branford, S; Cortes, J; Gonen, M; Hughes, T; Michor, F; Olshen, A; Quintás-Cardama, A; Tang, M | 1 |
| Chen, M; Jiang, X; Lin, H; Lorenzi, MV; Rothe, K; Woolfson, A | 1 |
| Beadling, C; Griffith, DJ; Heinrich, MC; Klug, LR; Macleod, AC; Patterson, J; Town, A | 1 |
| Ho, SL; Lavi, E; Singh, R; Souweidane, MM; Zhou, Z | 1 |
| Benet, LZ; Budha, N; Dean, B; Ding, X; Dresser, MJ; Frassetto, LA; Frymoyer, A; Jin, JY; Salphati, L; Smelick, GS; Ware, JA; Yago, MR | 1 |
| Darkow, T; Landsman-Blumberg, P; McMorrow, D; Mullins, CD; Smith, D; Trivedi, D | 1 |
| Chen, C; Du, Q; Gao, W; Hou, L; Hui, Z; Su, B; Sun, Y; Xie, H; Xu, Y; Zhang, P; Zhou, X | 1 |
| Takahashi, N | 1 |
| Agopian, J; Bertucci, F; Chauvot de Beauchêne, I; De Sepulveda, P; Dubreuil, P; Fouet, B; Fournier, B; Mescam-Mancini, L; Panel, N; Tchertanov, L; Tisserand, JC; Vita, M | 1 |
| Bai, Y; Chen, YA; Fang, B; Fisher, K; Haura, EB; Kim, JY; Kinose, F; Koomen, JM; Rix, U; Song, L; Teer, JK; Watters, JM | 1 |
| Clark, K; Ozanne, J; Prescott, AR | 1 |
| Betts, KA; Chen, L; DeAngelo, DJ; Galebach, P; Reichmann, WM; Signorovitch, JE; Thomason, D; Wu, EQ | 1 |
| Blijlevens, M; Frangou, C; Guo, J; Li, YW; Nowak, NJ; Shen, H; Wilson, KE; Yang, N; Zhang, J | 1 |
| Gambacorti-Passerini, C; Piazza, R | 1 |
| Cohen, D | 1 |
| Doki, Y; Ezoe, S; Hata, T; Kudo, T; Matsumoto, K; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Takemasa, I; Uemura, M; Yamamoto, H | 1 |
| Akimoto, S; Goto, H; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Kojima, Y; Matsumoto, K; Matsuoka, M; Mitsui, K; Miyagawa, N; Nagai, J; Ohara, A; Okada, Y; Okita, H; Ootsubo, K; Sultana, S; Takahashi, H; Ueno, H | 1 |
| Abramson, V; Arteaga, CL; Balko, JM; Estrada, MV; Fox, EM; Garrett, JT; González-Angulo, AM; Kelley, MC; Kuba, MG; Mayer, IA; Meszoely, IM; Mills, GB; Red-Brewer, M; Rizzo, M; Schwarz, LJ | 1 |
| Lin, D; Liu, B; Lyu, R; Mi, Y; Wang, J; Zhou, C | 1 |
| An, G; Fleisher, B; Shao, J; Unum, J | 1 |
| Blalock, SJ; Earnshaw, SR; Fang, G; Happe, LE; Richards, KL; Walko, CM; Ward, MA | 1 |
| Galanis, A; Levis, M | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Whiteley, J | 1 |
| Babiker, HM; Proytcheva, M | 1 |
| Anderson, KI; Herrmann, D; Magenau, A; McGhee, EJ; Morton, JP; Nobis, M; Timpson, P | 1 |
| Chen, T; Huo, X; Liu, K; Liu, Q; Liu, Z; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Yang, X | 1 |
| Appelmann, I; Carbonetti, G; Chen, C; de Stanchina, E; Lowe, SW; Rillahan, CD; Sherr, CJ | 1 |
| Fujisawa, S; Hatta, Y; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Daniel, KG; Gordian, E; Haura, EB; Li, J; Luddy, K; Mediavilla-Varela, M; Muñoz-Antonia, T; Ohaegbulam, K; Pevzner, Y | 1 |
| Bil, J; Bobrowicz, M; Bojarczuk, K; Dabrowska-Iwanicka, A; Dwojak, M; Efremov, DG; Golab, J; Juszczynski, P; Krol, M; Le Roy, A; Leusen, JH; Miazek, N; Olive, D; Pilch, Z; Podszywalow-Bartnicka, P; Pyrzynska, B; Rygiel, TP; Siernicka, M; Slabicki, M; Syta, A; Winiarska, M; Zagozdzon, A; Zapala, P; Zenz, T | 1 |
| Chang, HT; Hsiao, ES; Liao, PC; Sun, JL; Wang, CC; Wu, HY; Wu, WS; Yang, TH | 1 |
| Dong, C; Huang, X; Ren, J; Ruan, L; Shao, C; Su, D; Wang, J | 1 |
| Chiba, S; Fujisawa, S; Igarashi, T; Inokuchi, K; Iriyama, N; Kawakami, K; Kouzai, Y; Kumagai, T; Morita, S; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Taguchi, J; Takezako, N; Wakita, H; Yano, S; Yoshida, C | 2 |
| Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B | 1 |
| Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT | 1 |
| Stone, RM; Wolach, O | 1 |
| Bamdad, M; Berger, J; Berger, MG; Boiret-Dupré, N; Bourgne, C; Briançon, A; Guerci, A; Hermet, E; Janel, A; Lioret, F; Rapatel, C; Tournilhac, O | 1 |
| Audemard, A; Bergot, E; Chantepie, S; de la Gastine, B; Gac, AC; Reman, O; Verger, H | 1 |
| Alumkal, JJ; Chin, BB; Deng, X; Doot, RK; Duan, F; Febbo, PG; Hartfeil, D; Herman, B; Higano, CS; Mankoff, DA; Muzi, M; Taplin, ME; Taub, JM; Yu, EY | 1 |
| Dagger, SA; Duyvestyn, JM; Forfang, L; Langdon, WY; Myklebust, JH; Oksvold, MP; Smeland, EB; Taylor, SJ | 1 |
| Çengel, A; Özkurt, ZN; Taçoy, G; Türkoğlu, S | 1 |
| Bennuru, S; Dolan, MA; Nutman, TB; O'Connell, EM; Steel, C | 1 |
| Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Diverio, D; Latagliata, R; Mancini, M; Molica, M; Tafuri, A | 1 |
| Alvarez-Larrán, A; Bautista, G; Bobillo, S; Boqué, C; Cuevas, B; de Las Heras, N; Deben, G; Fernandez, A; García Garay, Mdel C; García-Gutiérrez, V; Giraldo, P; Guinea, JM; Iglesias Pérez, A; Lopez Lorenzo, JL; Maestro, B; Martin Mateos, ML; Martinez-Trillos, A; Mata, I; Ortega, F; Portero, A; Ramirez Sánchez, MJ; Romero, E; Romo Collado, A; Ruiz, C; Sebrango, A; Steegmann, JL; Tallón, J; Valencia, S | 1 |
| Wolf, D | 1 |
| Collassanti, MDS; Covas, DT; de Castro, FA; de Oliveira, GLV; de Souza, AM; Ferreira, AF; Hamerschlak, N; Kashima, S; Tognon, R; Zanichelli, MA | 1 |
| Chen, S; Chen, W; Dong, Y; He, X; Liang, C; Ma, J; Zhang, B; Zhang, X | 1 |
| Lee, CS; Liu, TC; Wang, HC | 1 |
| Akiba, H; Komiyama, M; Sumaoka, J; Tsumoto, K | 1 |
| Deng, P; Hantschel, O; Kuriyan, J; Lorenz, S; Superti-Furga, G | 1 |
| Eigendorff, E; Ernst, T; Hochhaus, A; La Rosée, P | 1 |
| Nishida, T; Tsukazaki, K | 1 |
| Dahl, J; Jabbour, EJ; Mace, ML | 1 |
| Chen, J; Dong, L; Fu, M; Hou, J; Kang, N; Lan, T; Liu, B; Liu, K; Zhan, Q; Zhang, C; Zhang, W | 1 |
| Imamura, J; Najima, Y; Ohta, S | 1 |
| Ar, MC; Eskazan, AE; Hatemi, İ; Öngören Aydın, S; Soysal, T | 1 |
| Cabezón, M; Cortés, M; Feliu, E; Grau, J; Marcé, S; Millá, F; Zamora, L | 1 |
| Amin, K; Dincer, HE; Podgaetz, E; Randall, N; Ustun, C | 1 |
| Cortes, JE; Huh, Y; Kanagal-Shamanna, R; Kantarjian, HM; Lin, P; Loghavi, S; Luthra, R; Medeiros, LJ; Mehrotra, M; Patel, KP; Pemmaraju, N; Verstovsek, S | 1 |
| Bisconte, A; Bradshaw, JM; Brameld, KA; Finkle, D; Funk, JO; Gerritsen, ME; Goldstein, DM; Hill, RJ; Karr, DE; Li, X; Loughhead, DG; McFarland, JM; Nunn, PA; Owens, TD; Paavilainen, VO; Patel, V; Phan, VT; Romanov, S; Shu, J; Tam, D; Taunton, J; Ton, T; Verner, E | 1 |
| Chen, XJ; Guo, Y; Liu, F; Liu, TF; Ruan, M; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Albano, F; Anelli, L; Brunetti, C; Casieri, P; Cellamare, A; Coccaro, N; Cumbo, C; Delia, M; Impera, L; Minervini, A; Minervini, CF; Orsini, P; Specchia, G; Tota, G; Zagaria, A | 1 |
| Lavie, M; Rottenstreich, A; Rottenstreich, M | 1 |
| Fujii, S; Miura, I; Tanaka, H | 1 |
| Ross, DM | 1 |
| Choi, YG; Kim, JA; Lee, J; Nam, YJ; Yim, E | 1 |
| Cai, ZP; Chai, XX; Fu, YJ; Xiong, YZ; Yang, MT; Zhou, Y | 1 |
| Fenton, B; Quick, DP; Shakespeare, A; Shanshal, M; Thirumala, S | 1 |
| Elias, AD; Hoffner, B; Villalobos, VM | 1 |
| Cho, N; Hattori, T; Imaeda, Y; Miyamoto, N; Nagai, K; Naito, M; Nara, H; Ohoka, N; Sameshima, T; Shibata, N; Shimokawa, K | 1 |
| Eskazan, AE | 1 |
| Bakhshi, S; Pushpam, D | 1 |
| Cantonetti, M; Cattel, F; Celeste, MG; Colasanto, I; Costantini, A; de Rosa, C; Di Biagio, K; Federici, F; Franceschini, L; Frazzetto, A; La Barba, G; Lanzillo, R; Luciano, L; Monteverde, M; Musicco, F; Pane, F; Pasquazi, A; Ranucci, E; Rizzo, M; Rossi, C; Santoleri, F; Scaldaferri, M; Scortechini, AR; Torquati, G; Vozza, A | 1 |
| Adewunmi, CY; Alrubaye, RR; Del Rio Lopez, L; Fadel, CA | 1 |
| Collins-Praino, LE; Corrigan, F; Guglietti, B; Mustafa, S; Sivasankar, S | 1 |
| Abad-Santos, F; Carvoeiro, DC; Cuesta-Mateos, C; Del Campo, L; Gómez-García de Soria, V; Laganá, C; Marcos-Jiménez, A; Muñoz-Calleja, C; Roy-Vallejo, E; Ruef, N; Stein, JV; Villapalos-García, G; Zubiaur, P | 1 |
| De Lavallade, H; Dillon, R; Green, A; Harrington, P; Harrison, C; Hussain, F; Kordasti, S; McLornan, DP; Ong, M; Radia, D; Raj, K; Rousselot, P; Verde, A | 1 |
| Dong, X; Gong, T; Li, G; Li, X; Liu, C; Niu, Y; Wang, Z; Xu, J; Yu, B; Zhang, C; Zhang, D; Zhang, L; Zhao, H; Zhao, X | 1 |
| Abdelhakeem, MM; Fadaly, WAA; Kahk, NM; Khalil, RG; Mohamed, FEA; Nemr, MTM; Zidan, TH | 1 |
227 review(s) available for thiazoles and dasatinib
| Article | Year |
|---|---|
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2005 |
Chronic myelogenous leukemia.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic | 2005 |
Targeted CML therapy: controlling drug resistance, seeking cure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Topics: Benzodioxoles; Clinical Trials, Phase I as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles | 2006 |
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[Novel inhibitors of Bcr-Abl].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles | 2006 |
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Molecular targeting therapy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
What is new in chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Splenomegaly; Thiazoles | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
The role of Src in prostate cancer.
Topics: Animals; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Dasatinib; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Sensitivity and Specificity; Signal Transduction; src-Family Kinases; Thiazoles; Treatment Outcome | 2007 |
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
[New horizon of chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzene Derivatives; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2007 |
Dasatinib: a new step in molecular target therapy.
Topics: Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Adult; Benzamides; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
What's blasting off in CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles | 2007 |
Promising new targeted agents in head and neck cancer.
Topics: Aurora Kinases; Carcinoma, Squamous Cell; Dasatinib; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Head and Neck Neoplasms; Humans; Protein Serine-Threonine Kinases; Pyrimidines; Sirolimus; src-Family Kinases; Thiazoles | 2007 |
Characterization of cancer stem cells in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2007 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
New strategies in controlling drug resistance.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Management of Bcr-Abl-positive leukemias with dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
New strategies in controlling drug resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles | 2007 |
Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Animals; Controlled Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
[Research advance on molecular genetics of CML blast crisis].
Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2008 |
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Overcoming kinase resistance in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Therapy options in imatinib failures.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2008 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2008 |
Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges.
Topics: Animals; Benzamides; Chronic Disease; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Immune System Diseases; Inflammation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Nilotinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Chemical; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Topics: Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Fibrosis; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides; Thiazoles | 2008 |
[Management of acute lymphoblastic leukemia].
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Thiazoles | 2008 |
[Management of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Topics: Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Pyrimidines; Thiazoles | 2009 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
Targeted drugs in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles | 2008 |
[Chronic myeloid leukemia 2008].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2008 |
Imatinib and its successors--how modern chemistry has changed drug development.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2009 |
Src as a therapeutic target in men with prostate cancer and bone metastases.
Topics: Antineoplastic Agents; Benzodioxoles; Bone Neoplasms; Dasatinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Receptors, Androgen; src-Family Kinases; Thiazoles | 2009 |
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Failure | 2009 |
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Topics: Clinical Trials as Topic; Contraindications; Dasatinib; Drug Interactions; Gastrointestinal Tract; Heart Diseases; Hematologic Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Pyrimidines; Thiazoles | 2009 |
New dosing schedules of dasatinib for CML and adverse event management.
Topics: Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Topics: Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
New approved dasatinib regimen available for clinical use.
Topics: Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Chronic-Phase; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Thrombocytopenia | 2009 |
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Benzamides; Cyclophosphamide; Dasatinib; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interleukin-13; Lung Diseases, Interstitial; Mycophenolic Acid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Respiratory Function Tests; Scleroderma, Systemic; Thiazoles; Treatment Outcome | 2009 |
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine | 2009 |
Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Utilization; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Genetic; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Failure | 2009 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2009 |
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Costs and Cost Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles; Treatment Outcome | 2009 |
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
Topics: Brain Neoplasms; Dasatinib; Glioblastoma; Humans; Prognosis; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Topics: Asian People; Clinical Trials as Topic; Dasatinib; Data Interpretation, Statistical; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Practical management of dasatinib for maximum patient benefit.
Topics: Antineoplastic Agents; Dasatinib; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
Topics: Administration, Oral; Benzamides; Carcinoma; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dasatinib; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2009 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
New insights into small-molecule inhibitors of Bcr-Abl.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Europe; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2009 |
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Topics: Algorithms; Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Water-Electrolyte Imbalance | 2009 |
[Clinical progress in chronic myelogenous leukemia].
Topics: Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dasatinib; Drug Discovery; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Comorbidity; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Mutation; Piperazines; Prognosis; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2010 |
Dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Thiazoles | 2010 |
Dasatinib in solid tumors.
Topics: Adult; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Humans; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Acute renal failure under dasatinib therapy.
Topics: Acute Kidney Injury; Aged; Dasatinib; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib: is it all in the dose?
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Pleural effusions due to dasatinib.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles | 2010 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2007 |
First-line therapy for chronic myeloid leukemia: new horizons and an update.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Clinical Trials as Topic; CSK Tyrosine-Protein Kinase; Dasatinib; Dogs; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolines; Rats; src-Family Kinases; Thiazoles; Triazines | 2010 |
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
[Development of ABL tyrosine kinase inhibitors].
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2010 |
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Topics: Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2011 |
Allosteric inhibition of BCR-ABL.
Topics: Allosteric Regulation; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Topics: Brain Neoplasms; Cell Proliferation; Dasatinib; Glioblastoma; Humans; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
[SRC kinases in tumor therapy].
Topics: Aniline Compounds; Benzodioxoles; Cell Physiological Phenomena; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; DNA Mutational Analysis; Drug Delivery Systems; Enzyme Activation; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2010 |
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Thiazoles; Transplantation, Homologous | 2010 |
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Topics: Benzamides; Clinical Trials as Topic; Congresses as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dasatinib; Disease-Free Survival; Humans; Lung Neoplasms; Pyrimidines; Thiazoles | 2011 |
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2011 |
Dasatinib: an anti-tumour agent via Src inhibition.
Topics: Animals; Antineoplastic Agents; Dasatinib; Drug Delivery Systems; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles | 2011 |
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
New drugs for chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2011 |
Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.
Topics: Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Chronic myelogenous leukemia: monitoring response to therapy.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Interpretation of cytogenetic and molecular results in patients treated for CML.
Topics: Benzamides; Cytogenetics; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.
Topics: Benzamides; Dasatinib; Drug Discovery; Imatinib Mesylate; Inflammation; Models, Molecular; Molecular Conformation; Neoplasms; Patents as Topic; Phosphotransferases; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2011 |
Predicting the response of CML patients to tyrosine kinase inhibitor therapy.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Topics: Dasatinib; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Current status of SRC inhibitors in solid tumor malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Humans; Neoplasms; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2011 |
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Clinical Trials, Phase III as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Novel nephrotoxins.
Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphosphonates; Glutamates; Guanine; HIV Protease Inhibitors; Humans; Indoles; Kidney Diseases; Organophosphonates; Oxalates; Pamidronate; Pemetrexed; Phenindione; Plants, Toxic; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Selective Serotonin Reuptake Inhibitors; Sunitinib; Tenofovir; Thiazoles; Triazines | 2011 |
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2011 |
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous | 2011 |
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transport Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles; Tumor Microenvironment | 2011 |
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Topics: Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Publication Bias; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2012 |
[A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Dasatinib; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Nitriles; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
[TKI therapy for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2011 |
Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Clinical Trials as Topic; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Targeted drug therapy: the platelet side.
Topics: Animals; Blood Platelets; Dasatinib; Humans; Molecular Targeted Therapy; Neoplasms; Platelet Activation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2011 |
Effects of BCR-ABL inhibitors on anti-tumor immunity.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2011 |
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Novel molecular targets for the therapy of castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cancer Vaccines; Carcinoma; Clinical Trials, Phase III as Topic; Clusterin; Dasatinib; Denosumab; Humans; Ipilimumab; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Pyridines; Pyrimidines; Quinolines; Quinolones; Radium; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Thiazoles; Tissue Extracts; Treatment Outcome; Vaccines, Synthetic | 2012 |
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles | 2012 |
Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2012 |
Clinical trials in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
Chronic myelogenous leukemia for primary care physicians.
Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
[Current therapy of chronic myeloid leukemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom | 2012 |
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2012 |
Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
Topics: Adult; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2010 |
Chronic myeloid leukemia: state of the art in 2012.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Leukemia: A highly malignant disease].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2012 |
Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor.
Topics: Bone Neoplasms; Cell Proliferation; Cell Survival; Dasatinib; Disease Progression; DNA Repair; Epothilones; Gene Fusion; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Receptors, Androgen; Taxoids; Thiazoles | 2012 |
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2012 |
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Thiazoles | 2012 |
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2012 |
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
Topics: Dasatinib; Drug Eruptions; Exanthema; Guideline Adherence; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2013 |
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2013 |
Treating chronic myeloid leukemia: improving management through understanding of the patient experience.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Style; Patient Compliance; Patient Education as Topic; Piperazines; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Management of the new patient with CML in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Topics: Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Topics: Clinical Trials as Topic; Dasatinib; European Union; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Skin; Thiazoles | 2013 |
Management options for refractory chronic myeloid leukemia: considerations for the elderly.
Topics: Age Factors; Aged; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2013 |
[Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2013 |
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoadjuvant Therapy; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2013 |
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).
Topics: Antihypertensive Agents; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Dasatinib; Diabetes Mellitus; Humans; Hypertension; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Current diagnostic requirements in chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Guideline Adherence; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome | 2013 |
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2013 |
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
[Bone targeted therapies: new agents].
Topics: Aniline Compounds; Benzodioxoles; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Dasatinib; Diphosphonates; Humans; Molecular Targeted Therapy; Nitriles; Parathyroid Hormone-Related Protein; Pyrimidines; Quinazolines; Quinolines; RANK Ligand; Receptors, Chemokine; src-Family Kinases; Thiazoles; Transforming Growth Factor beta1 | 2013 |
Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Topics: Animals; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Dasatinib; Female; Genes, abl; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Ever-advancing chronic myeloid leukemia treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2014 |
Which TKI? An embarrassment of riches for chronic myeloid leukemia patients.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Large granular lymphocytosis during dasatinib therapy.
Topics: Antineoplastic Agents; Clone Cells; Colitis; Dasatinib; Familial Primary Pulmonary Hypertension; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes, Cytotoxic; Thiazoles; Thrombocytopenia | 2014 |
[Chronic myeloid leukemia: up-to-date management].
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Discovery; Drug Monitoring; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Molecular Targeted Therapy; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
[Acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Humans; Imatinib Mesylate; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2014 |
Treatment strategies in mastocytosis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Bone and Bones; Central Nervous System; Dasatinib; Gastrointestinal Tract; Gene Expression; Histamine Antagonists; Humans; Mast Cells; Mastocytosis; Omalizumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin; Thiazoles | 2014 |
Dasatinib.
Topics: Animals; Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2014 |
Dasatinib.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Dasatinib; Drug Resistance, Neoplasm; Drug Stability; Humans; Molecular Structure; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Pleural effusions in acute and chronic leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Biopsy; Bone Marrow; Chronic Disease; Dasatinib; Humans; Leukemia; Myelodysplastic Syndromes; Pleura; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Microscopy, Electron; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
[Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Topics: Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Pyrimidines; Thiazoles; Young Adult | 2014 |
Severe agitation in depression precipitated by dasatinib.
Topics: Azabicyclo Compounds; Dasatinib; Depression; Diagnosis, Differential; Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Psychomotor Agitation; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2014 |
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic | 2014 |
[Management of advanced stage chronic myeloid leukemia].
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2014 |
How I treat newly diagnosed chronic myeloid leukemia in 2015.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2015 |
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Drug Monitoring; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Nitriles; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thiazoles | 2015 |
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Topics: Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2015 |
Paediatric chronic myeloid leukaemia: Is it really a different disease?
Topics: Antineoplastic Agents; Child; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatrics; Pyrimidines; Thiazoles | 2019 |
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzamides; Central Nervous System; Dasatinib; Humans; Molecular Targeted Therapy; Multiple Sclerosis; Myelin Sheath; Nerve Tissue Proteins; Neurodegenerative Diseases; Oligodendroglia; Parkinson Disease; Piperidines; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Receptors, N-Methyl-D-Aspartate; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; tau Proteins; Thiazoles | 2021 |
120 trial(s) available for thiazoles and dasatinib
| Article | Year |
|---|---|
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Thiazoles; Treatment Failure | 2007 |
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Topics: Administration, Oral; Adult; Aged; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; src-Family Kinases; Thiazoles | 2007 |
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2007 |
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Drug Resistance; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2007 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles | 2007 |
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Time Factors | 2007 |
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles | 2007 |
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pleural Effusion; Pyrimidines; Radiography; Risk Factors; Thiazoles; Treatment Failure | 2007 |
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Failure | 2008 |
American Society of Hematology annual meeting.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Dasatinib; Georgia; Hematology; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Pyrimidines; Societies, Medical; Survival Rate; Thiazoles; United States | 2008 |
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Topics: Adolescent; Adult; Aged; Animals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Cytogenetic Analysis; Dasatinib; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Monitoring; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Spinal Puncture; Survival Rate; Thiazoles; Treatment Outcome; Tumor Burden | 2008 |
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure | 2008 |
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Philadelphia Chromosome; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2008 |
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Dasatinib in relapsed or plateau-phase multiple myeloma.
Topics: Adult; Aged; Dasatinib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Thiazoles | 2009 |
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles | 2009 |
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hemorrhagic Disorders; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thiazoles; Withholding Treatment; Young Adult | 2009 |
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult | 2009 |
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Anti-Ulcer Agents; Biological Availability; Cross-Over Studies; Dasatinib; Drug Interactions; Drug Therapy, Combination; Famotidine; Histamine H2 Antagonists; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Incidence; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Pyrimidines; Retreatment; Thiazoles; Thrombocytopenia; Treatment Outcome | 2009 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Withholding Treatment | 2009 |
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2009 |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2009 |
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Dasatinib; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Pyrimidines; Thiazoles; Young Adult | 2010 |
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dasatinib; Drug Administration Schedule; Drug Interactions; Electrocardiography; Female; Heart; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; src-Family Kinases; Thiazoles; Young Adult | 2010 |
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int
Topics: Benzamides; Cytogenetic Analysis; Dasatinib; Drug Administration Schedule; Drug Resistance; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dasatinib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Vincristine; Young Adult | 2010 |
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; International Agencies; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2010 |
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Treatment Outcome | 2010 |
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytokines; Dasatinib; Disease-Free Survival; Enzyme Activation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; src-Family Kinases; Texas; Thiazoles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2010 |
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2011 |
The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dasatinib; Disease-Free Survival; Humans; Lung Neoplasms; Pyrimidines; Thiazoles | 2011 |
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Hospitals, Pediatric; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Neoplasms; Patient Selection; Pediatrics; Philadelphia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Benzoquinones; CD40 Ligand; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction; Stromal Cells; Syk Kinase; Thiazoles; Time Factors | 2011 |
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrimidines; Radiography, Abdominal; Recurrence; Thiazoles; Tomography, X-Ray Computed | 2011 |
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Dasatinib; Edema; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pleural Effusion, Malignant; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Child; Cytokines; Dasatinib; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
A phase 2 trial of dasatinib in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2011 |
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Thiazoles; Treatment Outcome | 2011 |
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dasatinib; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Topics: Aged; Anorexia; Antineoplastic Agents; Biomarkers; Bone Resorption; Dasatinib; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Diseases; Humans; Japan; Magnesium; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Osteoclasts; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; src-Family Kinases; Thiazoles | 2011 |
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Dasatinib; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thiazoles | 2011 |
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thiazoles; Transforming Growth Factor alpha | 2012 |
Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2011 |
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Dasatinib; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; src-Family Kinases; Thiazoles | 2011 |
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Immunophenotyping; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Steroids; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2011 |
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Dasatinib; Docetaxel; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles | 2012 |
A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Topics: Antineoplastic Agents; Calibration; Chromatography, Liquid; Dasatinib; Humans; Leukemia; Pyrimidines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazoles | 2012 |
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous | 2012 |
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dasatinib; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Pyrimidines; src-Family Kinases; Survival Analysis; Thiazoles; Treatment Outcome | 2012 |
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Age of Onset; Algorithms; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2012 |
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemokines; Cytokines; Dasatinib; Female; Humans; Imatinib Mesylate; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2012 |
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Probability; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2012 |
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Topics: Adult; Aged; Algorithms; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Thiazoles; Treatment Failure; Young Adult | 2012 |
Phase I trial of dasatinib and ixabepilone in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Epothilones; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tubulin Modulators | 2013 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Disease-Free Survival; Female; Humans; Macrophage Colony-Stimulating Factor; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Transcription, Genetic; Young Adult | 2012 |
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Dasatinib; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Thiazoles | 2012 |
A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2012 |
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Disease-Free Survival; Female; Glioblastoma; Humans; Lomustine; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrimidines; Thiazoles | 2012 |
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Dasatinib; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Interleukin-8; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neoplastic Cells, Circulating; Pyrimidines; Thiazoles; Young Adult | 2013 |
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Pyrimidines; Risk; Salvage Therapy; Severity of Illness Index; Standard of Care; Thiazoles; Treatment Failure | 2013 |
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Topics: Acebutolol; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome | 2013 |
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Topics: Animals; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription Factors | 2013 |
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Follow-Up Studies; Glioma; Humans; Infant; Knee Joint; Magnetic Resonance Imaging; Male; Osteonecrosis; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiography; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Dasatinib; Female; Glioma; Humans; Male; Piperidines; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2013 |
[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles | 2013 |
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Testosterone; Thiazoles; Treatment Outcome | 2013 |
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma.
Topics: Adolescent; Central Nervous System Neoplasms; Child; Dasatinib; Female; Germinoma; Humans; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thiazoles | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Topics: Benzamides; Cell Cycle; Dasatinib; Drug Substitution; Drug Synergism; Follow-Up Studies; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Dasatinib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2013 |
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2014 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dasatinib; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Taxoids; Thiazoles; Treatment Failure | 2013 |
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Asian People; Benzamides; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2014 |
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Time; Treatment Outcome | 2014 |
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dasatinib; Dexamethasone; Doxorubicin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Vincristine; Young Adult | 2014 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.
Topics: Antigens, CD; CD8-Positive T-Lymphocytes; Cell Communication; Cells, Cultured; Chemokine CCL19; Chemotaxis; Cytomegalovirus; Dasatinib; Dendritic Cells; Female; Gene Expression Regulation; Humans; Interleukin-12; Male; Monocytes; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, CCR7; Sialic Acid Binding Ig-like Lectin 3; Sialic Acid Binding Immunoglobulin-like Lectins; src-Family Kinases; Thiazoles | 2014 |
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Calcineurin Inhibitors; Cell Line, Tumor; Cyclosporine; Dasatinib; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Survival Analysis; Thiazoles | 2015 |
Gene signature-guided dasatinib therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Breast Neoplasms; Dasatinib; Female; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; src-Family Kinases; Thiazoles; Transcriptome; Treatment Outcome | 2014 |
The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
Topics: Absorption, Physiological; Achlorhydria; Adult; Antineoplastic Agents; Area Under Curve; Betaine; Cross-Over Studies; Dasatinib; Drug Interactions; Female; Gastric Acid; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Proton Pump Inhibitors; Pyrimidines; Rabeprazole; Thiazoles; Young Adult | 2014 |
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
Topics: Aged; Antineoplastic Agents; Dasatinib; Disease Progression; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Propensity Score; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Topics: Amino Acid Substitution; Aminopyridines; Animals; Breast Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Morpholines; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; src Homology Domains; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Pyrimidines; RNA, Messenger; RNA, Neoplasm; ROC Curve; Thiazoles; Time Factors; Transcription, Genetic; Young Adult | 2015 |
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Bone and Bones; Bone Neoplasms; Dasatinib; Disease-Free Survival; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; Thiazoles; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Topics: Antigens, CD; Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocytosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; ROC Curve; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thiazoles | 2015 |
912 other study(ies) available for thiazoles and dasatinib
| Article | Year |
|---|---|
Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Pyrimidines; Thiazoles | 2004 |
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Cell Line; Clinical Trials, Phase I as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutation; Piperazines; Protein Conformation; Pyrimidines; Thiazoles; Transfection | 2004 |
New generation leukaemia drugs are on their way.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2004 |
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Dasatinib; Enzyme Inhibitors; Humans; K562 Cells; Mice; Proto-Oncogene Proteins c-abl; Pyrimidines; Rats; Rats, Sprague-Dawley; src-Family Kinases; Thiazoles | 2004 |
Oral BMS-354825 rescues Gleevec-resistant CML.
Topics: Administration, Oral; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
Topics: Computer Simulation; Dasatinib; Models, Molecular; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2005 |
Two new agents effective in Gleevec-resistant CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2005 |
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Crk-Associated Substrate Protein; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; G1 Phase; Gentian Violet; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Laminin; Lung Neoplasms; Neoplasm Invasiveness; Neovascularization, Pathologic; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Proteoglycans; Pyrimidines; Retinoblastoma Protein; S Phase; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors; Trypan Blue | 2005 |
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genetic Vectors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Phosphotyrosine; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Stem Cells; Thiazoles; Time Factors | 2005 |
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Dasatinib; Dose-Response Relationship, Drug; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2005 |
Loss of response to imatinib: mechanisms and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Failure | 2005 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Topics: Amino Acid Substitution; Animals; Benzamides; Cell Growth Processes; Cell Survival; CHO Cells; Cricetinae; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; MAP Kinase Signaling System; Mice; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Topics: Aurora Kinases; Benzamides; Catalytic Domain; Crystallography; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Topics: Animals; Benzamides; Binding Sites; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Ligands; Mastocytosis, Systemic; Mice; Models, Molecular; Mutation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2006 |
Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
Topics: Animals; Aorta; Benzamides; Cell Line; Dasatinib; Imatinib Mesylate; Kinetics; Muscle, Smooth, Vascular; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2006 |
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Dosage; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2006 |
New assignments for multitasking signal transduction inhibitors.
Topics: Animals; Benzamides; Cell Line; Dasatinib; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Thiazoles | 2006 |
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Disease Progression; Humans; Interleukin-8; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-yes; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; RNA, Small Interfering; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2006 |
Dasatinib: BMS 354825.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2006 |
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Topics: Animals; Benzamides; Blast Crisis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Impact of genetic diagnostics on drug development strategy.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles | 2006 |
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.
Topics: Aged; Dasatinib; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Skin Neoplasms; Thiazoles | 2006 |
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gene Deletion; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2006 |
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Topics: Animals; Benzamides; Crystallography, X-Ray; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Imatinib Mesylate; Models, Molecular; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2006 |
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Screening Assays, Antitumor; Ethylnitrosourea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutagens; Piperazines; Point Mutation; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2006 |
Circumventing resistance to kinase-inhibitor therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Panniculitis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Dasatinib-related alveolar pneumonia responsive to corticosteroids.
Topics: Adrenal Cortex Hormones; Dasatinib; Humans; Hydroxyurea; Lung; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Pulmonary Alveoli; Pyrimidines; Remission Induction; Steroids; Thiazoles; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Tyrosine kinase inhibitors: the next generation.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Paracentesis; Pleural Effusion; Pleurodesis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Glivec and beyond.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2006 |
Dasatinib.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Dasatinib; Drug Approval; Guideline Adherence; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2006 |
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured; Vorinostat | 2006 |
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Topics: Aniline Compounds; Animals; Benzamides; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; K562 Cells; Mice; Mice, Nude; Models, Molecular; Mutation; Neoplasms; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; src-Family Kinases; Survival Analysis; Thiazoles; U937 Cells; Xenograft Model Antitumor Assays | 2006 |
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2006 |
Dasatinib induces a response in malignant thymoma.
Topics: Dasatinib; Humans; Male; Pyrimidines; Remission Induction; Thiazoles; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed | 2006 |
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Nuclear Proteins; Predictive Value of Tests; Pyrimidines; Structure-Activity Relationship; Thiazoles; Time Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Topics: Animals; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Dasatinib; Dose-Response Relationship, Drug; Epithelial Cells; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Leukocytes, Mononuclear; Mice; Mice, Nude; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatin
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cell Proliferation; Chronic Disease; Dasatinib; Female; Humans; In Vitro Techniques; Inflammation; Interleukin-2; Lipopolysaccharides; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Molecular; Protein Binding; Pyrimidines; Rats; Rats, Inbred Lew; src-Family Kinases; Structure-Activity Relationship; T-Lymphocytes; Thiazoles; Tumor Necrosis Factor-alpha | 2006 |
Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Dasatinib; DNA Damage; DNA Repair; Enzyme Inhibitors; Gene Expression Regulation; Humans; Imatinib Mesylate; K562 Cells; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-abl; Oncogenes; Piperazines; Pyrimidines; RNA, Small Interfering; Thiazoles | 2007 |
Dasatinib (Sprycel) for CML and Ph + ALL.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Topics: Administration, Oral; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dasatinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Keratins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; src-Family Kinases; Thiazoles; Vimentin | 2007 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Dasatinib.
Topics: Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Topics: Adolescent; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Models, Genetic; Patient Selection; Prognosis; Pyrimidines; Thiazoles | 2007 |
Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2008 |
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.
Topics: Animals; Chlorocebus aethiops; CSK Tyrosine-Protein Kinase; Cytotoxicity Tests, Immunologic; Dasatinib; Dengue Virus; Fluorescent Antibody Technique, Indirect; Humans; Microscopy, Electron, Transmission; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; src-Family Kinases; Thiazoles; Vero Cells; Virus Assembly | 2007 |
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Dasatinib; Enzyme Activation; Humans; Neoplasm Invasiveness; Osteosarcoma; Protein Kinase Inhibitors; Pyrimidines; Rhabdomyosarcoma; Sarcoma, Ewing; Signal Transduction; src-Family Kinases; Thiazoles | 2007 |
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anus Neoplasms; Base Sequence; Blotting, Western; Cell Line; Cell Proliferation; Dasatinib; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; In Situ Hybridization, Fluorescence; Male; Melanoma; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transfection | 2007 |
Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Dasatinib; Dogs; Enzyme Inhibitors; Haplorhini; Hepatocytes; Humans; In Vitro Techniques; Intestinal Absorption; Macaca fascicularis; Mice; Mice, Knockout; Microsomes, Liver; NADH, NADPH Oxidoreductases; Protein Binding; Proto-Oncogene Proteins c-bcr; Pyrimidines; Rats; Species Specificity; src-Family Kinases; Thiazoles; Uridine Diphosphate Glucuronic Acid | 2008 |
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Topics: Apoptosis; bcl-X Protein; Cell Count; Cell Survival; Cyclin D1; Dasatinib; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphotyrosine; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2007 |
Dasatinib is effective in imatinib-resistant CML.
Topics: Benzamides; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; United Kingdom | 2007 |
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells; Thiazoles; Treatment Outcome | 2007 |
Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
Topics: Brain; Central Nervous System Neoplasms; Dasatinib; Humans; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2007 |
Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2007 |
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Topics: Adult; Aged; Bronchoalveolar Lavage Fluid; Chest Pain; Cough; Dasatinib; Dyspnea; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lymphocytes; Male; Middle Aged; Myeloid Cells; Neutrophils; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Radiography; Thiazoles | 2007 |
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Dasatinib; Enzyme Activation; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mesothelioma; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2007 |
Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytokines; Dasatinib; Enzyme Activation; Humans; Neoplasm Proteins; Phosphoproteins; Protein Kinase Inhibitors; Pyridones; Pyrimidines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles | 2007 |
Cancer agents show first-line potential.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Dasatinib; Humans; Kidney Neoplasms; Leukemia; Oxides; Pyrimidines; Thiazoles | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Topics: Animals; Basophils; Dasatinib; Enzyme-Linked Immunosorbent Assay; Fusion Proteins, bcr-abl; Histamine Release; Humans; K562 Cells; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; U937 Cells | 2007 |
Drugs offer new hope for patients with CML who are resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2007 |
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine | 2007 |
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured | 2007 |
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Topics: Benzamides; Dasatinib; Discoidin Domain Receptor 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinone Reductases; Receptor Protein-Tyrosine Kinases; Thiazoles | 2007 |
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation, Missense; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2008 |
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Topics: Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Translocation, Genetic | 2007 |
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2007 |
American Chemical Society--234th National Meeting. Syntheses of novel compounds and data on novel therapeutics. 19-23 August 2007, Boston, MA, USA.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Dasatinib; DNA-Binding Proteins; Drug Design; Drug Evaluation, Preclinical; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Inflammation; Janus Kinase 3; Liver X Receptors; Orphan Nuclear Receptors; Pharmaceutical Preparations; PPAR alpha; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Thiazoles | 2007 |
Initial testing of dasatinib by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Child; Dasatinib; Female; Humans; Mice; Mice, Inbred Strains; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2008 |
Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; CD146 Antigen; Clinical Trials, Phase III as Topic; Dasatinib; Drug Delivery Systems; Female; Humans; Neoplasms, Basal Cell; Paclitaxel; Proto-Oncogene Proteins c-met; Pyrimidines; Thiazoles | 2007 |
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
Topics: Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chimerism; Cord Blood Stem Cell Transplantation; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Time Factors | 2007 |
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
Topics: Animals; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Dasatinib; Fluorine Radioisotopes; Fusion Proteins, bcr-abl; Humans; Mice; Mice, Nude; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2007 |
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Topics: Animals; Biomarkers; CD28 Antigens; CD3 Complex; Cell Proliferation; Cells, Cultured; Cyclosporine; Cytokines; Dasatinib; Humans; Lymphocyte Activation; Male; Mice; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; Sirolimus; T-Lymphocytes; Thiazoles | 2008 |
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dasatinib; Drug Synergism; Humans; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous | 2007 |
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Dasatinib; Gene Expression Profiling; Humans; Male; Monitoring, Physiologic; Patient Selection; Prostatic Neoplasms; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Chronic myeloid leukemia. Introduction.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Leukemia. Q&A highlights.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pyrimidines; Thiazoles | 2007 |
Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?
Topics: Cytomegalovirus Infections; Dasatinib; Herpesvirus 6, Human; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Parvoviridae Infections; Parvovirus B19, Human; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Virus Activation | 2007 |
Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
Topics: Acute Disease; Cytomegalovirus; Dasatinib; Female; Herpesvirus 6, Human; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Virus Activation | 2007 |
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Thiazoles | 2008 |
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2008 |
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.
Topics: Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Allergens; Animals; Basophils; Cells, Cultured; Dasatinib; Female; Histamine Release; Humans; Interleukin-4; Male; Mice; Middle Aged; Protein Binding; Protein-Tyrosine Kinases; Pyrimidines; Receptors, IgE; Thiazoles; Up-Regulation | 2008 |
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Topics: Adult; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell Proliferation; Cells, Cultured; Chromones; Colony-Forming Units Assay; Dasatinib; DNA Primers; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thiazoles; Transfection | 2008 |
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2008 |
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Humans; Neuroblastoma; Protein Kinase Inhibitors; Pyrimidines; Sarcoma, Ewing; Thiazoles | 2008 |
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Topics: Animals; Benzamides; Cell Line; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Imatinib Mesylate; Interleukin-3; Janus Kinase 2; Mice; Mitogen-Activated Protein Kinase Kinases; Models, Animal; Mutation, Missense; Paracrine Communication; Piperazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2008 |
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration | 2008 |
Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-
Topics: Actinobacteria; Animals; Biotransformation; Dasatinib; Drugs, Investigational; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Pyrimidines; Rats; Spiro Compounds; Swine; Thiazoles; Thiophenes | 2008 |
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Death; Cell Survival; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Genes, abl; Humans; I-kappa B Kinase; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transfection; Tumor Cells, Cultured | 2008 |
[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Dasatinib therapy for systemic mastocytosis: four cases.
Topics: Adult; Dasatinib; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Pyrimidines; Thiazoles | 2008 |
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers; Cell Division; Dasatinib; Drug Monitoring; Female; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphoproteins; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Specific Pathogen-Free Organisms; src-Family Kinases; Substrate Specificity; Thiazoles; Xenograft Model Antitumor Assays | 2008 |
Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Complications; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2008 |
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
Topics: Adult; Age of Onset; Aged; Biopsy; Cells, Cultured; Dasatinib; Fibroblasts; Humans; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Scleroderma, Systemic; Signal Transduction; Skin; Thiazoles | 2008 |
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Autoimmune Diseases; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pleural Effusion, Malignant; Pyrimidines; Retrospective Studies; Thiazoles | 2008 |
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; DNA Damage; DNA Repair; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kinetics; Leukocytes, Mononuclear; Mice; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2008 |
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Cell Proliferation; Dasatinib; Humans; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Lectins, C-Type; Lymphocyte Activation; Oncogene Proteins v-abl; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; T-Lymphocytes; Thiazoles | 2008 |
Dasatinib suppresses in vitro natural killer cell cytotoxicity.
Topics: Cytotoxicity, Immunologic; Dasatinib; Humans; Jurkat Cells; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; Thiazoles | 2008 |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; Dasatinib; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured | 2008 |
Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Topics: Apoptosis; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Humans; Immunologic Memory; Interleukin-2; Lymphocyte Activation; Protein Kinase Inhibitors; Pyrimidines; Receptor-CD3 Complex, Antigen, T-Cell; Receptors, Antigen, T-Cell; Staurosporine; T-Lymphocytes; Thiazoles | 2008 |
Metabolism and disposition of dasatinib after oral administration to humans.
Topics: Administration, Oral; Antineoplastic Agents; Dasatinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
Topics: Animals; Area Under Curve; Biotransformation; Carbon Radioisotopes; Dasatinib; Hepatocytes; Humans; Macaca fascicularis; Magnetic Resonance Spectroscopy; Male; Microsomes, Liver; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Thiazoles | 2008 |
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Dasatinib; Drug Design; Enzyme Inhibitors; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Piperazines; Protein Conformation; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2008 |
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Crk-Associated Substrate Protein; Dasatinib; Disease Models, Animal; Drug Delivery Systems; Focal Adhesion Kinase 1; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrimidines; src-Family Kinases; Thiazoles; Tumor Burden; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2008 |
Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Insufficiency; Thiazoles | 2008 |
Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Topics: Adult; Benzamides; Dasatinib; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retinal Diseases; Thiazoles | 2008 |
Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Topics: Aged; Dasatinib; Gynecomastia; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Selective Estrogen Receptor Modulators; Tamoxifen; Thiazoles; Treatment Outcome | 2008 |
Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib.
Topics: Adult; Chromosome Aberrations; Dasatinib; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Pyrimidines; Thiazoles | 2008 |
Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.
Topics: Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Dasatinib; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes; Thiazoles | 2008 |
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Dasatinib; Drug Delivery Systems; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Mice, SCID; Middle Aged; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; src-Family Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Topics: bcl-X Protein; Caspases; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2008 |
Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics.
Topics: Chromatography, High Pressure Liquid; Dasatinib; DNA, Complementary; Humans; Kinetics; Liver; Microsomes, Liver; Oxidative Stress; Protein Kinase Inhibitors; Pyrimidines; Tandem Mass Spectrometry; Thiazoles | 2008 |
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Temperature; Thiazoles; Tumor Cells, Cultured | 2008 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Interphase; Intracellular Signaling Peptides and Proteins; Lymphoma, Large B-Cell, Diffuse; Phospholipase C gamma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Antigen, B-Cell; src-Family Kinases; Syk Kinase; Thiazoles | 2008 |
Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Dasatinib-induced acute hepatitis.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2008 |
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Dasatinib; DNA Replication; Eosinophils; Flow Cytometry; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Protein Kinase Inhibitors; Pyrimidines; Sequence Deletion; Thiazoles; Thymidine | 2008 |
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Topics: Antigens, Neoplasm; Antigens, Viral; Apoptosis; CD8-Positive T-Lymphocytes; Cell Division; Dasatinib; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2008 |
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Topics: Adolescent; Adult; Aged; Alternative Splicing; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Genes, abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Cell Separation; Dasatinib; Dogs; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles | 2008 |
Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
Topics: Adult; Aged; Aged, 80 and over; Cell Proliferation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Female; Humans; Janus Kinase 2; Male; Middle Aged; Myeloid Progenitor Cells; Polycythemia Vera; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Dasatinib-induced lupus.
Topics: Aged; Autoantibodies; Autoimmunity; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Dasatinib; Feasibility Studies; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2008 |
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
Topics: Benzamides; Dasatinib; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Erythroblastic, Acute; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Substrate Specificity; Thiazoles | 2008 |
Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.
Topics: Animals; Antineoplastic Agents; Ascites; Cell Differentiation; Dasatinib; Disease Progression; Female; Fibroblasts; Humans; Interleukin-3; Macrophage Colony-Stimulating Factor; Macrophages; Models, Molecular; Neoplasm Proteins; Neovascularization, Pathologic; Osteoclasts; Ovarian Neoplasms; Point Mutation; Protein Conformation; Protein Kinase Inhibitors; Pyrimidines; RANK Ligand; Rats; Receptor, Macrophage Colony-Stimulating Factor; Recombinant Fusion Proteins; Thiazoles | 2009 |
Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
Topics: Animals; Area Under Curve; Autoradiography; Dasatinib; Female; Fetus; Milk; Molecular Structure; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Thiazoles; Tissue Distribution | 2008 |
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Topics: Animals; Benzoquinones; Cell Line, Tumor; Dasatinib; Gastrointestinal Stromal Tumors; Genes, abl; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles; Tumor Cells, Cultured | 2008 |
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; Humans; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptor, EphA2; Signal Transduction; Thiazoles | 2008 |
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles | 2008 |
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles | 2008 |
Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Poly(ADP-ribose) Polymerases; Pyrimidines; Signal Transduction; Thiazoles | 2008 |
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles | 2009 |
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Topics: Benzamides; Bone Marrow; Cell Death; Cell Line, Tumor; Culture Media, Conditioned; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; STAT3 Transcription Factor; Thiazoles | 2008 |
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers.
Topics: Adult; Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dasatinib; Epitopes, T-Lymphocyte; Flow Cytometry; HLA-A2 Antigen; HLA-DR Antigens; Humans; Mice; Mice, Transgenic; Models, Immunological; Protein Kinase Inhibitors; Pyrimidines; Staining and Labeling; Thiazoles | 2009 |
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Topics: Adenosine Triphosphate; Benzamides; Cell Line; Cloning, Molecular; Collagen; Dasatinib; Discoidin Domain Receptor 1; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structural Homology, Protein; Thiazoles | 2008 |
Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
Topics: Adolescent; Benzamides; Combined Modality Therapy; Dasatinib; Fatal Outcome; Genes, abl; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation Chimera | 2009 |
Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Cell Proliferation; Dasatinib; Disease Progression; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Immunohistochemistry; In Vitro Techniques; Liver; Liver Neoplasms; Male; Middle Aged; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thiazoles | 2009 |
Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Topics: Adenylyl Imidodiphosphate; Animals; Apoenzymes; B-Lymphocytes; Catalytic Domain; Crystallography, X-Ray; Dasatinib; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Dasatinib; Echocardiography; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2009 |
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Topics: Antineoplastic Agents; Blotting, Western; Dasatinib; DNA Primers; DNA Probes; Electrophoresis, Polyacrylamide Gel; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; In Situ Hybridization, Fluorescence; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neutropenia; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Splenic Rupture; Thiazoles; Vincristine; Young Adult | 2009 |
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Down-Regulation; Humans; Matrix Metalloproteinase 9; Melanoma; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptor, EphA2; Signal Transduction; src-Family Kinases; Thiazoles | 2008 |
Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Topics: Analysis of Variance; Antigens, CD; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Proliferation; Cells, Cultured; CTLA-4 Antigen; Dasatinib; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Humans; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Interleukin-4; Protein Kinase Inhibitors; Pyrimidines; Receptors, Tumor Necrosis Factor; Signal Transduction; Thiazoles | 2009 |
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Topics: Aged; Antineoplastic Agents; Cladribine; Dasatinib; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Leukemia, Mast-Cell; Mastocytosis, Systemic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Tryptases | 2008 |
Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2009 |
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Topics: Aniline Compounds; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dasatinib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid, Accelerated Phase; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nerve Tissue Proteins; Nitriles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Substrate Specificity; Thiazoles | 2009 |
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Topics: Apoptosis; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2008 |
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; RNA, Messenger; RNA, Small Interfering; src-Family Kinases; Thiazoles; Transfection | 2008 |
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Topics: Animals; Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Dasatinib; Fowlpox virus; Immunity, Cellular; Immunization; Killer Cells, Natural; Mice; Mice, Transgenic; Ovalbumin; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Thiazoles; Transduction, Genetic | 2009 |
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Topics: Antineoplastic Agents; Cell Lineage; Dasatinib; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Natural Killer T-Cells; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2009 |
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.
Topics: Animals; Bone Marrow; Cell Proliferation; Cells, Cultured; Dasatinib; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Mice; Myeloid Cells; Osteoclasts; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; src-Family Kinases; Thiazoles | 2009 |
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
Topics: Animals; Biotechnology; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Genetic Techniques; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.
Topics: Annexin A5; Apoptosis; Blotting, Western; Caspase 3; Dasatinib; Dose-Response Relationship, Drug; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Lentivirus; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Thiazoles; Time Factors | 2009 |
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.
Topics: Dasatinib; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Pulmonary; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pyrimidines; Thiazoles; Transplantation, Homologous; Ventricular Dysfunction, Right | 2009 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Autologous | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Glioma; Humans; PTEN Phosphohydrolase; Pyrimidines; Temozolomide; Thiazoles | 2009 |
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Topics: Child, Preschool; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Transplantation, Homologous | 2009 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
Topics: Adult; Bone Marrow Transplantation; Combined Modality Therapy; Dasatinib; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles | 2009 |
Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Head and Neck Neoplasms; Humans; Janus Kinase 2; Mice; Phosphorylation; Pyrimidines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; TYK2 Kinase | 2009 |
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Topics: Antineoplastic Agents; Benzamides; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Thiazoles | 2009 |
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Mice; Mice, Knockout; Protein Kinase Inhibitors; Pyrimidines; Tetrahydroisoquinolines; Thiazoles | 2009 |
Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Flow Cytometry; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, ErbB-3; src-Family Kinases; Thiazoles | 2009 |
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
Topics: Benzamides; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dasatinib; Diclofenac; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Imatinib Mesylate; K562 Cells; Microsomes, Liver; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Thiazoles | 2009 |
Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations.
Topics: Adult; Blast Crisis; Brain Neoplasms; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Radiography; Thiazoles | 2009 |
Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Dasatinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; Signal Transduction; src-Family Kinases; Thiazoles | 2009 |
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Cohort Studies; Colitis; Dasatinib; Female; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Pleurisy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Thiazoles | 2009 |
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Copper Radioisotopes; Dasatinib; Focal Adhesions; Glioblastoma; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Male; Mice; Mice, SCID; Oligopeptides; Organometallic Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Topics: Animals; Benzamides; Chromatography, Liquid; Dasatinib; Imatinib Mesylate; Linear Models; Mice; Piperazines; Pyrimidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2009 |
The toxicities of modern targeted therapies: learning from the price of progress.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; ErbB Receptors; Hemorrhage; Humans; Imatinib Mesylate; Interdisciplinary Communication; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; Skin; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Calcium; Cell Death; Cell Line, Tumor; Chloroquine; Dasatinib; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Mice; Mice, Inbred C3H; Microtubule-Associated Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; Thiazoles; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2009 |
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Hair Color; Humans; Hypopigmentation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; src-Family Kinases; Thiazoles | 2009 |
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Dasatinib; Down-Regulation; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Interleukin-8; Lectins, C-Type; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2008 |
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Colonic Neoplasms; Dasatinib; Down-Regulation; Drug Synergism; HCT116 Cells; HT29 Cells; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxidative Stress; Protein Kinase Inhibitors; Pyrimidines; Random Allocation; Reactive Oxygen Species; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2009 |
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Benzamides; Caspases; Cell Growth Processes; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mutation; Oncogene Protein v-akt; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrimidines; STAT3 Transcription Factor; Stem Cell Factor; Thiazoles | 2009 |
Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; ErbB Receptors; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2009 |
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles; Time Factors; Young Adult | 2009 |
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Topics: Benzamides; Blood Coagulation; Blood Platelet Disorders; Dasatinib; Health; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Transplantation, Autologous | 2009 |
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Inhibitory Concentration 50; Melanoma; Nitriles; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Skin Neoplasms; src-Family Kinases; Temozolomide; Thiazoles | 2009 |
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Dasatinib; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Thiazoles; Treatment Failure | 2009 |
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Survival Analysis; Thiazoles; Up-Regulation | 2009 |
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Topics: Animals; Apoptosis; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mice, SCID; Osteosarcoma; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Chronic myelogenous leukaemia market.
Topics: Benzamides; Dasatinib; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines; Thiazoles | 2009 |
Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib.
Topics: Child; Dasatinib; Flow Cytometry; Humans; Methods; Phosphorylation; Pyrimidines; src-Family Kinases; Thiazoles | 2009 |
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Topics: Acridines; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Cell Line; Cell Membrane Permeability; Dasatinib; Dibenzocycloheptenes; Dogs; Drug Resistance, Neoplasm; Indicators and Reagents; Mass Spectrometry; Mice; Mice, Knockout; Neurons; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Tetrahydroisoquinolines; Thiazoles; Vinblastine | 2009 |
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzamides; Blood Platelets; Dasatinib; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Middle Aged; Piperazines; Platelet Activation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Pyrimidines; Thiazoles | 2009 |
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
Topics: Actins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cytoskeleton; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Humans; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Tubulin | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
In situ monitoring of bindings between dasatinib and its target protein kinases using magnetic nanoparticles in live cells.
Topics: Cell Survival; Dasatinib; HeLa Cells; Humans; Magnetics; Nanoparticles; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Thiazoles | 2008 |
Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML.
Topics: Adult; Blast Crisis; Dasatinib; Female; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Pyrimidines; Thiazoles | 2010 |
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Spain; Survival Rate; Thiazoles | 2009 |
Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Delivery, Obstetric; Female; Humans; Imatinib Mesylate; Interferons; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Thiazoles | 2009 |
Abdominal pain in a patient with acute lymphoblastic leukaemia.
Topics: Abdominal Pain; Dasatinib; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles | 2009 |
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Topics: Benzamides; Cell Line, Tumor; Chondrosarcoma; Dasatinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; Jurkat Cells; MAP Kinase Signaling System; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; raf Kinases; ras Proteins; src-Family Kinases; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2009 |
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Docetaxel; Humans; Male; Mice; Mice, SCID; Osteolysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Topics: Child, Preschool; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
Optimizing first-line therapy for patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
New directions in the treatment of imatinib failure and/or resistance.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dasatinib; Disease Models, Animal; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Invasiveness; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; DNA Mismatch Repair; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Topics: Butadienes; Dasatinib; Databases, Protein; Epidermal Growth Factor; Fusion Proteins, bcr-abl; HeLa Cells; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridines; Pyrimidines; Signal Transduction; Thiazoles; Up-Regulation | 2009 |
Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Bone Marrow Transplantation; Child; Colitis; Colonoscopy; Combined Modality Therapy; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imatinib Mesylate; Melanoma; Models, Molecular; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2009 |
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; Signal Transduction; Thiazoles | 2009 |
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Cell Movement; Cell Survival; Central Nervous System Neoplasms; Dasatinib; Drug Synergism; Enzyme Activation; ErbB Receptors; Gene Silencing; Glioblastoma; Humans; Mice; Mutation; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2009 |
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.
Topics: Annexin A5; Apoptosis; Cell Division; Cell Survival; Cells, Cultured; Dasatinib; Hematopoietic Stem Cells; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfluidics; Microscopy, Fluorescence; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles | 2009 |
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Topics: Apoptosis; Dasatinib; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2009 |
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Topics: Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Biphenotypic, Acute; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Thiazoles | 2009 |
The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
Topics: Animals; Benzamides; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dasatinib; Flow Cytometry; Glycosylation; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Intracellular Space; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Fusion Proteins; Reproducibility of Results; Signal Transduction; Thiazoles | 2009 |
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Basophils; Dasatinib; Female; Flow Cytometry; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Middle Aged; Proteome; Pyrimidines; Thiazoles | 2009 |
Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 17; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2009 |
Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Calcium Signaling; Cell Line, Tumor; Cell Separation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Microscopy, Fluorescence; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles; Tissue Array Analysis | 2010 |
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.
Topics: Algorithms; Benzamides; Cell Cycle; Cell Line; Cluster Analysis; Computational Biology; Dasatinib; Diphenylamine; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2009 |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporins; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; Humans; Indoles; K562 Cells; Neoplasm Proteins; Neoplasms; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Substrate Specificity; Thiazoles | 2009 |
Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.
Topics: Animals; Bone Marrow Cells; Cell Line; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Injections, Intraperitoneal; Interleukin-10; Interleukin-6; Lipopolysaccharides; Lung; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neutrophils; Pyrimidines; Thiazoles; Toll-Like Receptor 3; Toll-Like Receptor 4; Toll-Like Receptor 9; Toll-Like Receptors; Tumor Necrosis Factor-alpha | 2009 |
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2009 |
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
Topics: Adult; Amino Acid Sequence; Dasatinib; Gene Fusion; Genes, abl; Humans; Intracellular Signaling Peptides and Proteins; Male; Molecular Sequence Data; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Pyrimidines; Thiazoles; Translocation, Genetic | 2009 |
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2009 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Bone Marrow Cells; Cell Differentiation; Clone Cells; Cytogenetic Analysis; Dasatinib; Female; Follow-Up Studies; Genes, p53; Hematopoiesis; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Sequence Data; Philadelphia Chromosome; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Topics: Amino Acid Substitution; Antineoplastic Agents; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylalanine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Lasker Awards and papal portraiture: turning fields upside down.
Topics: Awards and Prizes; Benzamides; Cellular Reprogramming; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orientation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Topics: Adult; Benzamides; Cohort Studies; Cytogenetic Analysis; Dasatinib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Dasatinib-induced pleural effusions: a lymphatic network disorder?
Topics: Adult; Aged; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; Ear Diseases; Fusion Proteins, bcr-abl; Humans; Keratoacanthoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Pyrimidines; Radiotherapy; Scalp; Thiazoles; Tongue Neoplasms; Vocal Cords | 2010 |
Systematically linking drug susceptibility to cancer genome aberrations.
Topics: Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2009 |
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dasatinib; Humans; Lapatinib; Limit of Detection; Mass Spectrometry; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sensitivity and Specificity; Thiazoles | 2009 |
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Collagen; Dasatinib; Humans; Male; Mice; Mice, Inbred C57BL; Monocytes; Neoplasm Proteins; Osteoclasts; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; RANK Ligand; src-Family Kinases; Thiazoles | 2009 |
Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation.
Topics: Adult; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Transplantation Chimera; Transplantation, Homologous | 2010 |
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Dasatinib; DNA Repair; Drug Interactions; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; src-Family Kinases; Thiazoles; Transcription, Genetic; Up-Regulation | 2009 |
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Dasatinib; Female; Flow Cytometry; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-yes; Pyrimidines; Receptor, EphA2; src-Family Kinases; Thiazoles | 2009 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2010 |
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Transplantation, Autologous | 2010 |
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles | 2010 |
Hematology: dasatinib regimens for patients with chronic myeloid leukemia.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
Topics: Clinical Trials as Topic; Dasatinib; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
p38 in chronic myelogenous leukemia: a target and a possible biomarker.
Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Signal Transduction; Thiazoles | 2009 |
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning | 2009 |
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dasatinib; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo.
Topics: Animals; Dasatinib; Humans; Immunity, Cellular; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Topics: Adenine; Animals; Benzamides; Binding Sites; Cell Line; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Dasatinib promotes ATRA-induced differentiation of AML cells.
Topics: Cell Differentiation; Dasatinib; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2010 |
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.
Topics: Antineoplastic Agents; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Topics: Animals; Cell Survival; Dasatinib; Humans; Lymphoma, B-Cell; Mice; Pyrimidines; RNA, Small Interfering; src-Family Kinases; Thiazoles | 2009 |
Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.
Topics: Blast Crisis; Cord Blood Stem Cell Transplantation; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
Topics: Agammaglobulinaemia Tyrosine Kinase; Amino Acid Sequence; Crystallography, X-Ray; Dasatinib; Enzyme Activation; Humans; Molecular Sequence Data; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Thiazoles | 2010 |
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Topics: Chronic Disease; Combined Modality Therapy; Dasatinib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Sclerosis; Severity of Illness Index; Thiazoles; Young Adult | 2010 |
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Cell Death; Dasatinib; Enzyme Activation; Female; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phospholipase C gamma; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Syk Kinase; Thiazoles; Tumor Cells, Cultured | 2010 |
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
Targeting the tumor microenvironment with SRC kinase inhibition.
Topics: Animals; Dasatinib; Endothelial Cells; Fusion Proteins, bcr-abl; Male; Mice; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Stromal Cells; Thiazoles | 2010 |
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Topics: Animals; Dasatinib; Endothelial Cells; Humans; Mice; Mice, Nude; Myeloid Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Cells, Cultured | 2010 |
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzene Derivatives; Cells, Cultured; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Mice; Mutation; Phosphorylation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tyrosine | 2010 |
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Cells, Cultured; Dasatinib; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Fusion Proteins, bcr-abl; Humans; Leukemia, Experimental; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, CXCR4; src-Family Kinases; Stromal Cells; Thiazoles | 2010 |
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Topics: Antigens, CD34; Apoptosis; Blotting, Western; Cytokines; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Janus Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2010 |
Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2010 |
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Topics: Adult; Aged; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Diphtheria Toxin; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2010 |
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Topics: Animals; Benzamides; beta Catenin; Cell Hypoxia; Cell Line, Tumor; Dasatinib; Humans; Imatinib Mesylate; Lactoylglutathione Lyase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Heterologous | 2010 |
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Topics: Aluminum Silicates; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Lck is a key target of imatinib and dasatinib in T-cell activation.
Topics: Animals; Benzamides; Blotting, Western; Chlorocebus aethiops; COS Cells; Dasatinib; Flow Cytometry; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Immunoprecipitation; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; T-Lymphocytes; Thiazoles | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
Topics: Apoptosis; Cell Line, Tumor; Dasatinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mass Spectrometry; Peptides; Phenotype; Phosphoproteins; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Signal Transduction; Thiazoles | 2010 |
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles | 2010 |
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Dasatinib; Epithelial Cells; Female; Gene Expression Profiling; Humans; Mesoderm; Prognosis; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
Topics: Absorptiometry, Photon; Animals; Bone Marrow Cells; Bone Remodeling; Cells, Cultured; Dasatinib; Female; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Thiazoles; Tibia | 2010 |
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Topics: Animals; Cell Differentiation; Cell Growth Processes; Dasatinib; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Osteoblasts; Osteonectin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Topics: Animals; Apoptosis; B-Lymphocytes; Calcium Signaling; Cell Line, Tumor; Cells, Cultured; Dasatinib; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Lymphocytes; Mice; Mice, Inbred Strains; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; RNA, Small Interfering; Signal Transduction; T-Lymphocytes; Thiazoles; Tumor Cells, Cultured | 2010 |
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Dasatinib; Disease Models, Animal; Female; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Humulane and germacrane sesquiterpenes from Ferula lycia.
Topics: Bone Marrow Cells; Dasatinib; Drug Screening Assays, Antitumor; Ferula; Humans; K562 Cells; Molecular Structure; Protein-Tyrosine Kinases; Pyrimidines; Sesquiterpenes; Sesquiterpenes, Germacrane; Thiazoles; Turkey | 2010 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Topics: Aged; Anti-Inflammatory Agents; Colonic Diseases; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Subcutaneous Tissue; Thiazoles; Thymosin; Treatment Outcome; Ulcer | 2010 |
Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dasatinib; Dose-Response Relationship, Drug; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Primary Myelofibrosis; Pyrimidines; Thiazoles | 2010 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
[Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colitis; Cytomegalovirus Infections; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2010 |
Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Topics: Androgen Receptor Antagonists; Animals; Cell Growth Processes; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Dasatinib; Humans; Immunoblotting; Male; Mice; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Signal Transduction; src-Family Kinases; Thiazoles; Transfection; Xenograft Model Antitumor Assays | 2010 |
Reversible cardiotoxicity with tyrosine kinase inhibitors.
Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left | 2010 |
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.
Topics: Antigens, CD34; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dasatinib; Fetal Blood; Humans; Infant, Newborn; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cells; Stromal Cells; Thiazoles; Time Factors | 2010 |
Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinases; Cells, Cultured; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Embryo, Mammalian; Fusion Proteins, bcr-abl; Humans; Mice; Mice, Knockout; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dasatinib; Female; Humans; Leukemia, Large Granular Lymphocytic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Lymphocytosis; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Dasatinib; Drug Synergism; Female; Humans; Mice; Mice, Nude; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tissue Array Analysis; Up-Regulation; Urologic Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2010 |
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Indoles; Inhibitory Concentration 50; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Receptors, Growth Factor; src-Family Kinases; Stomach Neoplasms; Sulfones; Thiazoles | 2010 |
Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aniline Compounds; Case-Control Studies; Centrosome; Dasatinib; Female; Fibroblasts; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2010 |
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CD8-Positive T-Lymphocytes; Clonal Anergy; Clone Cells; Cytomegalovirus; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Thiazoles; Virus Activation; Young Adult | 2010 |
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles | 2010 |
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Culture Techniques; Dasatinib; Humans; Imatinib Mesylate; K562 Cells; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genome, Human; Humans; Matched-Pair Analysis; Oligonucleotide Array Sequence Analysis; Patient Selection; Prognosis; Pyrimidines; Thiazoles | 2010 |
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Pyrimidines; Thiazoles | 2010 |
MASPECTRAS 2: An integration and analysis platform for proteomic data.
Topics: Aniline Compounds; Cell Line, Tumor; Dasatinib; Databases, Protein; Humans; Mass Spectrometry; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Proteomics; Pyrimidines; Quinolines; Software; Thiazoles; User-Computer Interface | 2010 |
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Topics: Chromosomes, Human, Pair 7; Dasatinib; Female; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Monosomy; Mutation; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Thiazoles | 2010 |
Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fertilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
Topics: Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Colonic Neoplasms; CSK Tyrosine-Protein Kinase; Curcumin; Dasatinib; Drug Synergism; Electrophoretic Mobility Shift Assay; Endothelium, Vascular; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Intestinal Neoplasms; Mice; Mice, Knockout; Neoplasm Invasiveness; Neovascularization, Pathologic; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; Thiazoles; Umbilical Veins | 2011 |
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
Topics: Blotting, Western; Bone Morphogenetic Proteins; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dasatinib; Humans; In Vitro Techniques; Mesenchymal Stem Cells; Osteoblasts; Osteogenesis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2010 |
Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells.
Topics: Cell Proliferation; Cells, Cultured; Dasatinib; Drug Synergism; Humans; Janus Kinase 2; Leukemia; Mast Cells; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrrolidines; Signal Transduction; STAT5 Transcription Factor; Sulfonamides; Thiazoles | 2010 |
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Topics: Antineoplastic Agents; Benzamides; Chromosome Breakpoints; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dasatinib; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Humans; Immunohistochemistry; Mice; Mice, SCID; Protein Structure, Tertiary; Pyrimidines; Rats; Receptor, ErbB-2; Recombinant Fusion Proteins; Recombinant Proteins; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Even better kinase inhibitors for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2010 |
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Topics: Adolescent; Adult; Alkaline Phosphatase; Ascorbic Acid; Bone Marrow Cells; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Cell Separation; Cells, Cultured; Child; Child, Preschool; Dasatinib; Dexamethasone; Dose-Response Relationship, Drug; Extracellular Matrix; Gene Expression Regulation; Glycerophosphates; Humans; Integrin-Binding Sialoprotein; Kinetics; Mesenchymal Stem Cells; Middle Aged; Osteoblasts; Osteogenesis; Osteopontin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; RANK Ligand; Sialoglycoproteins; src-Family Kinases; Thiazoles; Young Adult | 2010 |
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cats; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Loratadine; Mastocytoma; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Terfenadine; Thiazoles; Tumor Cells, Cultured | 2010 |
p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Topics: Antineoplastic Agents; Autophagy; Dasatinib; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrimidines; Thiazoles; Tumor Suppressor Protein p53 | 2011 |
Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.
Topics: Dasatinib; Fibroblasts; Humans; Lung Neoplasms; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Biosensing Techniques; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fluorescence; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Calcium; Cell Proliferation; Cyclosporine; Cytokines; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Wnt Proteins | 2010 |
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Drug Costs; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Sweden; Thiazoles; Treatment Outcome | 2010 |
Dasatinib induces autophagic cell death in human ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 12; Beclin-1; Cell Line, Tumor; Cell Proliferation; Dasatinib; Female; Humans; Membrane Proteins; Mice; Mice, Nude; Ovarian Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Small Ubiquitin-Related Modifier Proteins; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Topics: Adolescent; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Pyrimidines; Thiazoles | 2010 |
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Topics: Adolescent; Adult; Aged; Clone Cells; Dasatinib; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Neoplasm; Thiazoles; Young Adult | 2010 |
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Antigens, Surface; Benzamides; Blood Cells; Bone Marrow Cells; Cell Count; Cytotoxicity, Immunologic; Dasatinib; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immune System; Immunologic Memory; Immunophenotyping; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2010 |
Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Mitochondria; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Thiazoles; Transfection | 2010 |
Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dasatinib; ErbB Receptors; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Protein Kinase Inhibitors; Protein Transport; Pyrimidines; Squamous Cell Carcinoma of Head and Neck; Thiazoles | 2010 |
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.
Topics: Antineoplastic Agents; Autophagy; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrimidines; Thiazoles; Tumor Suppressor Protein p53 | 2011 |
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.
Topics: Animals; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Fowlpox virus; Humans; Immunotherapy; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Ovalbumin; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2010 |
Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; Thiazoles | 2010 |
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dasatinib; Disease Progression; Humans; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Stem Cell Assay | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Topics: Adult; Aged; Benzamides; Comparative Genomic Hybridization; Dasatinib; ErbB Receptors; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Male; Middle Aged; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Thiazoles; Tunica Intima; Vascular Neoplasms | 2010 |
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.
Topics: Aged; Dasatinib; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2010 |
Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Aged; Biopsy; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Models, Animal; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Integrins; Mice; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Up-Regulation | 2010 |
Src family kinases are essential for primary aggregation by G(i) -coupled receptors.
Topics: Aza Compounds; Blood Platelets; Cyclic AMP; Dasatinib; Epinephrine; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Platelet Activation; Platelet-Rich Plasma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Purinergic P2Y12; src-Family Kinases; Thiazoles; Tyrosine | 2010 |
A magnetic bead-based protein kinase assay with dual detection techniques.
Topics: Antibodies; Benzamides; Dasatinib; Imatinib Mesylate; Immunoassay; Luminescent Measurements; Magnetics; Peptides; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiazoles | 2011 |
Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Thiazoles; Trastuzumab; Up-Regulation | 2010 |
Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
Topics: Blast Crisis; Cell Differentiation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Dasatinib; Flow Cytometry; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Translocation, Genetic; Treatment Outcome | 2010 |
Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Biosensing Techniques; Cells, Cultured; Chlorocebus aethiops; Computer Systems; COS Cells; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorescence Resonance Energy Transfer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines; Thiazoles; Time Factors | 2010 |
Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
Topics: Adolescent; Dasatinib; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Transplantation, Homologous | 2010 |
Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.
Topics: Adult; Colon; Dasatinib; Female; Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ulcer | 2010 |
Expanding the diversity of allosteric bcr-abl inhibitors.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Transformed; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Mice; Models, Molecular; Mutation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2010 |
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Dasatinib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Thiazoles; Transcription Factors | 2010 |
Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Aged; Dasatinib; Female; Humans; Leukemic Infiltration; Optic Nerve; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Visual Acuity | 2010 |
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
Topics: Casein Kinase II; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dasatinib; HeLa Cells; Humans; Immunoblotting; Jurkat Cells; Karyotyping; Liposarcoma, Myxoid; NF-kappa B; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Triazoles | 2010 |
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2010 |
Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Prevalence; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland | 2010 |
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.
Topics: Aged; Brain; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2011 |
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzamides; Blast Crisis; Clofarabine; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Homologous | 2010 |
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinases; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Dasatinib; Embryo, Mammalian; Female; Fibroblasts; Flow Cytometry; Fluorescent Antibody Technique; Lung Neoplasms; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, SCID; NIH 3T3 Cells; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
On the assessment of dasatinib-induced autophagy in CLL.
Topics: Antineoplastic Agents; Autophagy; Dasatinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrimidines; Thiazoles | 2011 |
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transcription, Genetic | 2011 |
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Dasatinib; G1 Phase Cell Cycle Checkpoints; Granulocyte Precursor Cells; Humans; Leukemia, Prolymphocytic, B-Cell; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; STAT3 Transcription Factor; Thiazoles; Time Factors; Tumor Suppressor Protein p53 | 2012 |
Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
Topics: Cell Line, Tumor; Dasatinib; Focal Adhesion Protein-Tyrosine Kinases; Humans; Indoles; Integrin beta1; JNK Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor, EphA2; STAT3 Transcription Factor; Thiazoles; Thyroid Neoplasms | 2010 |
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; HCT116 Cells; Humans; Immunoblotting; Male; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; RNA Interference; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dasatinib; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Humans; Inhibitory Concentration 50; Neoplastic Stem Cells; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Survival Rate; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intention to Treat Analysis; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Algorithms; Ambulatory Care; Antineoplastic Agents; Cohort Studies; Comorbidity; Dasatinib; Databases, Factual; Female; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Pyrimidines; Retrospective Studies; Thiazoles | 2010 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
[Effect of low-dose dasatinib in an elderly patient with chronic myelogenous leukemia (CML)].
Topics: Aged; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Fusion Proteins, bcr-abl; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles | 2011 |
[Chronic myeloid leukemia and targeted therapies: too many choices?].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Crizotinib; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Mouth Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dasatinib; Down-Regulation; Drug Synergism; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Thiazoles; Transcription, Genetic; Tumor Suppressor Protein p53 | 2011 |
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Protocols; Benzamides; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Thiazoles; Withholding Treatment | 2011 |
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Topics: Animals; Cell Transformation, Neoplastic; CSK Tyrosine-Protein Kinase; Dasatinib; Epithelial-Mesenchymal Transition; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Invasiveness; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Signal Transduction; src-Family Kinases; Thiazoles; Up-Regulation | 2011 |
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Topics: Aniline Compounds; Animals; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Dasatinib; DNA Damage; Female; Gene Knockdown Techniques; Humans; In Vitro Techniques; MAP Kinase Signaling System; Mice; Mice, Nude; Multiple Myeloma; Mutation; Neovascularization, Pathologic; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Quinolines; RecQ Helicases; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2011 |
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dasatinib; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours.
Topics: Antineoplastic Agents; Brain; Child, Preschool; Dasatinib; Female; Humans; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2011 |
[A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosomes, Human, Pair 3; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.
Topics: Animals; Dasatinib; Female; Fluorine Radioisotopes; Male; Mice; Mice, Nude; Mice, SCID; Models, Animal; Molecular Imaging; Positron-Emission Tomography; Pyrimidines; Radiation Dosage; Radiopharmaceuticals; Thiazoles; Tissue Distribution | 2012 |
Significance of ER-Src axis in hormonal therapy resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Pyrimidines; Receptor, ErbB-2; RNA Interference; src-Family Kinases; Tamoxifen; Thiazoles; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunity, Innate; Immunoglobulins; Immunologic Factors; Interferon-alpha; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles; Treatment Outcome | 2010 |
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Drug Synergism; Female; Gene Expression; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thiazoles | 2011 |
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2011 |
CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Blotting, Western; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Dasatinib; Enzyme Activation; Fluorescent Antibody Technique; HEK293 Cells; Humans; Lung Neoplasms; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasm Proteins; Pyrimidines; src-Family Kinases; Tandem Mass Spectrometry; Thiazoles; Transplantation, Heterologous | 2011 |
2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
Topics: Amino Acid Sequence; Annexin A2; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Melanoma; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteome; Pyrimidines; Thiazoles; Two-Dimensional Difference Gel Electrophoresis | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Cyclin-Dependent Kinase Inhibitor p16; Dasatinib; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutagenesis; Mutation, Missense; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Transplantation, Isogeneic | 2011 |
Allosteric interactions between the myristate- and ATP-site of the Abl kinase.
Topics: Adenosine Triphosphate; Allosteric Regulation; Antineoplastic Agents; Binding Sites; Dasatinib; Humans; Mass Spectrometry; Myristic Acid; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2011 |
Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.
Topics: Animals; Carcinoma, Pancreatic Ductal; Dasatinib; Fluorescence Resonance Energy Transfer; Genes, p53; Mice; Mice, Knockout; Microscopy, Fluorescence; Models, Genetic; Mutation; Neoplasm Invasiveness; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Thiazoles | 2011 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dasatinib; Disease Progression; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Immunoblotting; Immunohistochemistry; Mice; Mice, Nude; Mutation; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrimidines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; src-Family Kinases; Thiazoles; Transfection; Up-Regulation | 2011 |
A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assay.
Topics: Cell Migration Assays; Cell Movement; Cells, Cultured; Dasatinib; Endothelial Cells; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Role of Pten in leukemia stem cells.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles | 2010 |
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Topics: Benzamides; Child; Dasatinib; Diseases in Twins; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
In vitro studies of dasatinib, its targets and predictors of sensitivity.
Topics: Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Humans; Melanoma; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; src-Family Kinases; Thiazoles | 2011 |
[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Panniculitis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Skin; Thiazoles | 2011 |
Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Pyrimidines; Safety-Based Drug Withdrawals; Thiazoles | 2011 |
Src: a potential target for the treatment of triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Cytoplasm; Dasatinib; Female; Humans; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; src-Family Kinases; Thiazoles | 2011 |
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Topics: Aged; Dasatinib; Diuretics; Drug Administration Schedule; Female; Furosemide; Glucocorticoids; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Severity of Illness Index; Thiazoles; Turkey | 2011 |
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Topics: Animals; Blood Platelets; Cell Differentiation; Cell Movement; Cell Separation; Dasatinib; Flow Cytometry; Immunohistochemistry; Megakaryocytes; Mice; Mice, Inbred C57BL; Ploidies; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Thrombocytopenia; Thrombopoiesis | 2011 |
Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2011 |
Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Disease-Free Survival; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Medical Records; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia.
Topics: Biomarkers, Tumor; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Netherlands; Protein Kinases; Pyrimidines; Thiazoles | 2011 |
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Topics: Dasatinib; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Topics: Apoptosis; Caspase 3; Cell Line; Ceramides; Dasatinib; Dose-Response Relationship, Drug; Glucosyltransferases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Oxidoreductases; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Duplication; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Topics: Blast Crisis; Bone Marrow; Dasatinib; Femur; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; Orbital Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2011 |
Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cross Reactions; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Topics: Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Talc crystals in pleurodesis-associated talc granuloma.
Topics: Aged; Biopsy, Fine-Needle; Cytoplasm; Dasatinib; Giant Cells; Granuloma, Foreign-Body; Humans; Immunohistochemistry; Macrophages; Male; Melanoma; Multimodal Imaging; Neoplasm Metastasis; Pleural Effusion; Pleurodesis; Positron-Emission Tomography; Pyrimidines; Talc; Thiazoles; Tomography, X-Ray Computed | 2012 |
How does a drug molecule find its target binding site?
Topics: Binding Sites; Dasatinib; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Pyrazoles; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells.
Topics: Animals; Cellular Reprogramming; Dasatinib; Doxycycline; Fibroblasts; High-Throughput Screening Assays; Induced Pluripotent Stem Cells; Mice; Protein Kinase Inhibitors; Pyrimidines; SOXB1 Transcription Factors; src-Family Kinases; Thiazoles; Transforming Growth Factor beta | 2011 |
Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazoles | 2011 |
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.
Topics: Algorithms; Antibodies; Antigens, Surface; B-Lymphocytes; Bone Marrow Cells; Cytokines; Dasatinib; Flow Cytometry; Hematopoiesis; Humans; Immunophenotyping; Lanthanoid Series Elements; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Subsets; Mass Spectrometry; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Single-Cell Analysis; T-Lymphocytes; Thiazoles; Transition Elements | 2011 |
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Enzyme Activation; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Models, Biological; Mutant Proteins; Phosphatidylinositol 3-Kinase; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; Thiazoles | 2011 |
Synthesis and biological activities of 2-amino-thiazole-5-carboxylic acid phenylamide derivatives.
Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combinatorial Chemistry Techniques; Dasatinib; Female; HT29 Cells; Humans; Inhibitory Concentration 50; Leukemia; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2011 |
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Topics: Aged; Dasatinib; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Female; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Smoking; Thiazoles; Thymidylate Synthase | 2012 |
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Immunoprecipitation; In Vitro Techniques; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Von Hippel-Lindau Tumor Suppressor Protein | 2011 |
Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Death; Cell Line, Transformed; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Dasatinib; Female; Fibroblasts; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Protease Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; Quinazolines; Radiation Tolerance; src-Family Kinases; Thiazoles | 2011 |
[Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase].
Topics: Adult; Colitis; Cytomegalovirus Infections; Dasatinib; Enterocolitis; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Myeloid, Chronic-Phase; Pyrimidines; Thiazoles | 2011 |
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Topics: Adult; Aged; Apoptosis; Base Sequence; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Division; Cytomegalovirus; Dasatinib; DNA Primers; Female; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Virus Activation | 2011 |
HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
Topics: Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Dasatinib; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Immunoenzyme Techniques; Immunoprecipitation; Melanoma; Nerve Growth Factors; Nuclear Receptor Coactivator 1; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Thiazoles; Tumor Cells, Cultured | 2011 |
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles; Vault Ribonucleoprotein Particles | 2011 |
Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
Topics: Benzamides; Chromatography, Liquid; Dasatinib; Gene Expression Profiling; Hep G2 Cells; Humans; Imatinib Mesylate; Liver Neoplasms; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Staurosporine; Thiazoles | 2011 |
Dasatinib for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aniline Compounds; Cell Line, Tumor; Dasatinib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mast Cells; Mastocytosis, Systemic; Mutation; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Staurosporine; Thiazoles; Tumor Cells, Cultured | 2011 |
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Dasatinib; Dose-Response Relationship, Drug; Enzyme Assays; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Thiazoles | 2010 |
In situ kinase profiling reveals functionally relevant properties of native kinases.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Dasatinib; Humans; MAP Kinase Kinase 5; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; raf Kinases; Recombinant Proteins; Thiazoles | 2011 |
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Topics: Aged; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2011 |
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Blood Pressure; Dasatinib; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pulmonary Medicine; Pyrimidines; Thiazoles; Treatment Outcome; Ventricular Dysfunction, Right | 2011 |
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Transcriptome | 2012 |
Targeting SRC in mucinous ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dasatinib; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; Computational Biology; Dasatinib; Databases, Protein; Humans; Intracellular Space; Models, Biological; Neoplasm Proteins; Neoplasms; Phosphotyrosine; Proteome; Pyrimidines; Signal Transduction; Thiazoles; Transforming Growth Factor beta | 2011 |
Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Docetaxel; Drug Synergism; Esophageal Neoplasms; Female; Humans; Mad2 Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Repressor Proteins; src-Family Kinases; Taxoids; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Line; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Female; Fibroblasts; Glycolysis; Humans; Pyrimidines; Tamoxifen; Telomerase; Thiazoles | 2011 |
Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Topics: Aged; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2011 |
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinases; Cell Adhesion; Cell Line, Tumor; Dasatinib; Female; Humans; Mitosis; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrroles; src-Family Kinases; Thiazoles | 2012 |
Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.
Topics: Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Dasatinib; Diagnosis, Differential; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Multiple Primary; Pyrimidines; Recurrence; Remission Induction; Skin Neoplasms; Thiazoles; Tumor Burden | 2011 |
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Topics: Apoptosis; Dasatinib; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Confounding Factors, Epidemiologic; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, bcl-1; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Research Design; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Serine; src-Family Kinases; Thiazoles; Threonine; Tyrosine; Xenograft Model Antitumor Assays | 2011 |
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2012 |
[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].
Topics: Aged; Benzamides; Chronic Disease; Dasatinib; Drug Monitoring; Drug Tolerance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Thiazoles; Treatment Outcome | 2011 |
The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Polarity; Cell Proliferation; Dasatinib; Focal Adhesion Protein-Tyrosine Kinases; Indoles; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Sulfonamides; Thiazoles | 2012 |
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
Topics: Adult; Dasatinib; Female; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Thiazoles | 2011 |
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromosomes, Human, Pair 8; Clone Cells; Dasatinib; DNA Mutational Analysis; Genomic Instability; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Philadelphia Chromosome; Piperazines; Preleukemia; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Selection, Genetic; Thiazoles; Trisomy | 2012 |
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinases; Breast Neoplasms; Computer Simulation; Dasatinib; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Inhibitory Concentration 50; Melanocytes; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Oncogenes; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrazines; Pyrimidines; RNA-Binding Proteins; Structure-Activity Relationship; Thiazoles | 2011 |
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Immunoprecipitation; Metformin; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrimidines; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Trastuzumab | 2011 |
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
Topics: Antibodies, Monoclonal; Benzamides; Cells, Cultured; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Thiazoles; Up-Regulation | 2012 |
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2011 |
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
Topics: Cell Line, Tumor; Dasatinib; Endoplasmic Reticulum; ErbB Receptors; Extracellular Matrix Proteins; Glioblastoma; Glucose; Golgi Apparatus; Humans; Hydrogen-Ion Concentration; Mitochondria; Mutagenesis, Site-Directed; Oxygen Consumption; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Transcriptional Activation; Transfection | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase.
Topics: Agammaglobulinaemia Tyrosine Kinase; Binding Sites; Chromosomes, Human, X; Crystallography, X-Ray; Dasatinib; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2011 |
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; Remission, Spontaneous; Thiazoles; Time Factors | 2012 |
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Topics: 3T3 Cells; Animals; Cell Death; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Dasatinib; DNA-Binding Proteins; Female; Humans; Leukemia; Lymphoma, B-Cell; Lymphoma, T-Cell; Membrane Proteins; Mice; Mice, Inbred BALB C; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; src-Family Kinases; Thiazoles; Transcription Factors; Translocation, Genetic | 2011 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |
Dasatinib: pulmonary arterial hypertension. French data.
Topics: Antineoplastic Agents; Dasatinib; Familial Primary Pulmonary Hypertension; France; Humans; Hypertension, Pulmonary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
[Roles of the 2nd generation TKIs for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2011 |
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib.
Topics: Adolescent; Blast Crisis; Bone Marrow Transplantation; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dasatinib; Fatal Outcome; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles | 2011 |
Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Dasatinib; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; src-Family Kinases; Thiazoles | 2011 |
Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Pyrimidines; Thiazoles | 2011 |
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
Topics: Antineoplastic Agents; Benzamides; Calibration; Cells, Cultured; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Limit of Detection; Mass Spectrometry; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; Reproducibility of Results; Thiazoles | 2012 |
Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Antineoplastic Agents; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Dasatinib; Hydrophobic and Hydrophilic Interactions; Ligands; Mice; Models, Molecular; Molecular Sequence Data; Pyrimidines; Receptor, EphA4; Thiazoles | 2011 |
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Dasatinib; Humans; In Vitro Techniques; Lymphocytes; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Compound immobilization and drug-affinity chromatography.
Topics: Animals; Cell Extracts; Cells, Cultured; Chromatography, Affinity; Chromatography, Liquid; Dasatinib; Drug Compounding; Electrophoresis, Polyacrylamide Gel; Immunoblotting; Mass Spectrometry; Pharmaceutical Preparations; Proteins; Pyrimidines; Silver Staining; Thiazoles | 2012 |
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Confidence Intervals; Dasatinib; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Mucosa; Odds Ratio; Organs at Risk; Oropharyngeal Neoplasms; Pyrimidines; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Stomatitis; Taxoids; Thiazoles; Tumor Burden | 2012 |
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Thermostability and crystal structure of anticancer drug dasatinib].
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Crystallization; Dasatinib; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Temperature; Thermogravimetry; Thiazoles; X-Ray Diffraction | 2011 |
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biphenyl Compounds; CD40 Antigens; CD40 Ligand; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; NIH 3T3 Cells; Nitrophenols; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Vidarabine | 2012 |
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Male; Mice; Mice, Nude; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Metastasis; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2012 |
Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cells, Cultured; Dasatinib; Female; Humans; Male; Mice; Mice, Inbred C57BL; Microglia; Phosphotyrosine; Plaque, Amyloid; Polymers; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
Changes in tumor tissue organization in collagen-I sensitize cells to ionizing radiation in an ex vivo model of solid mammary tumor growth and local invasion.
Topics: Animals; Apoptosis; Cell Shape; Collagen; Collagen Type I; Dasatinib; Drug Combinations; Female; Laminin; Mammary Neoplasms, Animal; Mice; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proteoglycans; Pyrimidines; Radiation, Ionizing; Thiazoles; Tissue Culture Techniques | 2011 |
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nizatidine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2012 |
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2011 |
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Thiazoles; Time Factors; United Kingdom | 2011 |
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Topics: Adipocytes; Adipogenesis; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Dasatinib; Humans; K562 Cells; Mesenchymal Stem Cells; Mesoderm; Neoplasms; Osteoblasts; Phenotype; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells; Thiazoles | 2011 |
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; International Classification of Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome; Young Adult | 2012 |
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Topics: Animals; Cell Transformation, Neoplastic; Dasatinib; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Genes, src; Growth Hormone; Humans; Mice; Mitochondria; Phosphorylation; Pituitary Neoplasms; Polymorphism, Single Nucleotide; Prolactin; Pyrimidines; Rats; Receptor, Fibroblast Growth Factor, Type 4; Serine; STAT3 Transcription Factor; Thiazoles | 2011 |
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Differentiation; Dasatinib; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Immunoprecipitation; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrimidines; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Thiazoles; Tretinoin; Tumor Cells, Cultured | 2012 |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Young Adult | 2011 |
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HEK293 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Nuclear Proteins; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles | 2012 |
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Topics: Animals; Benzamides; Cell Communication; Cell Differentiation; Collagen; Culture Media, Conditioned; Dasatinib; Drug Combinations; Endocytosis; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; K562 Cells; Laminin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Nanotubes; Neovascularization, Physiologic; Piperazines; Proteoglycans; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors | 2012 |
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Topics: Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles | 2012 |
Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2012 |
Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome | 2012 |
p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes.
Topics: Animals; Cell Line; Dasatinib; Disease Models, Animal; Enzyme Activation; Fanconi Anemia; Fanconi Anemia Complementation Group A Protein; Fanconi Anemia Complementation Group C Protein; Gene Expression Regulation; Gene Knockout Techniques; Humans; Macrophages; Matrix Metalloproteinases; Mice; Mice, Knockout; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phagocytes; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-jun; Pyrazoles; Pyrimidines; RNA Processing, Post-Transcriptional; Small Molecule Libraries; src-Family Kinases; Thiazoles; Toll-Like Receptors; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2012 |
Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Secondary Prevention; Thiazoles; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
Topics: Adenosine Triphosphate; Animals; Cell Proliferation; CHO Cells; Cricetinae; CSK Tyrosine-Protein Kinase; Dasatinib; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Hep G2 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Models, Chemical; Oligonucleotide Probes; Phosphorylation; Protein-Tyrosine Kinases; Proteome; Proteomics; Pyrimidines; Solvents; src-Family Kinases; Technology, Pharmaceutical; Thiazoles; Ultraviolet Rays | 2012 |
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Nucleus; Cells, Cultured; Cyclin D1; Cytokines; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleimides; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2012 |
Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cytomegalovirus Infections; Dasatinib; Databases, Factual; Female; Humans; Infections; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pyrimidines; Research Design; Risk Factors; Thiazoles; Treatment Outcome | 2012 |
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Topics: Adult; Benzamides; Comorbidity; Dasatinib; Disease Management; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; South Africa; Thiazoles; Treatment Outcome | 2011 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.
Topics: Adolescent; Dasatinib; Drug Eruptions; Hair Diseases; Humans; Hypopigmentation; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Vitiligo | 2012 |
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2012 |
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; Asia, Southeastern; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
Topics: Active Transport, Cell Nucleus; bcl-X Protein; Cell Nucleus; Cytoplasm; Dasatinib; Fusion Proteins, bcr-abl; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfluidic Analytical Techniques; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2012 |
A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deuterium; Enzyme Activation; Humans; Lung Neoplasms; Mice; Mice, Nude; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Dasatinib; Female; Hemorrhage; Humans; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Subdural Space; Thiazoles; Thrombocytopenia | 2012 |
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Delivery of Health Care; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Dasatinib inhibits proinflammatory functions of mature human neutrophils.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Adhesion; Cell Respiration; Cells, Cultured; Dasatinib; Down-Regulation; Drug Evaluation, Preclinical; Humans; Inflammation; Inflammation Mediators; Mice; Mice, Inbred C57BL; Neutrophil Activation; Neutrophils; Pyrimidines; Respiratory Burst; Thiazoles | 2012 |
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Topics: Apoptosis; Calcium; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dasatinib; GPI-Linked Proteins; Granzymes; Histocompatibility Antigens Class I; HLA-E Antigens; Humans; Killer Cells, Natural; Leukemia; Lymphoma; Lysosomal-Associated Membrane Protein 1; Lysosomal-Associated Membrane Protein 2; Necrosis; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrimidines; Receptors, IgG; Thiazoles | 2012 |
A dramatic fetal outcome following transplacental transfer of dasatinib.
Topics: Dasatinib; Female; Fetus; Humans; Hydrops Fetalis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Topics: Actins; Antineoplastic Agents; Apoptosis; Bone Marrow; Bone Resorption; Cell Line; Cell Proliferation; Coculture Techniques; Dasatinib; Dexamethasone; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Multiple Myeloma; Oncogene Proteins v-abl; Osteoclasts; Pyrimidines; src-Family Kinases; Stromal Cells; Thiazoles; Tumor Microenvironment | 2012 |
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Europe; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Validation Studies as Topic; Young Adult | 2012 |
NICE backs leukaemia drug after manufacturer drops price.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Double-edged sword of the new cancer therapeutics.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome | 2012 |
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States | 2012 |
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Stromal Cells; Thiazoles | 2012 |
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Disease Progression; ErbB Receptors; Head and Neck Neoplasms; Humans; Immunoprecipitation; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-yes; Pyrimidines; Random Allocation; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2012 |
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction | 2012 |
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Choice Behavior; Dasatinib; Health Services Needs and Demand; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Risk Assessment; Risk Factors; Thiazoles | 2012 |
CML treatment in Asia-Pacific region.
Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Role of Src tyrosine kinases in experimental pulmonary hypertension.
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemotaxis; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imatinib Mesylate; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Time Factors | 2012 |
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
Topics: Benzamides; CD28 Antigens; CD3 Complex; Cyclosporine; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lymphocyte Activation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2012 |
Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.
Topics: Adenocarcinoma, Papillary; Cell Proliferation; Dasatinib; High-Throughput Screening Assays; Humans; Metabolome; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Thyroid Neoplasms; Tumor Cells, Cultured; Tyrosine; Up-Regulation | 2012 |
Subcellular distribution of Lck during CD4 T-cell maturation in the thymic medulla regulates the T-cell activation threshold.
Topics: Animals; Blotting, Western; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Membrane; Cells, Cultured; Dasatinib; Histocompatibility Antigens Class II; Intracellular Space; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microscopy, Immunoelectron; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; Thiazoles; Thymocytes; Thymus Gland | 2012 |
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
Topics: Acetylcysteine; Alanine Transaminase; Animals; Antioxidants; Apoptosis; Blotting, Western; Cell Separation; Dasatinib; DNA; Electrophoresis, Gel, Pulsed-Field; Fluorescent Dyes; Hepatocytes; In Situ Nick-End Labeling; Indoles; L-Lactate Dehydrogenase; Male; Membrane Potential, Mitochondrial; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Stress; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiazoles | 2012 |
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Topics: Anabolic Agents; Animals; Bone Remodeling; Bone Resorption; Cathepsin K; Cell Differentiation; Cell Line; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Female; Humans; Integrin alphaVbeta3; Leukocytes, Mononuclear; Mesenchymal Stem Cells; Mice; NFATC Transcription Factors; Osteoclasts; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; src-Family Kinases; Thiazoles; Wnt Signaling Pathway | 2012 |
Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dasatinib; Delayed-Action Preparations; Deoxycytidine; Ethers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Prodrugs; Pyrimidines; Silanes; Thiazoles | 2012 |
Design, synthesis and antiproliferative activity of 2-acetamidothiazole-5-carboxamide derivatives.
Topics: Amides; Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Design; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Molecular Structure; Neoplasms; Pyrimidines; Thiazoles | 2012 |
Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.
Topics: Dasatinib; Humans; K562 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Thiazoles | 2012 |
Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.
Topics: Allergens; Antigens, Plant; Basophils; Cells, Cultured; Dasatinib; Glucocorticoids; Histamine Release; Humans; Immunoglobulin E; Plant Proteins; Pregnanes; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Female; Humans; Indoles; Neoplasm Invasiveness; Paxillin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Sulfonamides; Thiazoles | 2012 |
[Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2012 |
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Focal Adhesion Kinase 1; Humans; Male; Mice; Mice, Nude; Phosphorylation; Protein Processing, Post-Translational; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Thyroid Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Male; Middle Aged; Mutation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosomes, Human; Dasatinib; Female; Gene Amplification; Gene Dosage; Humans; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Nuclear Proteins; Peptides; Pyrimidines; Stomach Neoplasms; Thiazoles | 2012 |
Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Burkitt Lymphoma; Cell Proliferation; Dasatinib; Disease Models, Animal; Gene Expression; Herpesvirus 4, Human; Mice; Mice, Transgenic; Oncogene Protein p55(v-myc); Pyrimidines; Splenomegaly; Thiazoles; Viral Matrix Proteins | 2012 |
Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Integrin beta4; Lung Neoplasms; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Pyrimidines; Thiazoles | 2012 |
The shady side of dasatinib.
Topics: Animals; Dasatinib; Humans; Inflammation; Neutrophils; Pyrimidines; Thiazoles | 2012 |
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dasatinib; Feeder Cells; Hedgehog Proteins; Humans; Intracellular Space; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Thiazoles; Transcription Factors; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2012 |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Thiazoles | 2012 |
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Lineage; Dasatinib; Disease Models, Animal; Drug Resistance; Drug Resistance, Neoplasm; Erythrocytes; Exons; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mutation; Phenotype; Piperazines; Polycythemia; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2012 |
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy.
Topics: Autophagy; Cell Death; Cell Line, Tumor; Clarithromycin; Dasatinib; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles | 2013 |
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Cell Line; Cell Line, Transformed; Cells, Cultured; Dasatinib; Disease Models, Animal; Enzyme Activation; Longitudinal Studies; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Peptide Fragments; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].
Topics: Adolescent; Benzamides; Core Binding Factor Alpha 2 Subunit; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mutation; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Thiazoles; Transcription Factors | 2012 |
Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
Topics: Child; Dasatinib; Female; Gene Amplification; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Thiazoles | 2012 |
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.
Topics: AMP-Activated Protein Kinases; Animals; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dasatinib; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Melanocytes; Melanoma; Mice; Mice, Nude; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-yes; Proto-Oncogene Proteins p21(ras); Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thiazoles; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2012 |
MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Topics: Antineoplastic Agents; Benzamides; beta-Globins; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Erythroid Cells; Gene Expression; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; S-Phase Kinase-Associated Proteins; Thiazoles | 2013 |
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14.
Topics: Amino Acid Sequence; Animals; Cell Transformation, Neoplastic; Colorectal Neoplasms; Crk-Associated Substrate Protein; Dasatinib; Epidermal Growth Factor; Female; Gene Knock-In Techniques; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Molecular Sequence Data; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases, Non-Receptor; Pyrimidines; Signal Transduction; Thiazoles; Transplantation, Heterologous | 2013 |
Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood.
Topics: CD3 Complex; CD56 Antigen; Cell Proliferation; Cells, Cultured; Dasatinib; Drug Evaluation, Preclinical; Fetal Blood; Gene Expression Regulation; Humans; Infant, Newborn; Killer Cells, Natural; Protein Kinase Inhibitors; Pyrimidines; T-Box Domain Proteins; Thiazoles; Up-Regulation | 2012 |
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles | 2012 |
Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytomegalovirus; Dasatinib; Female; Gene Rearrangement, T-Lymphocyte; Humans; Immunophenotyping; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Thiazoles; Treatment Outcome; Virus Activation; Young Adult | 2012 |
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Drug Synergism; Estrogen Receptor alpha; Female; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neovascularization, Pathologic; Paclitaxel; Peptidomimetics; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Progesterone; src-Family Kinases; Thiazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Lysosomes; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Pyrimidines; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2012 |
A sharp fluctuation in peripheral blood cells shortly after dasatinib administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cells; Blood Platelets; Cell Adhesion Molecules; Dasatinib; Humans; Leukemia; Leukocyte Count; Leukocytes; Middle Aged; Platelet Count; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2012 |
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Topics: Aged; Cytogenetics; Dasatinib; Female; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2013 |
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, KIR; Thiazoles | 2012 |
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Gene Expression Profiling; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Receptors, KIR; Thiazoles | 2012 |
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Dried Blood Spot Testing; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2012 |
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; RNA, Small Interfering; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Dasatinib; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Leukemia; Phosphorylation; Polymerase Chain Reaction; Pyrimidines; Signal Transduction; Thiazoles; Transcription Factors; Vascular Endothelial Growth Factor A | 2012 |
High-resolution enabled TMT 8-plexing.
Topics: Dasatinib; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Indicators and Reagents; K562 Cells; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Tandem Mass Spectrometry; Thiazoles | 2012 |
Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Monitoring; Female; Hematocrit; Humans; Imatinib Mesylate; Linear Models; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2013 |
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles | 2012 |
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Dasatinib; Disease Models, Animal; Endothelium, Vascular; Glioblastoma; Humans; Mice; Mice, Knockout; Molecular Targeted Therapy; Oncogenes; Permeability; Pyrimidines; Signal Transduction; Survival Analysis; Tetrahydroisoquinolines; Thiazoles; Tight Junctions; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Dasatinib in chronic myeloid leukemia: a limited Indian experience.
Topics: Adult; Dasatinib; Female; Humans; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemokines; Dasatinib; Drug Administration Schedule; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Neoplastic; Interferon-gamma; Mastocytoma; Mice; Mice, Inbred DBA; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, OX40; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; T-Lymphocytes, Regulatory; Thiazoles; Tumor Burden; Tumor Microenvironment | 2012 |
An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.
Topics: Benzamides; Cell Line; Dasatinib; Drug Discovery; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Mutation; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2012 |
10 years of progress in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles | 2012 |
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Topics: Dasatinib; Echocardiography; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Thiazoles; Treatment Outcome; Vasodilator Agents; Withholding Treatment | 2012 |
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2012 |
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Topics: Active Transport, Cell Nucleus; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Nucleus; CSK Tyrosine-Protein Kinase; Dasatinib; DNA Repair; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Pyrimidines; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Thiazoles | 2012 |
Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminopyridines; Animals; Anti-Inflammatory Agents; Atrophy; Dasatinib; Dermatitis, Allergic Contact; Drug Evaluation; Female; Mice; Mice, Hairless; Mice, Inbred BALB C; Oxazolone; Protein Kinase Inhibitors; Pyrimidines; Skin; Thiazoles; Thiophenes | 2013 |
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; Thiazoles; Vincristine | 2012 |
c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Dasatinib; Disease Models, Animal; Mice; Motor Neurons; Phosphorylation; Proto-Oncogene Proteins c-abl; Pyrimidines; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles | 2012 |
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Italy; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Colchicine; Computational Biology; Cyclin-Dependent Kinases; Dasatinib; Databases, Genetic; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Pimozide; Purines; Pyrimidines; Terfenadine; Thiazoles; Tubulin Modulators; Verapamil | 2012 |
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
Topics: Antigens, CD34; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Substrate Specificity; Thiazoles | 2013 |
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
Topics: Adult; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dasatinib; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Interleukin-2; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; Stimulation, Chemical; T-Lymphocyte Subsets; Thiazoles; Zoledronic Acid | 2013 |
The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA.
Topics: Cells, Cultured; Cytokines; Dasatinib; Dendritic Cells; Endosomes; Humans; Immune System Diseases; Immunosuppressive Agents; Inflammation Mediators; Molecular Targeted Therapy; Oligodeoxyribonucleotides; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2013 |
Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Membrane; Dasatinib; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles; Young Adult | 2013 |
Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.
Topics: Actins; Adult; Aged; Animals; Apoptosis; Cell Movement; Chemokine CXCL12; Dasatinib; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Leukemic; Humans; Ligands; Male; Mice; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Signal Transduction; Thiazoles | 2012 |
[Treatment for de novo chronic myeloid leukemia in chronic phase].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Treatment of imatinib-intolerant or -resistant CML patients].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biotransformation; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Drug Interactions; Half-Life; Indicators and Reagents; Male; Methotrexate; Protein Kinase Inhibitors; Pyrimidines; Quality Control; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Thiazoles | 2012 |
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Topics: Apoptosis; Barrett Esophagus; Biopsy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Dose-Response Relationship, Drug; Enzyme Activation; Esophageal Neoplasms; Esophagus; Flow Cytometry; Humans; Phosphorylation; Precancerous Conditions; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2013 |
CML: the good, the better, and the difficult choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Dasatinib; Enzyme Activation; Humans; K562 Cells; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles; Translocation, Genetic | 2013 |
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
Topics: Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dasatinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Phosphorylation; Pre-B Cell Receptors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor Tyrosine Kinase-like Orphan Receptors; Signal Transduction; Thiazoles; Translocation, Genetic | 2012 |
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.
Topics: Adult; Antineoplastic Agents; Cytokines; Dasatinib; Gene Expression Profiling; Humans; Immunophenotyping; K562 Cells; Male; Pyrimidines; T-Lymphocytes, Cytotoxic; Thiazoles | 2013 |
Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System; Dasatinib; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2013 |
Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine.
Topics: Animals; Antibodies; Dasatinib; Mastocytoma; Pyrimidines; T-Lymphocytes; Thiazoles | 2012 |
Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues.
Topics: Allografts; CD8-Positive T-Lymphocytes; Child; Dasatinib; DNA Virus Infections; Humans; Immunologic Deficiency Syndromes; Lymphocyte Count; Lymphocytosis; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles | 2013 |
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2012 |
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Immunoblotting; Indoles; Melanoma; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Molecular Sequence Data; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Sulfonamides; Thiazoles; Vemurafenib; Xenograft Model Antitumor Assays | 2013 |
Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Dasatinib; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA Interference; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Burden; Vanadates; Xenograft Model Antitumor Assays | 2013 |
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dasatinib; Focal Adhesion Kinase 1; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaV; Paxillin; Phosphorylation; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2013 |
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Thiazoles; Treatment Outcome | 2013 |
As leukemia options grow, drugs jockey to be first-line therapies.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2013 |
Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dasatinib; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Liver Neoplasms; Male; Pharmacogenetics; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; src-Family Kinases; Thiazoles | 2013 |
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Topics: Animals; Apoptosis; Blotting, Western; Bone Diseases; Cell Cycle; Cell Proliferation; Dasatinib; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Immunoprecipitation; Male; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; src-Family Kinases; Thiazoles; Triazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Dasatinib; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Thiazoles; Transplantation, Homologous | 2013 |
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dasatinib; Disease Models, Animal; Fluorine Radioisotopes; Glioblastoma; Kaplan-Meier Estimate; Liposomes; Mice; Micelles; Molecular Targeted Therapy; Nanoconjugates; NIH 3T3 Cells; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Radioactive Tracers; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Thiazoles | 2012 |
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-yes; Pyrimidines; Rhabdomyosarcoma; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.
Topics: Animals; Benzamides; Cluster Analysis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Spectroscopy, Fourier Transform Infrared; Thiazoles; Tumor Cells, Cultured | 2013 |
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Blood Proteins; Cell Survival; Cells, Cultured; Dasatinib; Enzyme Activation; Female; Gene Expression Regulation, Leukemic; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles | 2013 |
Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Dasatinib; Disease Models, Animal; Electroretinography; Female; Fetus; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Retinal Detachment; Retinal Pigment Epithelium; Swine; Thiazoles; Vitreoretinopathy, Proliferative; Vitreous Body | 2013 |
Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Dog Diseases; Dogs; Histiocytic Sarcoma; Pyrimidines; Thiazoles | 2013 |
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoblasts; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytokine Receptor Common beta Subunit; Dasatinib; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; HEK293 Cells; Humans; Leukemia, Myelomonocytic, Juvenile; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Pyrimidines; src-Family Kinases; Thiazoles; Ubiquitination | 2013 |
Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cisplatin; Dasatinib; Dose-Response Relationship, Drug; Flow Cytometry; Humans; In Vitro Techniques; Laryngeal Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Pyrimidines; Rats; Thiazoles | 2013 |
Chronic myeloid leukemia: advances in diagnosis and management.
Topics: Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2013 |
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Biological Transport; Bone Marrow Cells; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Nuclear Proteins; Osmolar Concentration; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2013 |
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Topics: Adult; Dasatinib; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles | 2013 |
Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2013 |
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Thiazoles; Vimentin | 2013 |
Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Enzyme Activation; Glioma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2013 |
[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Topics: Benzamides; Dasatinib; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Topics: Antigens, Viral; Apoptosis; Cell Degranulation; Cell Division; Cells, Cultured; Cytokines; Cytomegalovirus; Cytotoxicity, Immunologic; Dasatinib; Dexamethasone; Drug Evaluation, Preclinical; Drug Synergism; Herpesvirus 4, Human; HLA Antigens; Humans; K562 Cells; Lymphocyte Activation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Thiazoles | 2013 |
[Chronic myeloid leukemia].
Topics: Dasatinib; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2012 |
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Dasatinib; Humans; Liver Neoplasms; Molecular Targeted Therapy; Precision Medicine; Pyrimidines; Thiazoles | 2013 |
A case study of personalized therapy for osteosarcoma.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Dog Diseases; Dogs; Osteosarcoma; Protein Kinase Inhibitors; Pyrimidines; Radiography; src-Family Kinases; Thiazoles; Time Factors | 2013 |
Dasatinib-induced nephrotic-range proteinuria.
Topics: Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nephrotic Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Taming of the shrew--overcoming extramedullary blast crisis in the era of the new tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Blast Crisis; Central Nervous System Neoplasms; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles | 2013 |
Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Bone Marrow; Brain; Central Nervous System Neoplasms; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Pyrimidines; Radiography; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2013 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
Topics: Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Models, Chemical; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases; Thiazoles; U937 Cells | 2013 |
Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Topics: Apoptosis; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytokines; Dasatinib; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lysosomal-Associated Membrane Protein 1; Lysosomal-Associated Membrane Protein 2; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Thalidomide; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
SRC signaling is crucial in the growth of synovial sarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Dasatinib; Drug Synergism; Enzyme Activation; Humans; Mice; Mitosis; Neoplasm Proteins; Phosphorylation; Phosphotransferases; Protein Array Analysis; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Repressor Proteins; rhoA GTP-Binding Protein; RNA Interference; Sarcoma, Synovial; Signal Transduction; src-Family Kinases; Thiazoles; Translocation, Genetic; Tumor Burden; Tyrosine; Xenograft Model Antitumor Assays | 2013 |
Enhanced antitumor activity by the combination of dasatinib and combretastatin A-4 in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Synergism; Humans; Mice; Mice, Nude; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Stilbenes; Thiazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dasatinib : a novel therapy for breast cancer?
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; ErbB Receptors; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles | 2013 |
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Eruptions; Folliculitis; Hair Follicle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles | 2014 |
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cadherins; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Enhancer Elements, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Integrases; Lactoglobulins; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neoplasm Invasiveness; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors | 2013 |
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Topics: Antibodies, Monoclonal; Benzodioxoles; Blotting, Northern; Blotting, Western; Cell Survival; Dasatinib; Dengue Virus; Dimethyl Sulfoxide; DNA Primers; HEK293 Cells; Humans; Mycophenolic Acid; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Quinazolines; Replicon; RNA Interference; RNA, Viral; Thiazoles; Virus Replication | 2013 |
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; United Kingdom; Young Adult | 2013 |
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
T315I, more or less, predicts for major molecular response: the devil is in the details!
Topics: Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Pyrimidines; Thiazoles | 2013 |
Analyses of the combination of 6-MP and dasatinib in cell culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Synergism; Humans; In Vitro Techniques; MCF-7 Cells; Mercaptopurine; Neoplasms; Pyrimidines; Thiazoles; Tumor Stem Cell Assay | 2013 |
Synthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrug.
Topics: Animals; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macaca mulatta; Male; Prodrugs; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2013 |
Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Long Noncoding; Thiazoles | 2014 |
Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.
Topics: Adult; Dasatinib; Drug Eruptions; Female; Hair Diseases; Hair Follicle; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
Topics: Amino Acid Substitution; Cell Line; Cytokine Receptor Common beta Subunit; Dasatinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Janus Kinase 2; Leukemia, Myelomonocytic, Juvenile; Mutation, Missense; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Pyrimidines; Pyrrolidines; RING Finger Domains; Signal Transduction; src-Family Kinases; Sulfonamides; Thiazoles | 2013 |
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult | 2014 |
A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
Topics: Aniline Compounds; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dasatinib; Gene Expression Profiling; Humans; Lymphoma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; src-Family Kinases; Thiazoles | 2013 |
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Dasatinib; Drug Synergism; Gastric Mucosa; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Random Allocation; RNA Interference; Stomach Neoplasms; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling.
Topics: Biomarkers; Dasatinib; Data Mining; Glutathione; Humans; Lipids; Mass Spectrometry; Metabolomics; Microsomes, Liver; Pyrimidines; Thiazoles | 2013 |
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Movement; Cell Proliferation; Dasatinib; Humans; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2013 |
Src inhibitors in suppression of papillary thyroid carcinoma growth.
Topics: Animals; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Dasatinib; Disease Models, Animal; Indoles; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; Sulfonamides; Thiazoles; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Cells, Cultured | 2014 |
Dasatinib plus chemotherapy to achieve full donor chimerism and complete molecular remission in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Time Factors; Transplantation Chimera; Transplantation, Homologous | 2013 |
Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fertilization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
Detection of leukemia associated antigen-specific cytotoxic T cells in a patient with Philadelphia chromosome-positive leukemia during treatment with dasatinib.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Dasatinib; Epitopes, T-Lymphocyte; Humans; Leukemia; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes, Cytotoxic; Thiazoles; Treatment Outcome | 2014 |
Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Cells, Cultured; Dasatinib; Disease Models, Animal; Fluorescence Resonance Energy Transfer; Imaging, Three-Dimensional; Mice; Mice, Transgenic; Microscopy, Fluorescence; Pancreatic Neoplasms; Pyrimidines; src-Family Kinases; Thiazoles | 2013 |
Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Bone Marrow Purging; Child; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Long-Term Care; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Secondary Prevention; Thiazoles | 2013 |
Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.
Topics: Absorption; Animals; Antineoplastic Agents; Biological Transport; Dasatinib; Gastric Mucosa; Humans; Male; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.
Topics: Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Molecular Dynamics Simulation; Protein Structure, Secondary; Pyrimidines; Thiazoles | 2013 |
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Dasatinib; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; STAT1 Transcription Factor; Thiazoles | 2013 |
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Topics: Benzamides; Cell Line; Cell Survival; Chromatography, Affinity; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Leukemia; NF-kappa B; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles | 2013 |
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Topics: Animals; Cells, Cultured; Dasatinib; Dendritic Cells; Flow Cytometry; Humans; Interleukin-12; Lymphocyte Activation; Macaca mulatta; Mice; Myeloid Cells; NF-kappa B; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; src-Family Kinases; T-Lymphocytes; Thiazoles; Toll-Like Receptors | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
[Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
Topics: Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Thiazoles | 2013 |
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; src-Family Kinases; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Young Adult | 2013 |
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cetuximab; Cisplatin; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Humans; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Triple Negative Breast Neoplasms | 2013 |
A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.
Topics: Aniline Compounds; Animals; Biopsy; Carcinoma, Non-Small-Cell Lung; Chromatography, Affinity; Dasatinib; Humans; K562 Cells; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Annotation; Molecular Targeted Therapy; Neoplasm Transplantation; Nitriles; Protein Interaction Maps; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinolines; Thiazoles | 2013 |
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chondrosarcoma; Dasatinib; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Indoles; Male; MCF-7 Cells; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-fyn; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Suppressor Protein p53; Young Adult | 2013 |
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Dasatinib; Discoidin Domain Receptors; DNA Mutational Analysis; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Multiple Primary; Pyrimidines; Radiography; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Thiazoles; Treatment Outcome | 2013 |
Investigation of the rat model for preclinical evaluation of pH-dependent oral absorption in humans.
Topics: Administration, Oral; Animals; Dasatinib; Famotidine; Humans; Hydrogen-Ion Concentration; Ketoconazole; Male; Mefenamic Acid; Pentagastrin; Pyrimidines; Rats; Rats, Sprague-Dawley; Solubility; Thiazoles | 2013 |
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Topics: Absorption; Achlorhydria; Animals; Antineoplastic Agents; Betaine; Dasatinib; Dogs; Famotidine; Gastric Mucosa; Hydrogen-Ion Concentration; Indazoles; Male; Pentagastrin; Proton Pump Inhibitors; Pyrimidines; Stomach; Sulfonamides; Thiazoles | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Biomarkers, Pharmacological; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Paxillin; Phosphorylation; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Topics: Benzamides; Dasatinib; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Satisfaction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States | 2013 |
High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study.
Topics: Acetates; Animals; Chromatography, High Pressure Liquid; Cyclopropanes; Dasatinib; Drug Stability; Limit of Detection; Linear Models; Male; Pyrimidines; Quinolines; Rabbits; Reproducibility of Results; Spectrometry, Fluorescence; Sulfides; Thiazoles | 2013 |
DMSO-enhanced MALDI MS imaging with normalization against a deuterated standard for relative quantification of dasatinib in serial mouse pharmacology studies.
Topics: Animals; Dasatinib; Deuterium; Female; Isotope Labeling; Kidney; Mice; Mice, Inbred C57BL; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiazoles | 2013 |
Effects of SRC and STAT3 upon gap junctional, intercellular communication in lung cancer lines.
Topics: Animals; Cell Communication; Cell Line, Tumor; Dasatinib; Down-Regulation; Gap Junctions; Gene Expression; Humans; Lung Neoplasms; Pyridones; Pyrimidines; rac1 GTP-Binding Protein; Rats; src-Family Kinases; STAT3 Transcription Factor; Thiazoles | 2013 |
Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.
Topics: Abdominal Neoplasms; Acid Ceramidase; Amino Acid Chloromethyl Ketones; Animals; Annexin A5; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Caspase 9; Cell Line, Tumor; Ceramides; Dasatinib; Enzyme Activation; Head and Neck Neoplasms; Indoles; Mice; Mice, Inbred C3H; Mitochondria; Oxidoreductases; Photochemotherapy; Propidium; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Sphingosine; Thiazoles | 2013 |
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.
Topics: Allografts; Animals; Atorvastatin; Biopsy; Cohort Studies; Dasatinib; Databases as Topic; Disease Models, Animal; Drug Approval; Electronic Health Records; Gene Expression Regulation; Gene Regulatory Networks; Graft Rejection; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Kidney; Kidney Transplantation; Meta-Analysis as Topic; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Organ Specificity; Pyrimidines; Pyrroles; Reproducibility of Results; Retrospective Studies; Thiazoles; Transplantation; United States; United States Food and Drug Administration | 2013 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Reversible pre-capillary pulmonary hypertension due to dasatinib.
Topics: Dasatinib; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Thiazoles | 2014 |
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine | 2014 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Dasatinib; Drug Administration Schedule; Drug Substitution; Humans; Hyperplasia; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Topics: Acute Kidney Injury; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pleural Effusion; Pyrimidines; Thiazoles | 2014 |
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dasatinib; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Imidazoles; Isoxazoles; Leflunomide; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; STAT5 Transcription Factor; STAT6 Transcription Factor; Thiazoles; Tumor Suppressor Proteins | 2013 |
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
Topics: Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Dasatinib; Drug Carriers; Female; Humans; Lactic Acid; Mesoporphyrins; Molecular Docking Simulation; Nanomedicine; Neoplasm Metastasis; Photochemotherapy; Photosensitizing Agents; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein-Tyrosine Kinases; Pyrimidines; Serum Albumin; Thiazoles | 2014 |
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Dasatinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles; Translocation, Genetic | 2014 |
A fluorescence anisotropy-based Myt1 kinase binding assay.
Topics: Crystallography, X-Ray; Dasatinib; Dose-Response Relationship, Drug; Fluorescence Polarization; Humans; Membrane Proteins; Protein Binding; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bcl-2-Like Protein 11; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dasatinib; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Melphalan; Membrane Proteins; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; src-Family Kinases; Survivin; Thiazoles; Up-Regulation; Verapamil | 2014 |
Optimization of enrichment conditions on TiO2 chromatography using glycerol as an additive reagent for effective phosphoproteomic analysis.
Topics: Amino Acid Sequence; Cell Line, Tumor; Chromatography, Affinity; Dasatinib; Drug Discovery; Glycerol; Humans; Male; Molecular Sequence Data; Phosphopeptides; Phosphoproteins; Protein Kinase Inhibitors; Proteolysis; Proteomics; Pyrimidines; Thiazoles; Titanium; Tromethamine | 2013 |
Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Biomarkers, Tumor; Caco-2 Cells; Cell Adhesion Molecules; Cell Line, Tumor; Colorectal Neoplasms; Dasatinib; HCT116 Cells; Humans; Mice; Mice, Nude; Neoplasm Proteins; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Phosphotyrosine; Protein Kinase C-delta; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrimidines; Receptor-Like Protein Tyrosine Phosphatases, Class 5; src-Family Kinases; Thiazoles | 2013 |
Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.
Topics: Aged; Dasatinib; Drug Eruptions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pemphigus; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
Topics: Clone Cells; Dasatinib; Female; Genes, abl; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Point Mutation; Pyrimidines; Thiazoles; Thrombocythemia, Essential; Translocation, Genetic | 2013 |
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Dasatinib; Female; Humans; Melanoma; Melphalan; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; src-Family Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Recurrent cardiac chloroma presenting as acute chest pain.
Topics: Adult; Angina Pectoris; Antineoplastic Agents; Dasatinib; Echocardiography; Heart Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Pyrimidines; Sarcoma, Myeloid; Thiazoles | 2014 |
Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Topics: Adolescent; Adult; Combined Modality Therapy; Dasatinib; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Young Adult | 2013 |
Multilayered polymer-coated carbon nanotubes to deliver dasatinib.
Topics: Cell Proliferation; Dasatinib; Drug Delivery Systems; Glioblastoma; Humans; Kinetics; Lactic Acid; Microscopy, Electron, Transmission; Nanoparticles; Nanotubes, Carbon; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymerization; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2014 |
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Discoidin Domain Receptors; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exome; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoblotting; Lung Neoplasms; Mutation; Neurofibromin 1; Protein Kinase Inhibitors; Pyrimidines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thiazoles | 2014 |
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Neoplasm Staging; Phenotype; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Chronic myeloid leukaemia masquerading as primary myelofibrosis.
Topics: Biopsy; Blood Cell Count; Bone Marrow; Dasatinib; Diagnosis, Differential; Genes, abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Phenotype; Piperazines; Pyrimidines; Thiazoles | 2013 |
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic | 2014 |
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Development and validation of an indirect pulsed electrochemical detection method for monitoring the inhibition of Abl1 tyrosine kinase.
Topics: Benzamides; Calibration; Chromatography, Liquid; Dasatinib; Electrochemical Techniques; Fusion Proteins, bcr-abl; Gluconates; Imatinib Mesylate; Inhibitory Concentration 50; Limit of Detection; Linear Models; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis.
Topics: Blast Crisis; Colitis; Colon, Descending; Dasatinib; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Dasatinib; HIV Infections; HIV-1; Humans; Pyrimidines; Thiazoles; Virus Replication | 2014 |
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cluster Analysis; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Intercellular Signaling Peptides and Proteins; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptors, Erythropoietin; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Thiazoles | 2014 |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Vectors; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Retroviridae; Sorting Nexins; Thiazoles; Transfection | 2014 |
Src controls castration recurrence of CWR22 prostate cancer xenografts.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Dasatinib; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Morpholines; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrimidines; RNA, Small Interfering; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Bone Marrow; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Dasatinib; DNA Mutational Analysis; Female; Glycogen Synthase Kinase 3; Humans; Janus Kinase 2; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phosphoproteins; Phosphorylation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; src-Family Kinases; Thiazoles | 2014 |
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paxillin; Pyrimidines; Signal Transduction; src-Family Kinases; Taxoids; Thiazoles; Topotecan | 2014 |
Stromal fibroblasts mediate extracellular matrix remodeling and invasion of scirrhous gastric carcinoma cells.
Topics: Actomyosin; Adenocarcinoma, Scirrhous; Cell Line, Tumor; Cell Movement; Dasatinib; Extracellular Matrix; Fibroblasts; Humans; Models, Biological; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrimidines; rho-Associated Kinases; src-Family Kinases; Stomach Neoplasms; Thiazoles; Tumor Cells, Cultured | 2014 |
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Drug Synergism; Endoplasmic Reticulum Stress; Female; Head and Neck Neoplasms; Humans; Metformin; Mice; Mice, Nude; Pyrimidines; Squamous Cell Carcinoma of Head and Neck; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
Topics: Animals; Cell Line, Tumor; Dasatinib; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; Receptor, EphA2; Thiazoles; Uterine Neoplasms | 2014 |
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Aged; Benzamides; Capsule Endoscopy; Dasatinib; Drug Substitution; Endoscopes, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Dasatinib-letrozole gets split verdict.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dasatinib; Female; Humans; Letrozole; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Treatment Outcome; Triazoles | 2014 |
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2015 |
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Dasatinib; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; K562 Cells; Mesoderm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcriptional Regulator ERG | 2014 |
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Topics: Aminophenols; Animals; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Disease Progression; Enzyme Activation; Glycogen Synthase Kinase 3; Humans; Male; Maleimides; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Pyrimidines; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Thiazoles; Transfection | 2014 |
Expression of the essential Kinase PfCDPK1 from Plasmodium falciparum in Toxoplasma gondii facilitates the discovery of novel antimalarial drugs.
Topics: Antimalarials; Cell Membrane; Dasatinib; Immunoblotting; Indoles; Microscopy, Fluorescence; Plasmodium falciparum; Protein Kinases; Protozoan Proteins; Pyrimidines; Sulfonamides; Thiazoles; Toxoplasma | 2014 |
Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damage.
Topics: Active Transport, Cell Nucleus; alpha Karyopherins; Animals; Apoptosis; Cell Nucleus; CSK Tyrosine-Protein Kinase; Dasatinib; DNA Damage; Female; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Phosphorylation; Protein Binding; Protein Kinase C-delta; Proto-Oncogene Proteins c-abl; Pyrimidines; Salivary Glands; src-Family Kinases; Thiazoles; Tyrosine | 2014 |
Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells.
Topics: Androstadienes; Autophagy; Cell Differentiation; Cell Line, Tumor; Chloroquine; Chromones; Dasatinib; DNA Primers; Humans; Leukemia, Myeloid, Acute; Morpholines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Thiazoles; Up-Regulation; Wortmannin | 2014 |
Pneumatosis intestinalis and imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Child, Preschool; Dasatinib; Daunorubicin; Dexamethasone; Drug Substitution; Female; Humans; Imatinib Mesylate; Parenteral Nutrition, Total; Piperazines; Pneumatosis Cystoides Intestinalis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Vincristine | 2014 |
PKA signaling drives mammary tumorigenesis through Src.
Topics: Androstadienes; Animals; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Dasatinib; Epithelial Cells; Female; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Phosphorylation; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Wortmannin | 2015 |
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Pyrimidines; Retinal Dehydrogenase; Thiazoles | 2014 |
Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.
Topics: Adaptor Proteins, Signal Transducing; ADP-ribosyl Cyclase 1; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Dasatinib; HL-60 Cells; Humans; Leukemia, Myeloid; Membrane Glycoproteins; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-vav; Pyrimidines; src-Family Kinases; Thiazoles; Tretinoin | 2014 |
Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Triple Negative Breast Neoplasms | 2014 |
Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myeloid, Accelerated Phase; Philadelphia Chromosome; Pyrimidines; Thiazoles | 2014 |
Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Topics: Animals; B-Lymphocytes; Bone Marrow Cells; Cell Lineage; Dasatinib; Dose-Response Relationship, Drug; Germinal Center; Hematopoietic Stem Cells; Humans; Lymphocyte Count; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Myeloproliferative Disorders; Neutrophils; Phosphorylation; Phosphotyrosine; Precursor Cells, B-Lymphoid; Proto-Oncogene Proteins c-cbl; Pyrimidines; RING Finger Domains; src-Family Kinases; Thiazoles | 2014 |
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; HLA-A2 Antigen; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; WT1 Proteins | 2014 |
PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Adhesion; Cell Proliferation; Cell Survival; Dasatinib; Ephrin-B2; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Imatinib Mesylate; Mice; Paired Box Transcription Factors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor Cross-Talk; Receptor, EphB4; Receptor, Platelet-Derived Growth Factor beta; Rhabdomyosarcoma, Alveolar; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2014 |
NKT cell-infiltrating aseptic meningitis on the central nervous system in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib.
Topics: Central Nervous System; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meningitis, Aseptic; Middle Aged; Natural Killer T-Cells; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imidazoles; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Mutation; Pyridazines; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Outcome | 2015 |
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
Topics: Animals; Azacitidine; Blotting, Western; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dasatinib; Decitabine; Dioxygenases; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Inhibitors; Esophagus; Gastric Mucosa; Humans; Mast Cells; Mastocytosis, Systemic; Mice, Knockout; Mice, Transgenic; Mutation, Missense; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; Skin; Stomach; Thiazoles | 2014 |
Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
The role of Src family kinases in growth and migration of glioma stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Glioma; Glycoproteins; Humans; Mice; Neoplasms, Experimental; Neoplastic Stem Cells; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Proto-Oncogene Proteins c-yes; Pyrimidines; src-Family Kinases; Thiazoles; Up-Regulation | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
Fluorescent visualization of Src by using dasatinib-BODIPY.
Topics: Animals; Benzodioxoles; Boron Compounds; Cell Line; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Fluorescence; Humans; Mice; Microscopy, Fluorescence; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; Structure-Activity Relationship; Thiazoles | 2014 |
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Male; Middle Aged; Neoplasm Grading; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2014 |
[A case report of dasatinib-induced tumor lysis syndrome].
Topics: Dasatinib; Humans; Pyrimidines; Thiazoles; Tumor Lysis Syndrome | 2014 |
Chronic myelogenous leukemia presenting with bilateral optic disc neovascularization.
Topics: Combined Modality Therapy; Dasatinib; Fluorescein Angiography; Humans; In Situ Hybridization, Fluorescence; Laser Coagulation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Magnetic Resonance Imaging; Male; Middle Aged; Optic Disk; Protein Kinase Inhibitors; Pyrimidines; Retinal Neovascularization; Thiazoles; Visual Acuity; Vitrectomy | 2014 |
The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Topics: Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Dasatinib; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Regulation; Glucuronosyltransferase; Graves Ophthalmopathy; Humans; Hyaluronan Synthases; Imatinib Mesylate; Interleukin-6; Interleukin-8; Orbit; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-sis; Pyrimidines; RNA, Messenger; Thiazoles | 2014 |
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Topics: Aged; Anticonvulsants; Cell Death; Cell Differentiation; Cell Line, Tumor; Dasatinib; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Valproic Acid | 2014 |
B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dasatinib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Neoplasm Transplantation; Neoplasms; Phosphorylation; Pyrimidines; src-Family Kinases; Thiazoles | 2014 |
Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Pneumocystis carinii; Pneumonia, Pneumocystis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Topics: ADP-ribosyl Cyclase 1; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Sirtuin 1; Thiazoles; Tretinoin | 2014 |
[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
Topics: Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors | 2014 |
Toward therapeutic effects evaluation of chronic myeloid leukemia drug: electrochemical platform for caspase-3 activity sensing.
Topics: Apoptosis; Biosensing Techniques; Caspase 3; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Electrochemical Techniques; Equipment Design; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Topics: Acinar Cells; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, IGF Type 1; Receptors, Estrogen; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Synergism; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Mastocytosis; Piperazines; Protein Kinase C; Protein Kinase C-delta; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Transfection | 2014 |
A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Dasatinib; Drug Carriers; Humans; Lactic Acid; Male; Nanomedicine; Photosensitizing Agents; Phototherapy; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins; Pyrimidines; Rats; Rats, Wistar; Thiazoles | 2014 |
Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Female; Genes, src; Humans; MCF-7 Cells; Mice; Phosphorylation; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases | 2014 |
VEGF receptors mediate hypoxic remodeling of adult ovine carotid arteries.
Topics: Animals; Carotid Arteries; Contractile Proteins; Dasatinib; Hypoxia; Muscle Contraction; Muscle, Smooth, Vascular; Myosin-Light-Chain Kinase; Phosphorylation; Phthalazines; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sheep; Thiazoles; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2014 |
Optic coherence tomography of foveal hemorrhage associated with chronic myelogenous leukemia.
Topics: Adult; Dasatinib; Female; Fovea Centralis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retinal Hemorrhage; Thiazoles; Tomography, Optical Coherence; Vision Disorders; Visual Acuity | 2015 |
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
Topics: ADAM Proteins; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antigens, Neoplasm; Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Dasatinib; Dexamethasone; Disease Models, Animal; Gene Knockdown Techniques; Heterografts; Humans; Lung Neoplasms; Membrane Proteins; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Proteins; Plasminogen Activators; Pyrimidines; Thiazoles | 2014 |
Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dasatinib; DNA Replication; Dose Fractionation, Radiation; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrimidines; ras Proteins; src-Family Kinases; Thiazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Presence and utility of intrinsically disordered regions in kinases.
Topics: Cell Line; Cell Proliferation; Computational Biology; Dasatinib; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Humans; Intrinsically Disordered Proteins; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Signal Transduction; Smad Proteins; Thiazoles | 2014 |
Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Autophagy; Benzimidazoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Enzyme Inhibitors; G2 Phase; Humans; Medulloblastoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Suppressor Protein p53; Urea | 2014 |
Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells.
Topics: Aniline Compounds; Animals; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cytokines; Dasatinib; Dendritic Cells; Drug Evaluation, Preclinical; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-10; Intestine, Small; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Signal Transduction; T-Lymphocytes, Regulatory; Thiazoles; Transcription Factors | 2014 |
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles | 2014 |
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Topics: Aminosalicylic Acids; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Luciferases; Molecular Docking Simulation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Sulfonamides; Thiazoles | 2015 |
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult | 2014 |
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Amino Acid Sequence; Animals; Binding Sites; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Jumonji Domain-Containing Histone Demethylases; Luciferases; Mammary Glands, Human; Methylation; Models, Molecular; Molecular Sequence Data; Neuregulin-1; Protein Binding; Protein-Tyrosine Kinases; Pyrimidines; Receptor, ErbB-2; Signal Transduction; Tamoxifen; Thiazoles; Transcription, Genetic | 2014 |
Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia.
Topics: Apoptosis; Caspase 3; Dasatinib; Enzyme Assays; Gold; Humans; K562 Cells; Leukemia; Nanoparticles; Nanotechnology; Proteomics; Pyrimidines; Silicon Dioxide; Thiazoles | 2014 |
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Recurrence; Thiazoles | 2015 |
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.
Topics: Base Sequence; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles; Translocation, Genetic | 2014 |
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Cyclohexylamines; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Structure-Activity Relationship; Thiazoles | 2015 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Dasatinib; Drug Substitution; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pulmonary Alveolar Proteinosis; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2014 |
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.
Topics: Apoptosis; Calcineurin; Calcineurin Inhibitors; Calcium; Cell Line; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; Humans; Mast Cells; Mutation; NFATC Transcription Factors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles; Transcription, Genetic | 2014 |
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem.
Topics: Animals; Antineoplastic Agents; Brain Stem; Convection; Dasatinib; Drug Delivery Systems; Everolimus; Female; Infusions, Intraventricular; Phosphorylcholine; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sirolimus; Thiazoles | 2015 |
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Topics: Adolescent; Adult; Aged; Dasatinib; Databases, Factual; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2014 |
Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
Topics: Adenocarcinoma; Aged; Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Topics: Aged, 80 and over; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Fatal Outcome; Female; Fibroblasts; Humans; Imatinib Mesylate; Lung Neoplasms; Melanoma; Mutation, Missense; Phosphorylation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Skin Neoplasms; Spinal Neoplasms; Thiazoles | 2014 |
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Topics: Adaptive Immunity; Apoptosis; Cell Line, Tumor; Dasatinib; Discoidin Domain Receptors; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Mutation; Neoplasms, Squamous Cell; Proto-Oncogene Proteins c-ret; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Receptors, Somatomedin; Signal Transduction; Thiazoles | 2014 |
The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Topics: Aniline Compounds; Animals; Arginase; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cytokines; Dasatinib; Immunity, Innate; Macrophages; Mice; Nitriles; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Thiazoles; Transcription Factors; Tumor Necrosis Factor Ligand Superfamily Member 14 | 2015 |
Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Flow Cytometry; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transcriptome; Transduction, Genetic; Transfection; Triple Negative Breast Neoplasms | 2014 |
US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says.
Topics: Antineoplastic Agents; Commerce; Dasatinib; Dissent and Disputes; Drug Industry; Drugs, Generic; Health Services Accessibility; Humans; India; Pyrimidines; Thiazoles; United States | 2014 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinations; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Protein Kinase Inhibitors; Pyrimidines; Tegafur; Thiazoles | 2014 |
TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Topics: Child; Dasatinib; Humans; Male; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Repressor Proteins; Thiazoles; Transcription Factors; Translocation, Genetic | 2015 |
[Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].
Topics: Acute Disease; Central Nervous System; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Pyrimidines; Thiazoles | 2014 |
Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Beverages; Biological Transport; Cell Line; Coumarins; Dasatinib; Dogs; Flavonoids; Food-Drug Interactions; Fruit; Humans; Madin Darby Canine Kidney Cells; Membrane Transport Modulators; Neoplasm Proteins; Phytochemicals; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Sus scrofa; Thiazoles | 2015 |
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Topics: Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Dasatinib; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Patient Care; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; United States | 2015 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Topics: Adult; Antineoplastic Agents; Australia; Benzamides; Canada; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Therapy Management; Middle Aged; Piperazines; Practice Patterns, Physicians'; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2015 |
Basophilic blast phase of chronic myelogenous leukemia.
Topics: Adult; Basophils; Blast Crisis; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Thiazoles; Treatment Failure | 2014 |
Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging.
Topics: Biosensing Techniques; Cell Line, Tumor; Dasatinib; Extracellular Matrix; Fluorescence Resonance Energy Transfer; Humans; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2014 |
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Dasatinib; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles | 2015 |
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Topics: ADP-Ribosylation Factor 1; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Dasatinib; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Interleukin-7; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mutation; Neoplasm Recurrence, Local; Nitriles; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazoles; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Thiazoles; Tumor Cells, Cultured | 2015 |
Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Humans; Intracellular Space; Lung Neoplasms; Molecular Docking Simulation; Nitriles; Protein Conformation; Protein Serine-Threonine Kinases; Pyrimidines; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thiazoles; Transforming Growth Factor beta | 2014 |
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Blotting, Western; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; K562 Cells; Killer Cells, Natural; Mice, Inbred C57BL; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; Signal Transduction; src-Family Kinases; Thiazoles; Transcriptome | 2014 |
iPhos: a toolkit to streamline the alkaline phosphatase-assisted comprehensive LC-MS phosphoproteome investigation.
Topics: Adenocarcinoma; Alkaline Phosphatase; Chromatography, Liquid; Dasatinib; Humans; Immunoprecipitation; Lung Neoplasms; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrimidines; Signal Transduction; Software; Tandem Mass Spectrometry; Thiazoles; Tumor Cells, Cultured | 2014 |
A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy.
Topics: Antineoplastic Agents; Dasatinib; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Spectrometry, Fluorescence; Thiazoles | 2015 |
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.
Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moxifloxacin; Peritonitis, Tuberculous; Protein Kinase Inhibitors; Pyrazinamide; Pyrimidines; Thiazoles | 2015 |
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Cardiovascular Diseases; Dasatinib; Databases, Factual; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Lung Diseases; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration; Young Adult | 2015 |
How I treat mixed-phenotype acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Chromosome Aberrations; Combined Modality Therapy; Dasatinib; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Immunophenotyping; Leukemia; Middle Aged; Myeloid Cells; Pyrimidines; Stem Cell Transplantation; T-Lymphocytes; Thiazoles; Transplantation, Homologous | 2015 |
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Child; Chronic Disease; Dasatinib; Disease Progression; Female; Flow Cytometry; Follow-Up Studies; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oxazines; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Syk Kinase; Thiazoles; Tumor Cells, Cultured; Young Adult | 2015 |
[Dasatinib-related pneumonia? An example of pharmacovigilance survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Pharmacovigilance; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Thiazoles; Tomography, X-Ray Computed; Vincristine | 2015 |
The targeting of human and mouse B lymphocytes by dasatinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antigens, CD19; Apoptosis; B-Lymphocytes; Bone Marrow Cells; Dasatinib; Flow Cytometry; Humans; Male; Mice, Inbred C57BL; Phospholipase C gamma; Piperidines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Receptors, Antigen, B-Cell; Receptors, Antigen, T-Cell; Signal Transduction; Spleen; Thiazoles; Time Factors | 2015 |
Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Topics: Antineoplastic Agents; Dasatinib; Humans; Hypertension, Pulmonary; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles | 2015 |
Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.
Topics: Animals; Benzamides; Brugia malayi; Dasatinib; Female; Filaricides; Imatinib Mesylate; Inhibitory Concentration 50; Larva; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2015 |
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Thiazoles | 2015 |
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Retrospective Studies; Spain; Survival Analysis; Thiazoles | 2015 |
Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Transcriptome | 2015 |
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptotic Protease-Activating Factor 1; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Immunoprecipitation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2015 |
Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
Topics: Adult; Antineoplastic Agents; Dasatinib; Drug Substitution; Echocardiography; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Click conjugation of a binuclear terbium(III) complex for real-time detection of tyrosine phosphorylation.
Topics: Click Chemistry; Dasatinib; Luminescence; Molecular Structure; Organometallic Compounds; Peptides; Phosphorylation; Phosphotransferases; Protein Kinase Inhibitors; Pyrimidines; Terbium; Thiazoles; Time Factors; Tyrosine | 2015 |
Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.
Topics: Benzamides; Binding Sites; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; src Homology Domains; Substrate Specificity; Thiazoles | 2015 |
[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Topics: Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2015 |
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dasatinib; Drug Synergism; Esophageal Neoplasms; Human Umbilical Vein Endothelial Cells; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; STAT3 Transcription Factor; Thiazoles | 2015 |
Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Endoscopes, Gastrointestinal; Gastric Antral Vascular Ectasia; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.
Topics: Acute Disease; Adolescent; Colitis; Dasatinib; Gastrointestinal Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Exons; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Pyrimidines; RNA, Messenger; Sequence Analysis, DNA; Thiazoles | 2015 |
Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Topics: Aged; Dasatinib; Dyspnea; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tomography, X-Ray Computed | 2015 |
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
Topics: Aged; Antineoplastic Agents; Calreticulin; Dasatinib; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Male; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2015 |
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Cell Line, Tumor; Crystallography, X-Ray; Cyanoacrylates; Dasatinib; Female; Gene Expression; Humans; Ligands; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sf9 Cells; Spodoptera; Structure-Activity Relationship; Substrate Specificity; Thiazoles; Time Factors | 2015 |
[Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dasatinib; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2015 |
BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Topics: Antineoplastic Agents; Blast Crisis; Dasatinib; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
[CHRONIC MYELOID LEUKEMIA IN A YOUNG MALE PRESENTING WITH BILATERAL CALF PAIN DUE TO LEUKOSTASIS].
Topics: Allopurinol; Bone Marrow Examination; Dasatinib; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hydroxyurea; Leg; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukostasis; Male; Myalgia; Ophthalmoscopy; Philadelphia Chromosome; Pyrimidines; Retinal Hemorrhage; Thiazoles; Treatment Outcome; Young Adult | 2015 |
Treatment-free remission after stopping second-line dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Colitis; Dasatinib; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Thiazoles | 2018 |
2-Aminoxazole and 2-Aminothiazole Dasatinib Derivatives as Potent Inhibitors of Chronic Myeloid Leukemia K562 Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxazoles; Structure-Activity Relationship; Thiazoles | 2016 |
Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature.
Topics: Colitis; Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2016 |
We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas.
Topics: Dasatinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Thiazoles | 2017 |
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Ligands; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Mas; Thiazoles; Ubiquitination | 2017 |
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Thiazoles | 2018 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2021 |
Pleural Effusion Secondary to Dasatinib Following Allogenic Hematopoietic Stem Cell Transplantation.
Topics: Aged; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Male; Pleural Effusion; Pyrimidines; Thiazoles | 2021 |
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Topics: Dasatinib; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pyrimidines; Spleen; Thiazoles | 2023 |
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Topics: Dasatinib; Humans; Interleukin-2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; Thiazoles | 2023 |
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Topics: Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dasatinib; G1 Phase; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2023 |
New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Celecoxib; Cyclooxygenase 2; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Thiazoles | 2023 |